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Chapter 1 
Introduction 
 
1.1  Overview and objectives 
Oral inhalation (OI) is not only the most attractive therapy for the regional 
delivery of drugs to the lungs, but also a promising candidate route for the systemic 
administration of therapeutics through the lungs.[1, 4]  There are many advantages in 
using the pulmonary route for targeting the systemic circulation, including the fact that 
it is non-invasive (both in terms of compliance and reducing the risk of transmission 
of infectious diseases), the alveolar region has a large surface area for drug 
absorption (~ 140 m2), and the lung tissue has limited biochemical activity compared 
to the liver, thus typically resulting in improved drug bioavailability.[5-7]  Despite 
these advantages, the potential of OI therapies remains relatively unexploited; a fact 
underscored by the absence of commercially available OI formulations for systemic 
drug delivery, or for the treatment of medically relevant, debilitating pulmonary 
diseases such as lung cancer and tuberculosis, which are currently being targeted 
with oral/intravenous (i.v.) formulations.[8-9]  The advancement of OI formulations 
has been hindered to a large extent by our limited knowledge of the interaction of 
drugs with the lung tissue, extra and intra-cellular barriers to drug delivery, and the 
lack of efficient OI drug delivery carriers and systems.[10] 
Pressurized metered dose inhalers (pMDIs) and dry powder inhalers (DPIs) 
are two of the most widely used pulmonary drug delivery devices in the market today.  
With an estimated market share in excess of $2 billion, and a patient base of over 70 
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million, pMDIs are the most commonly prescribed aerosol delivery devices in the 
world.[11-12]  Following the pMDIs in terms of usage are the DPIs.[13]  Owing to 
their high compliance, extensive usage, and portability, pMDIs and DPIs are potential 
candidates for the delivery of medically relevant therapeutics including proteins, 
peptides, and nucleotides to (regionally) and through (systemically) the lungs.[11] 
The impact of OI formulations is expected to be even broader if such technologies 
can be successfully combined with the desirable characteristics of polymeric 
nanocarriers (NCs), including targeted and controlled release of therapeutics, the 
ability to carry/encapsulate various types of solutes, and the ability to protect 
sensitive cargo.[14-18]  Other advantages of NCs include the fact that due to their 
sub-micron size, they can be trafficked with relative ease into the cell cytosol, are 
capable of reaching intracellular organelles, can penetrate deep into tissues, and 
most importantly, may be tailored to overcome relevant barriers, including the 
epithelial cell layer (required for systemic delivery), the mucus layer (present in the 
upper airways), and alveolar macrophages and lung surfactant (present in the 
alveolar region), as well as intracellular barriers.[16, 19] 
           The formulation aspects of NCs in pMDIs and DPIs also pose significant 
challenges.  One major hurdle that needs to be overcome is related to the aerosol 
size of the NCs.[20]  Aerosol delivery with maximal particulate deposition in the deep 
lung occurs for those within the size between 0.5-5 µm.[1]  Aerosols larger than 
approximately 5µm are deposited in mouth and throat, and those with sizes smaller 
than the lower limit (which is the range of interest for polymeric NCs), may be 
efficiently exhaled and have severely reduced deposition.  The ability to target 
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different regions of the pulmonary epithelia is also relevant as different diseases are 
targeted (regional delivery).  Another challenge that needs to be addressed while 
incorporating polymeric NCs into OI devices is their interaction (particles) with media 
and carriers.  In the case of pMDIs, in order to obtain good dispersions in the 
compressed solvents used as dispersing and propellant media, and thus to achieve 
enhanced aerosol properties, the particle chemistry must be chosen such that it will 
be well solvated by the propellants.[21]  For DPIs, the physicochemical 
characteristics of NCs should be tailored to ensure that adhesive/cohesive balance 
between NCs and/or NC/excipient are balanced so that they reach the lungs as un-
aggregated particles, and release from the large carrier particles to get access to the 
deep lungs.[3]   Finally, the interaction of NCs and other excipients used in the 
formulations with the lung milieu in vivo needs to be evaluated in order to understand 
the retention of these moieities in the airspace and potential inflammatory response 
they might stimulate, as addition of extraneous agents to the lung has been shown to 
foment inflammation.[16 , 20] 
         While the capabilities of polymeric NCs and delivery vehicles have been 
extensively investigated with respect to conventional delivery routes (e.g. oral and 
intravenous; i.v.), reports of the incorporation of NCs into inexpensive and portable OI 
devices, and their interaction with the lung epithelia has been fairly limited.[17, 22-23]  
Our long term goal is to develop novel inhalation formulations for the targeted and 
controlled delivery of therapeutics to (regional) and through (systemically) the lungs.  
The objective of this dissertation is to design polymeric NCs capable of modulating 
drug transport across the lung epithelium, and to develop efficient OI formulations of 
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such carriers.  The rationale that underlies this investigation is that issues typically 
associated with the poor performance of free drugs delivered via OI, including the 
lack of control of the transport across / localization in the respiratory epithelium, and 
lack of controlled release and of tissue specificity may all be circumvented by 
employing polymeric NCs as delivery vehicles. 
           The primary objectives of this work were achieved by pursuing the following 
two aims: 
Aim #01.  Develop strategies for the formulation of polymeric NCs in portable 
inhalers.  The size of the aerosol particles greatly affects lung deposition.  The 
optimum aerosol size range varies between 0.4 to 5.0 µm, which falls outside the 
desirable size range for polymeric NCs (< 200 nm).  This issue is relevant for both 
DPIs and pMDIs.  In the case of propellant-based inhalers, the stability of colloidal 
particles in the low dielectric hydrofluoroalkanes (HFAs) also needs to be addressed.  
Particle aggregation leads to change in overall particle size, which may in turn affect 
both aerosol characteristics and dosage.  In DPIs the concern is to optimize the 
forces between NC and inert carrier particles (or NC-NC if no inert carrier is used).  In 
order to address these issues, we propose a new particle engineering strategy.  
Micron-sized core-shell particles will be produced via emulsification diffusion.  The 
particle core will consist of polymeric NCs (polymeric nanoparticles- PNPs, dendrimer 
nanocarriers, DNCs, and their composites), while the shell that provides integrity to 
the micron particles will consist of a biodegradable co-oligomer.  This co-oligomer 
shell will have an appropriate chemistry so as to enhance the stability of the colloids 
in propellant HFAs for propellant-based inhalers, and to modulate particle-particle 
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interaction for DPIs.  We will discuss the feasibility of the proposed particle 
engineering strategy for the formation of micron-sized core shell particles, and the 
physical characterization of such constructs.  The synthesis of candidate co-
oligomers and their characterization will also be discussed.  Finally, we will study the 
aerosol characteristics of the core-shell particles formulated in pMDIs.  These studies 
will serve to guide the design of the co-oligomer shell in order to optimize the 
characteristics of the aerosol. 
Aim #02:  Investigate the interaction between polymeric NCs with varying 
chemistry and architecture with the lung epithelium in vitro and in vivo.  The 
ability to modulate the interactions between the polymeric NCs and the lung 
epithelium offers many opportunities in terms of drug delivery via oral inhalation.  One 
major challenge in targeting lung diseases via OI is that certain drugs permeate too 
rapidly across the epithelium, and are thus rendered ineffective for regional delivery.  
There are also issues related to tissue toxicity that might arise once these drugs 
reach the systemic circulation.  On the other hand, the permeability of certain poorly 
water soluble drugs and large molecular weight (MW) therapeutics (e.g. 
biomacromolecules) through the lungs may be slow and/or too small.  Targeting the 
alveolar and upper respiratory regions, and overcoming extracellular and intracellular 
barriers, especially in diseased lungs, are also major challenges.  In this study we 
seek to design polymeric NCs capable of modulating the transport of therapeutics 
across the lung epithelium.  The structure, size, chemistry, and surface 
characteristics of the NCs will be explored in an attempt to modulate transport.  
Polymeric nanoparticles (PNPs), dendrimer nanocarriers (DNCs), and composites of 
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DNCs and PNPs with and without functionalization will be investigated.  Studies in 
healthy and diseased in vitro models of the lung epithelium, as well as the interaction 
of selected NCs with lung tissue in vivo will also be studied.  The in vivo inflammatory 
potential of PNCs and the co-oliogomer utilized in formulating the core-shell 
structures and their rate of elimination from the lung will also be evaluated in an effort 
to understand the interaction of the co-oligomer and PNCs with the lung epithelium in 
vivo.  
           Results demonstrating the progress made towards these aims are discussed 
below.  Some of the work shown next has been compiled in the form of a manuscript:  
Bharatwaj. B., Wu, L., Whittum-Hudson, J. A., and da Rocha S. R. P. “The potential 
for the noninvasive delivery of polymeric nanocarriers using propellant-based inhalers 
in the treatment of Chlamydial respiratory infections.” Biomaterials 31 (2010) 7376-
7385. 
Studies detailing the interaction and the modulation of DNCs, NPs and their blends  
with pulmonary epithelium have been compiled into two other manuscripts entitled  
(a)  Bharatwaj, B., Dimovski,R., Conti, D.S.,  and da Rocha, S.R.P.,  Polymer   
Nanocarriers for Transport Modulation Across the Pulmonary Epithelium: 
Dendrimers, Polymeric Nanoparticles, and their Nanoblends.  J Control Rel, 
2012.  To be submitted.  
     (b)  Bharatwaj, B.,  Mohammad, A.K.,  Dimovski, R.,  Cassio, F., Conti, D.S.,   
Bazio, R.,   Reineke, J., and da Rocha, S. R. P.,  PEGylated Dendrimer 
Nanocarriers for Transport Modulation Across the Pulmonary Epithelium.  
Biomaterials, 2012. To be submitted 
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           In chapter 2, we discuss the formulation of polymeric nanoparticles (PNPs) in 
pMDIs and their subsequent interaction with a disease model of pulmonary 
epithelium in vitro.  A major hurdle impeding the development of NP laden pMDI 
formulations, in addition to their chemistry, is their size which is not conducive for 
deep lung deposition.   Here, we discuss the formulation of NPs as micron-sized 
core-shell constructs and their evaluation of their stability and aerosol properties.  
Furthermore, we also discuss the ability of these NPs to internalize into infected 
epithelial cell models.  This chapter is based on the following publication-  Bharatwaj. 
B., Wu, L., Whittum-Hudson, J. A., and da Rocha S. R. P. “The potential for the 
noninvasive delivery of polymeric nanocarriers using propellant-based inhalers in the 
treatment of Chlamydial respiratory infections.” Biomaterials 31 (2010) 7376-7385. 
           In Chapter 3, we discuss the interaction of DNCs with model airway 
epithelium, Calu-3.  The objective of this study was to evaluate the permeability and 
uptake of generation-3 (G3) poly (amido amine) (PAMAM) dendrimers across an in 
vitro model of the airway epithelium – Calu-3.  Additionally, we also discuss the ability 
of arresting (thereby modulating) the transport and enhancing the uptake of DNCs 
across and into Calu-3 monolayers by encapsulating the conjugates into 
biodegradable NPs.  The ability to formulate DNCs as micron-sized structures in 
pMDIs and evaluating the pertinent aerodynamic properties of the resulting aerosol is 
also discussed here.  This chapter is based on the following publication-   Bharatwaj, 
B., Dimovski,R., Conti, D.S.,  and da Rocha, S.R.P.,  Polymer   Nanocarriers for 
Transport Modulation Across the Pulmonary Epithelium: Dendrimers, Polymeric 
Nanoparticles, and their Nanoblends.  J Control Rel, 2012.  To be submitted.  
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            Modifying amine terminated DNCs with PEG imparts several advantageous 
properties to the dendrimers.  Some of them include, lower cytotoxic potential, 
enhancement of mucosal transport and increased circulation time.[R]  Chapter 4 
deals with the synthesis of PEG tethered DNCs, their preparation, characterization 
and their ability to modulate transport and uptake across and into polarized Calu-3 
monolayers.  Furthermore, the pharmacokinetic (PK) behavior of select PEGylated 
DNCs was evaluated in BALB/C mice upon pulmonary administration and their 
bioavailability contrasted against conjugates administered intravenously (i.v) to mice.  
The chapter is based on the following publication-    Bharatwaj, B.,  Mohammad, 
A.K.,  Dimovski, R.,  Cassio, F., Conti, D.S.,   Bazito, R.,   Reineke, J., and da Rocha, 
S. R. P.,  PEGylated Dendrimer Nanocarriers for Transport Modulation Across the 
Pulmonary Epithelium. Biomaterials, 2012. To be submitted.            
            Chapter 5, deals with evaluating the inflammatory potential of the co-oligomer, 
oligolactide grafted chitosan (OLA-g-CS) in mice.   OLA-g-CS, is the excipient widely 
used in our formulations to form dispersions in HFA.  In vitro cytotoxic evaluation of 
the compound deemed it to be non-toxic up to concentrations as high as ca.13 
mg·mL-1. Here, the co-oligomer was administered to mice lung intranasally and the 
inflammatory response was elicited by counting cell population in the bronchoalveolar 
lavage fluid (BALF) and lung tissue.   Epithelial integrity to estimate the serum protein 
infiltration into the airspace was also determined to reaffirm the results obtained from 
the BALF cell count.  Furthermore, the study also evaluated the inflammatory 
potential of the NP laden core-shell formulation discussed in chapter 2.  The 
residence times of the co-oligomer and the NP laden core-shell formulation is also 
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discussed here.   This chapter is based on the following publication - Bharatwaj, B., 
Gao, X., Conti, D. S., Wu,L., Bassett, D. J. P., and da Rocha, S. R. P,  “Pulmonary 
Inflammatory Response of a Versatile Chitosan-based Co-oligmeric Excipient for 
Pressurized-Metered Dose Inhalers”. Biomaterials, 2012. To be Submitted. 
           Conclusions and future directions are detailed in the final chapter.  
           
1.2   Background.  
 
 
 
 
 
 
 
 
 
 
 
 
1.2.1  Portable devices for oral inhalation (OI) delivery of drugs.  
           pMDIs are the least expensive and most widely used portable inhalers.[4, 11]  
They are reliable, have high compliance, and are easy to use.[24]  A schematic 
diagram of a typical pMDI system is shown in Figure 1.1a.  The ensemble consists of 
Aerosol 
Plume 
Figure 1.1 (a). A representative schematic of a pMDI 
housing a typical formulation (b) Schematic illustration of 
a Spinhaler® DPI. Adapted from [2]. 
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three major components: (i) a canister that houses the propellant containing the drug 
formulation; (ii) a metering valve, which serves to dispense a specific quantity of the 
aerosol (~ 50-100 µl); (iii) and an actuator, which serves to lodge the canister upside 
down, and to direct the  aerosol into the patients’ respiratory tract.  Commercially 
available pMDI formulations contain the liquid HFA propellant in equilibrium with its 
vapor (98% of the formulation), a drug (typically in suspension as most drugs of 
interest are insoluble in propellant HFAs which are simultaneously hydrophobic and 
oleophobic), and excipients.[25]  Upon actuation, the propellant containing the drug 
and excipients flash vaporizes into an aerosol plume that is inhaled by the patient. 
           In DPIs, the active therapeutic is brought to an appropriate size, and (typically) 
mixed with a carrier, which is usually lactose.  The function of the carrier particles is 
primarily to prevent aggregation, enhance flow and assist in the improvement of 
handling and metering of the drug.[3]  A schematic diagram of a DPI is shown in 
Figure 1.1b.  Different from pMDIs, the delivery of medicaments from typical DPIs to 
the lungs is achieved by way of the patient’s inspiratory flow, thus not requiring 
coordinated actuation and inhalation.[3]  The shear and turbulence created by the 
patients’ inspiration causes fluidization and separation of the drug-carrier (when part 
of the formulation) blend.  Owing to their larger size (tens of microns), the carrier 
particles remain in the oropharyngeal region and are cleared, and the smaller drug 
particles (appropriate size for deep lung deposition) are subsequently transported 
into the airways. [3, 13] 
           The delivery of polymeric NCs from pMDIs and DPIs may be challenging given 
that the size of the carriers fall outside the range desired in order to ensure maximal 
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Figure 1.2. (a) NCs of PLGA prepared using 
emulsification solvent evaporation. Size bar denotes 
0.5 µm; (b) A Pictographic rendition of G3 PAMAM 
dendrimer with 32 surface groups (-NH2). 
 
 
lung deposition.  One potential approach to overcome this challenge is the 
formulation of NCs as micron-sized agglomerates.[15]  However, there are potential 
drawbacks when using this approach.  Upon administration, these agglomerates may 
persist as micron-sized entities upon reaching the lung tissue, thereby presenting 
themselves to the cellular milieu in a clustered form, which could hamper cellular 
uptake and/or allow for more efficient uptake by macrophages.[16, 26]  Additionally, 
the NCs need to possess appropriate chemistry in order to form stable dispersions in 
HFA.  For instance, PLGA NCs are not dispersible in HFAs.[23]  Ideally, having a 
common versatile formulation platform for NCs that would serve the needs of both 
DPIs and pMDIs in augmenting the delivery efficiency of NCs to and through the 
lungs would be greatly beneficial in expanding the drug delivery capabilities of both 
the devices, as there are several parameters that govern the patient choice/selection 
of one over the other.[3, 9, 15]. 
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1.3  Polymeric NC candidates for OI delivery of drugs.   
           Two examples of polymeric NCs that may be employed for the delivery of 
drugs via OI are shown in Figure 1.2.  In Figure 2a, an SEM micrograph of polymeric 
(PLGA) NPs (particle nanocarriers or PNPs) prepared by emulsification solvent 
evaporation is shown.  PNPs have been extensively employed as drug and gene 
delivery vehicles.[19, 27]  PNPs protect the payload from premature degradation, 
enhance drug penetration into cells and tissues, and may be designed in order to 
target and controllably release therapeutics.[17, 27]  Additionally, it has been shown 
that certain PNPs can evade the mucociliary clearance, which is a particularly 
relevant barrier present in the respiratory system.[5, 22, 28]  While PNPs have 
several notable advantages that would make them very amenable to local and sub-
cellular delivery of therapeutics, their ability to target the pulmonary epithelia, and to 
translocate into systemic circulation via pulmonary route is just beginning to be 
investigated.[16].  One may expect that the translocation across the highly regulated 
and small tight junctional spaces, and transcellular transport may both be hindered to 
some extent by the large size of PNPs.[29-30]  Additionally, prolonged accumulation 
of PNPs in the nether regions of the lung can lead to unwanted inflammatory 
effects.[31] 
           Other promising candidates for the regional and systemic delivery to and 
through the lungs are dendrimers nanocarriers (DNCs).[32-34]  DNCs are well-
defined, highly branched, nanostructured polymers, with a unique tree-like 
architecture comprising of distinct dendritic arms branching out from a common core.  
The monodispersity in their mass or size confers them with a controlled geometry, 
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with numerous surface groups that can be utilized for chemical modifications for a 
variety of purposes.[35-37]  Figure 1.2b is a pictographic representation of a typical 
dendrimer.  Each branching series is coined a ‘generation’.  Those with terminal 
amine groups are termed full generation (G1,2,3..) dendrimers, and those that are 
carboxylate ended are referred to as ‘half-generation’ (G1.5, 2.5O.).[38]  Their size is 
a function of dendrimer generation, with G3 dendrimers having a size of 
approximately 3 nm.[36, 38]  This controlled geometry and size range is expected to 
be of great relevance when designing NCs that can overcome the mucus and 
epithelial barriers that the lung epithelium poses to drug delivery.  For example, 
macromolecular therapeutics with sizes < 40KDa (5-6 nm in solution) are known to 
be quickly translocated through the lung epithelial cells, with peak circulation in blood 
in a matter of minutes,[39-40] while larger solutes may take days to translocate.  It 
may be expected, therefore, that the transport of DNCs (and thus of therapeutics) 
across the epithelial monolayer may be modulated by controlling their size and 
functionality.  Another example of the potential utility of DNCs is the fact that the 
permeability of PNPs across the mucus layer may be enhanced by the introduction of 
polyethylene glycol (PEG) moieties onto the surface of the PNPs.[41-42]  A similar 
strategy may be easily implemented by functionalization of the many surface groups 
of dendrimers with PEG, in a very well controlled manner (density including). 
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1.4   Physiology of pulmonary epithelium and extracellular barriers to the 
        delivery of drugs to the lungs.     
           The respiratory system consists of two functional parts, the airways (trachea, 
bronchi and bronchioles), and the alveoli (the region of gas exchange), as 
schematically shown in Figure 1.3.  The surface area of the adult human lungs is 
estimated to be between 75 and 140 m2, of which the bulk of the surface area is 
taken up by the alveolar region, which is nearly 100 m2.  The airways are pseudo- 
stratified, comprising of a leakier, gradually thinning columnar epithelium populated 
mainly by mucus and ciliatory cells collectively called the mucociliary escalator.[43-
44]  There are at least six major types of airway epithelial cells, including the basal, 
ciliated, the goblet, serous, granular and Clara cells.  The thickness of the mucus 
layer in lungs under non-pathological circumstances is approximately between 10 
and 30 µm in the airways and between 2 and 5 µm in the bronchial region.  
Respiratory mucus is composed primarily of a three-dimensional network of cross-
linked mucin chains that bestow upon the mucus its viscoelastic properties.[45]   The 
mucus layer offers a barrier to the transport of NCs.  Both the chemistry and size of 
the NCs are known to influence their transport across the  
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mucus layer.[42]  The alveolar epithelium consists of only two major cell types, viz. 
type I and type II.  Type II cells serve as the progenitor for type I cells and produce 
the lung surfactant.[43]  The alveolar epithelium is covered with an extremely thin 
layer of fluid (tens of nanometers) containing a water-insoluble surfactant layer, and 
alveolar macrophages.  This surfactant layer may also work as a barrier to the 
transport of NCs, and the macrophages work in removing foreign particles - with 
preference to micron-sized.  The pulmonary surfactant layer is a thin continuous 
coating of phospholipids and surfactant-associated proteins secreted by type II 
alveolar cells.  The average thickness of this layer ranges between 0.18 µm to 0.89 
µm and their primary function is to reduce tension at the air-water interface thereby 
minimizing the urge of alveoli to collapse.[45] 
 
 
 
Figure 1.3. Diagrammatic illustration of the pulmonary 
epithelium showing various cell types lining its 
vasculature. Image sourced from [1]. 
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1.5    In-vitro models of the pulmonary epithelia.   
            In order to design novel carrier systems for drug delivery to and through the 
lungs, it is essential to understand the interaction of therapeutics and carriers with the 
complex pulmonary physiology.[10]  Such fundamental information can be obtained 
by studying drug uptake, sub cellular localization, and their transport across model 
pulmonary epithelia.[10]  The human bronchial adenocarcinoma cell line Calu-3 has 
been shown to best mimic the human airways in vitro.[6, 10, 46]  When cultured 
under an air-interface (AIC), these cells form confluent monolayers, exhibit tight 
junctional proteins and possess all the relevant morphological features of the airway 
epithelium (mucus, cilia and apical microvilli).[10, 46]  While, Calu-3 cells best mimic 
the airway epithelia, alveolar type-II cells sourced directly from the lungs (animal 
models typically used) through specific lavage techniques offer the best in vitro 
representation of the epithelial cells populating the alveolar region.[6, 10]  Note here 
that A549 cells do not form tight junctions and thus cannot be utilized in transport 
experiments, but may be employed to understand cell uptake mechanisms.  
However, the studies with primary cells fall outside the scope of this work.  Studies 
with primary alveolar epithelial cells are expected to be undertaken by our group in 
the future.  Owing to their increased predictability and higher (and faster) throughput, 
these in vitro approaches are quite attractive, cost effective options when compared 
to in vivo studies.[10, 47-48] 
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Figure 1.4. A schematic representation of in 
vitro transport studies undertaken in this work.  
1.6   Determining the mechanisms of transport and uptake of PNPs, DNCs, and 
        their composites in in-vitro models of the pulmonary epithelium.   
            Although transport of polymeric NCs (PNPs and DNCs) across pulmonary 
epithelia has not been established yet, in pulmonary epithelia in general, it is believed 
that NCs may translocate through an assortment of mechanisms,[43, 49-51] some of 
the most common being illustrated in Figure 1.4.  Previous studies have 
hypothesized that translocation of PNPs (~<200 nm) across model intestinal and 
pulmonary epithelia occurs via a non-specific, size and charge driven caveolae-
mediated or in certain cases receptor mediated mechanism.[50, 52-53]  DNCs, on 
the other hand  
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have been known to traverse through combinations of paracellular and transcellular 
mechanisms across intestinal epithelium.[40, 54]  Their ability to exploit the 
paracellular pathways can be attributed to their small size (which is similar to the 
pores in the tight junctions), and their inherent nature in opening up these junctions 
as evidenced by electrophysiological measurements.[55]  However, little is known 
about transport of DNCs or their composites with PNPs across Calu-3 cells, as earlier 
studies have been performed mostly on intestinal epithelial cells.[51]  In the particular 
case of Calu-3 cells, previous literature has reported a strong correlation between 
permeability coefficients assessed in vitro to those obtained in in vivo lung absorption 
studies in rodents for certain low MW peptides,[56-57] which reinforce the idea that 
Calu-3 is one of the best in vitro cell models for the proposed work. 
Figure 1.4 is a schematic representation of transport studies undertaken in this 
work.  The transport of solutes, and, in our case, of DNCs, across the lung epithelium 
in vitro can be investigated by determining the apparent permeability coefficient (Papp) 
in an experiment as schematically represented in Figure 5.  Papp is determined using 
the equation shown below (1) 
 
                               Papp = F*(1/A*Co)                                              (1.1)           
 
where F is the flux (rate of change in the cumulative mass transported – typically the 
value of slope obtained from a plot of mass transported against time), A is the area of 
the transwell insert, and Co is the initial concentration in the donor chamber (apical 
side). 
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             In a typical experiment, Calu-3 cells of a known cell density are seeded on 
the apical side of Transwell® inserts and grown to confluence.  The monolayer 
confluence can be gauged by recording the increase in transepithelial electrical 
resistance (TEER), and also by staining the monolayers to detect presence of the 
tight junctional protein Zona Occludens-1 (ZO-1).[46]   Alcian blue staining is done to 
assess the presence of mucosal glycoproteins on the monolayer surface.[46]  SEM of 
cell monolayers fixed and stained with Osmium tetroxide (OsO4) is also conducted to 
ascertain morphology of the cultured monolayer.[10, 46]   Transport experiments are 
conducted after the qualitative and quantitative characterization of the monolayer 
confluence.  A known concentration of DNCs (tethered with a fluorophore) and/or 
composites with PNPs dissolved or dispersed (in case of PNPs containing DNCs) in 
1X Hank’s balanced salt solution (HBSS) is pulsed on the apical side on the insert.  
At predetermined time points, samples are removed from the basolateral side and 
analyzed for the transported/translocated conjugates (and NPs) using fluorometry.  
The mass transported across is determined by comparing the fluorescence values to 
a previously prepared calibration curve.  This data is then used in determining the 
flux (F), which is incorporated into equation (1) to calculate the apparent permeability, 
Papp which is a measure of the ease with which moieties traverse the epithelium.[46, 
56]. After transport studies, the cell monolayers are lysed (using 2% Triton-X-100) 
and analyzed for internalized conjugates and NPs in order to quantitatively assess 
the extent of their uptake into Calu-3.   In addition to cell lysis, flow cytometry studies 
is also employed as a means to evaluate the entry of DNCs as a function of time into 
polarized  monolayers of Calu-3 in order to better understand 
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the kinetics of uptake.   It is widely acknowledged that moieties traverse epithelial  
cell monolayers through either paracellular (via the tight junctions) or transcellular 
(through the cells) pathways, or a combination of those (Figure 1.5). 
 
1.7   Relevance, innovation and broader impacts of research. 
           The research undertaken here is innovative in several aspects.  For the first 
time, we report the formulation of PNPs in propellant based formulations.  The 
evaluation of aerosol characteristics of such formulations is also reported here.   The 
ability of PNPs to exclusively target an intracellular bacterium of the lung is also 
evaluated in this work.  The transport and uptake of DNCs across and into model 
airway epithelium, Calu-3 is also undertaken here.   The ability of surface tailored 
DNCs to modulate transport and their uptake across and into polarized monolayers of 
 
Transcellular traversal 
Paracellular traversal 
Tight junctions 
Nanocarriers 
Figure 1.5.  A diagrammatic illustration of transport 
mechanisms occurring across epithelial 
monolayers.  
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Calu-3 and the formulation of DNCs as core-shell micron structures in pMDIs has 
also been evaluated.  These results are highly relevant as utilizing nanocarriers to 
overcome cellular barriers and subsequently transport therapeutics across pulmonary 
epithelia can open up new possibilities of utilizing respiratory tract as a portal to 
target systemic circulation.  The ability to modulate therapeutic transport across such 
epithelia could address the long standing issue of ensuring retention of the drug in 
the airspace for extended periods of time if the target is local milieu or rapidly 
percolate to systemic circulation if the therapeutic is intended for the bloodstream.    
Additionally, the synergy of such versatile nanoscopic vehicles like DNCs with 
compact, portable inhalation devices like pMDIs is expected to greatly enhance their 
applicability by expanding the realm of therapeutics that can be administered utilizing 
such inexpensive inhalers.  
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Chapter 2 
 
The potential for the noninvasive delivery of polymeric nanocarriers using 
propellant-based inhalers in the treatment of Chlamydial respiratory infections 
 
2.1   Introduction 
Besides its non-invasive nature, pulmonary drug delivery has many other 
advantages compared to alternative drug delivery strategies, including a large 
surface area for solute transport, fast drug uptake, and improved drug 
bioavailability.[1-2]  It is, therefore, not surprising that oral inhalation therapy is 
considered not only the preferred mode of administration of drugs to the lungs 
(regional drug delivery), but also as a potential pathway to the blood stream.[1]  
However, the many challenges in formulation development,[3] and little 
understanding of the interactions between the therapeutic molecules and the 
respiratory surfaces has significantly constrained advances in pulmonary drug 
delivery strategies.[4-5]  In this work we integrate aspects of both formulation 
development and therapeutic-tissue interaction.  We propose a strategy to deliver 
polymeric nanocarriers (NCs) to the lungs using propellant-based formulations, and 
to investigate the ability of such carriers to gain access to inclusions of an 
intracellular pathogen (Chlamydia pneumoniae), which is associated with a host of 
chronic and acute lung diseases.[6-7] 
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           One natural (but as will be discussed, non-trivial) step towards the 
development of the next generation of formulations that may help achieve the full 
potential of oral inhalation formulations is to take advantage of the high functionality 
that may be embedded into polymeric nanocarriers (NCs).[8-9]  However, there are 
several issues associated with the delivery of polymeric NCs to the lungs.  
Biocompatibility and clearance are two very important considerations.[8, 10]  A 
stringent aerosol particle size requirement represents another important 
challenge.[11-12]  The delivery efficiency of many traditional aerosol formulations is 
low due to the fact that a large fraction of the particles have aerosol sizes that are too 
large (> ~ 5µm), and are thus retained in the mouth and throat to reach in the 
digestive tract rather than lungs.  In contrast, aerosol particles that are too small (< 
0.4 µm, which is within the range of typical polymeric NCs described in the literature) 
are also expected to have very low deposition efficiency.[11] 
           Several approaches have been suggested in order to address the issues 
related to the aerosol size of polymeric NCs for oral inhalation formulations.  
However, most studies have focused on dry powder inhalers (DPIs) and 
nebulizers.[10, 13-14]  While the formulation of nanoscale active pharmaceutical 
ingredients in pressurized metered-dose inhalers (pMDIs) has been documented in 
the literature,[15-16] to the best of our knowledge, there has been no previous study 
on the formulation of polymeric NCs in propellant-based inhalation devices.[17-18] 
pMDIs are of great technological relevance as they are the least expensive oral 
inhalation devices.[2]  Moreover, they are portable, easy to use and have high 
compliance, making pMDIs the most widely used devices for administration of 
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therapeutics to the pulmonary tract.[2]  Compared to DPIs and nebulizers, however, 
there is yet an additional challenge in the development of polymeric NC-based 
pMDIs: it has been shown to be difficult to stabilize particle dispersions in the low 
dielectric hydrofluoroalkane (HFA) propellants.[3, 19]  The particles for pMDIs thus 
need not only to be within the desired size range, but must also have an appropriate 
surface chemistry – one that is well solvated by the propellant so as to prevent 
particle aggregation, which may otherwise negatively impact the aerosol 
characteristics of the formulation.[19-21] 
           Based on this rationale, we propose in this work to develop a core-shell 
formulation which facilitates the delivery of polymeric NCs using pMDIs.  Our 
approach consists of entrapping NCs within micron-sized particles whose shell is 
designed to be well-solvated by the propellant, and thus to provide adequate physical 
stability to the formulation, and consequently good aerosol characteristics.[19, 22]  A 
suitable particle engineering technology that allows for easy control of the particle 
size was devised to prepare the core-shell particles containing the polymeric NCs.  
The shell is also designed with two key features: (1) to maintain the integrity of the 
construct while dispersed in the propellant (shell is insoluble in the propellant), and 
(2) to break down when in contact with an aqueous fluid (shell is soluble in 
water).[19]  The aqueous solubility is an important design consideration.  The micron-
sized particles containing the NCs need to disintegrate into its separate constituents 
(shell and NCs) in order to efficiently evade the immune system.  Macrophages in the 
alveolar region are known to quickly engulf micron-sized particles.[23]  If the target 
region is the upper airways instead of the alveolar region, it is also desirable to 
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quickly release the NCs as particles in the sub-micron-nano range are expected to 
have better penetration in the mucus layer, and will thus be more likely to reach the 
underlying epithelial layer.[24]  The aqueous solubility, biodegradability and low 
molecular weight of the shell are also important design considerations when selecting 
the appropriate chemistry of the polymer shell as the residence time of the polymer in 
the lungs needs to be minimized, and its biodegradation accelerated.[14] 
           Chlamydia pneumoniae (C. pneumoniae) is an obligate intracellular bacterium 
that is associated with a broad spectrum of acute and chronic diseases.[25] C. 
pneumoniae is a common cause of upper and lower respiratory tract infections in 
humans (all age groups), and is one of the leading causes of community–acquired 
pneumonia.  It has been also recently linked to neutrophilic allergic airway disease, a 
rare form of asthma characterized by neutrophilic inflammation.[7]  C. pneumoniae-
related infections have been associated with asthma exacerbations, and are 
considered an important cofactor in chronic airway inflammation.[6] 
           All Chlamydiae, including C. pneumoniae, undergo an unusual biphasic 
developmental cycle, which is of great relevance when considering the design of 
novel drug delivery strategies.[26]  After the attachment of the infectious form of the 
organism (elementary body, EB) onto the host cells, EBs reside within a vacuole 
termed an inclusion, and subsequently develop into the non-infectious, metabolically 
active form called the reticulate body (RB).  Reinfection occurs after RBs 
dedifferentiate back to EBs and are released back into the tissue milieu by host cell 
lysis.  Importantly, C. pneumoniae, along with other chlamydial strains, can enter a 
persistent state which can give rise to diseases like arthritis and asthma.[26-27] 
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           Despite proven effectiveness of certain antibiotics (currently having oral or 
parenteral administration regimens[27]) to treat primary chlamydial infections, in 
certain cases, the infection may become persistent owing to a combination of factors 
ranging from metabolic refractivity to treatment, reinfection, and/or inaccessibility of 
the antibiotic to the region of infection.[27-28]  The ability to target the inclusion 
membrane, where chlamydial development, replication and dedifferentiation take 
place, may offer new opportunities to overcome not only primary infections, but also 
persistent infections, which have been linked to other medically relevant diseases 
including atherosclerosis, neurological disease, and inflammatory arthritis.[29-33] 
           Polymeric NCs may offer an opportunity to target chlamydial organism within 
the inclusions, as NCs have been shown to be excellent intracellular carriers, and 
can be tailored to encapsulate a variety of therapeutics including 
biomacromolecules.[8]  Compared to free drugs, polymeric NCs have several other 
advantages including improved drug bioavailability, high carrier capacity, the ability to 
release the payload in a controlled manner and to adapt to different routes of 
administration,[13] and to concentrate in inflammatory and infectious sites by virtue of 
their enhanced permeability and retention.[8]  Conjugating NCs with specific moieties 
has also been shown to enhance their targeting to specific cells and tissues.[8, 34]  
The delivery of polymeric NCs to the respiratory tract is, therefore, a promising 
strategy in the treatment of pulmonary infections caused by C. pneumoniae,[35] as 
well as a range of other pulmonary disorders including cystic fibrosis and lung 
cancer.[8, 36] 
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           Based on this rationale, the aim of this work is to develop a pMDI-based 
platform capable of efficiently delivering polymeric NCs to the lungs, and to 
demonstrate the potential of the formulation in the treatment of a medically relevant 
disease (C. pneumoniae-related infections).  More specifically, we sought to test the 
ability of those NCs to target Chlamydial inclusions in airway epithelial cells in vitro.  
In what follows, we describe (i) the synthesis of the NCs with a fluorescent marker 
that allows us to follow the fate of the NCs in vitro; (ii) the engineering of micron-
sized, core-shell particles that provides for a means of encapsulating the NCs onto 
particles with suitable sizes for oral inhalation delivery and with enhanced physical 
stability in HFA propellants; (iii) the aerosol characteristics of the corresponding NC-
based pMDI formulations; and (iv) the ability of those formulations to target 
chlamydial inclusion membranes in airway epithelial cells. 
 
2.2   Materials  
Poly(d,l-lactide-co-glycolide) (PLGA, 50:50, MW 31.3 - 45.0 K) was purchased 
from Birmingham Polymers.  Poly-vinyl alcohol (PVA), 6-Coumarin (98%) and Tin(II) 
2-ethylhexanoate (95%) were purchased from Sigma.  Chitosan (CS, medium 
molecular weight) was purchased from Aldrich Chemicals Ltd.  D,L-lactide was 
obtained from Frinton Laboratories Inc., and was recrystallized twice from ethyl 
acetate.  2H,3H perfluoropentane (HPFP, Vertrel XF, > 99.5% purity) was kindly 
provided by TMC industries.  1,1,1,2,3,3,3-heptafluoropropane (HFA227, Dymel, 
pharmaceutical grade, purity > 99%) was a gift from Dupont Inc.  Pressure proof 
glass vials (6800318) were purchased from West Pharmaceutical Services.  The 
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metering valves (EPDM Spraymiser) were a gift from 3M.  Actuators from Ventolin 
HFA® (Glaxo Smithkline) were used for cascade impaction studies.  Deionized (DI) 
water (Nanopure Barnstead) with a resistivity of 18 MΩcm-1 was used in all 
experiments.  All other chemicals were obtained from Fisher and were of analytical 
grade. 
 
 2.3   Methods 
2.3.1 Preparation and morphological characterization of the 6-Coumarin- 
          loaded PLGA NCs. 
  Poly(d,l-lactide-co-glycolide) (PLGA) NCs were prepared by an emulsion 
solvent evaporation technique previously described in the literature.[37]  Briefly, a 1 
ml polymer solution (100 mg PLGA in 1 ml chloroform) containing a known 
concentration of 6-Coumarin (120 µg) was emulsified in a 2 % (w/v) poly(vinyl 
alcohol) (PVA) aqueous solution (5 ml) with the help of a sonicating probe (Omni 
Ruptor 250, Omni international Inc.) set to 55 W, for a period of 3 minutes.  The 
resulting oil-in-water emulsion was stirred overnight.  The organic phase evaporates, 
thus forming the dye-laden NC dispersion in water.  The NCs were recovered by 
centrifugation (13000 rpm for 60 minutes at 4 °C, Thermo Fisher Sorvall Legend 
X1R), and then washed repeatedly with DI water to remove residual PVA.  The NCs 
were subsequently lyophilized, and their morphology confirmed by scanning electron 
microscopy (SEM, Hitachi S-2400).  Several drops of an aqueous dispersion of the 
NCs were transferred onto a cover glass slide (18 mm2, Corning Inc.) and allowed to 
dry.  The substrates were then sputter-coated with gold (Ernest Fullam) for 30s, and 
36 
 
 
 
SEM micrographs taken at 22 kV.  The size of the PLGA NCs after lyophilization was 
determined by dynamic light scattering (DLS, ZetaPlus, Brookhaven Instruments, 
Holtsville, NY). 
 
2.3.2 Preparation and morphological characterization of the core-shell 
         particles containing the PLGA NCs. 
Core-shell particles with a shell composed of oligo(lactide)-grafted-chitosan 
(LA-g-CS) co-oligomer and a core comprising of dye loaded PLGA NCs were 
prepared by a modified emulsification diffusion technique.[19]  Medium molecular 
weight CS was degraded in presence of hydrogen peroxide to 1,400 Da as 
determined by size exclusion chromatography (Shimadzu LC-10ADVP), with a static 
light scattering detector and differential refractometer (BIMWA, BIDNDC, from 
Brookhaven).  Known amounts of degraded CS and DL-lactide were charged into a 
dry vessel containing toluene.  The contents were dispersed, and then made to react 
over an oil bath at a temperature of 110 °C in presence of tin (II) 2-ethylhexanoate for 
over 48 hours.  The final product obtained was repeatedly washed with acetone, 
centrifuged, dried using a light stream of air, and stored in a desiccator.  The 
copolymer obtained was characterized by NMR.  The LA grafting ratio onto the CS 
was calculated to be 108% based on the weight difference before and after grafting 
as reported previously.[19]  The procedure for encapsulating the NCs consisted of 
dissolving 25 mg of LA-g-CS in 0.9 ml DI water.  Subsequently, 35 mg of dye-loaded 
PLGA NCs were added to the same solution, and the contents were dispersed gently 
using a sonicating probe.  Once dispersed, the aqueous phase was emulsified into 
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19 ml ethyl acetate in a sonicating bath (VWR P250D, set to 180 W for 15 min).  The 
water-in-oil emulsion thus formed was transferred into a round bottom flask 
containing a larger volume of ethyl acetate (200 ml).  Due to the high solubility of 
water in ethyl acetate, the water that makes the dispersed emulsion phase diffuses 
out (similar to the solvent evaporation method) into the bulk phase, resulting in the 
formation of core-shell particles, as the interfacially active co-oligomer remains at the 
interface.  The core-shell particles were collected by centrifugation and their 
morphology confirmed by SEM, TEM, and fluorescence microscopy.  A small amount 
of the core-shell particles was dispersed in the model propellant (HPFP).  Some 
drops of the dispersion were then transferred onto glass slides and dried.  For SEM 
studies, the substrate was sputter coated as described earlier. For the fluorescence 
microscopy studies, the glass slides were directly observed under a fluorescence 
microscope (Nikon Diaphot 300, USA).  For TEM analysis, the particle dispersion in 
HPFP was deposited onto a 200-mesh copper grid and observed at 200 kV.  For DLS 
measurements, an appropriate mass (5 mg) of freshly prepared core-shell particles 
was dissolved in a known volume (3 mL) of serum-free culture media or DI water.  
The resulting NC dispersion was gently dispersed using a probe sonicator 
(OmniRuptor 250) and analyzed immediately using Zetasizer™ (Nano, Malvern 
Instruments) to determine the size of the NCs released from the oligomeric shell.  
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2.3.3 Loading of the NCs onto the LA-g-CS core-shell particles, and total  
         6-coumarin content. 
In order to determine the loading of the PLGA NCs onto the core-shell 
particles, a simple gravimetric technique was employed.  Briefly, a known mass of the 
core-shell particles was initially loaded in a known volume of DI water.  As the LA-g-
CS co-oligomer is soluble in water, the PLGA NCs were immediately released, and 
dispersed into the continuous phase.  After the complete dissolution of the shell, a 
known volume of chloroform was added to the aqueous phase and the mixture was 
then transferred to a separating funnel and shaken vigorously to speed the 
dissolution of the polymer into the organic phase.  While PLGA and 6-Coumarin are 
highly soluble in chloroform, the LA-g-CS shell is not.  The organic phase was then 
carefully collected onto pre-weighed aluminum pans, evaporated, and weighed.  The 
difference in the mass of the aluminum pans after evaporation of the solvent is the 
mass of the PLGA NCs.  Based on the total mass added to the aqueous phase and 
the mass of the NCs, the loading of the NCs into the LA-g-CS particles was 
determined.  Subsequently, the 6-Coumarin content in the NCs was determined by 
extracting the dye from the polymer by soaking in methanol which is a good solvent 
for only the dye, for 12 hours.  The methanol extract was filtered (0.45 µm, VWR), 
and analyzed for levels of 6-Coumarin using high performance liquid chromatography 
(HPLC), with a reverse phase C18 column (100×3.5 µm, Waters).  A fluorescence 
detector (Waters, Model 2475) set at an excitation wavelength of  450 nm and 
emission wavelength of 490 nm was used to quantify the levels of 6-Coumarin in the 
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extract by comparison to a standard curve.  The experiments were performed in 
triplicate. 
 
2.3.4 Calu-3 cell culture and infection with C. pneumoniae. 
Calu-3 cells were purchased from ATCC (ATCC#: HTB-55; Manassas, VA).  
The cells (passage 20-24) were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS, Atlanta Biologicals, 
Lawrenceville, GA), 0.02% (100 µl) gentamycin (Sigma) and 200 mM of 10 mL (2%) 
100X L-glutamine (Sigma). C. pneumoniae (strain AR-39) was cultured as described 
earlier.[38]  Calu-3 cells were seeded onto two well chamber slides (NUNC, 
Rochester, NY) at a density of 1×106 cells per chamber, and allowed to attach for 
about 6 hours prior to infection.  The growth medium was aspirated from the 
chambers and the cells in one of the chambers were infected with C. pneumoniae at 
a multiplicity of infection (MOI) of ~5 (5×106 inclusion forming units (IFU).  The cells in 
other chamber were left uninfected as control.  The cells were then incubated at 35 
°C for one hour with gentle rocking of the chamber slides every 15 minutes in order 
to distribute the inoculum evenly on the cells, and to facilitate attachment and uptake 
of the IFUs.  The inoculum was aspirated, and the cells were incubated at 35 °C in a 
freshly prepared growth medium supplemented with 1 µgml-1 cycloheximide (Sigma) 
for 72 hours.  Infected and uninfected cells were fixed with absolute methanol and 
stained with Pathfinder FITC-labeled anti-chlamydial LPS antibody (Bio-Rad, 
Redmond, WA) and observed under a fluorescent microscope (Nikon E600) to 
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determine the level of infectivity.  Images of the infected cells and cell clusters were 
captured using ImagePro Plus (Media Cybernetics, Bethesda, USA). 
 
2.3.5 Pulsing of the infected cells with the core-shell particles and PLGA NCs. 
Infected cells were pulsed with both the dye-loaded PLGA NCs, and the LA-g-
CS core-shell particles containing the dye-loaded PLGA NCs.  Pulsing was carried 
out at 72 hours post infection (hpi) when inclusions were approaching maximum size.  
Both infected and the uninfected (control) cells in the respective two chambers were 
pulsed.  In a typical experiment, a known concentration (0.600 mgml-1 of core-shell 
particles containing the dye-loaded NCs, or 0.25 mgml-1 of PLGA NCs alone) of 
freshly prepared particles were dispersed in serum-free culture media with the help of 
a sonicating bath.  In the case of the core-shell particles, this process results in the 
immediate release of the NC, as the co-oligomer is water-soluble.  The medium 
containing the particles (0.5 ml) was then added to the chamber slides.  The total 
volume of each chamber was maintained at 1 ml for the duration of all experiments.  
The cells were then incubated at 35 °C for up to 3 hours post pulsing (hpp).  
 
2.3.6 Imaging of the Calu-3 cells post-infection and post–particle pulsing. 
Imaging of the infected cells pulsed with the NCs were performed using 
fluorescence and confocal microscopy.  The fluorescence microscopy procedure for 
the infected cells pulsed with NCs involved 4 sets of two chamber slides (a total of 
eight chambers).  Out of the 8 chambers, 4 were infected with C. pneumoniae, and 
four of the chambers were uninfected.  All of the chambers were prepared at the 
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same time to ensure consistency.  Among the four infected chambers, two were 
pulsed with core-shell particles and two with dye loaded NCs in the absence of LA-g-
CS shell.  The remaining four chambers that were uninfected also received the same 
concentration of both types of particles and served as controls.  Cells in the 
respective chambers were observed at 15 minutes (0.25 hours) and 3 hours post 
pulsing (hpp).  Chamber slides intended for fluorescence microscopy were washed 
twice with PBS, fixed with 4% paraformaldehyde, and counterstained with Evans’ 
Blue (Sigma) prior to imaging. 
           Confocal microscopy was also performed on another set of Calu-3 cells that 
were similarly infected with C. pneumoniae and pulsed with the particles as described 
above.  Cells were fixed with 4% paraformaldehyde in PBS, and counter staining with 
Evan’s Blue.  The confocal imaging system consisted of a conventional fluorescent 
microscope with a Zeiss Axiophot Triple-Camera Photomicroscope and the Zeiss live 
cell imaging microscope with Apotome module capable of four dimensional imaging 
(and 3D in time).  Stacks of 0.7 µm were analyzed axially for 6-Coumarin 
fluorescence.  Confocal images were then quantified for their fluorescence intensity 
using the Metamorph Software (Molecular devices, CA). 
 
2.3.7 Physical stability of PLGA NC-loaded core-shell particles in propellant 
         HFAs. 
A known mass of the core-shell particles containing the dye-loaded PLGA NCs 
was added to pressure proof vials and crimp-sealed using 50 µl metering valves.  A 
known volume of the propellant HFA227 was then pressure-filled into the vials with 
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the aid of a manual syringe pump (HiP 50-6-15) and a home-made pressure filler, 
such that the concentration of the core-shell particles in the system was 2 mgml-1.  
The formulation was then subjected to gentle sonication in a low energy sonicating 
bath (VWR, P250D, set to 180 W) in order to break down any large aggregates.  
Digital images of the dispersed formulations as a function of the dispersion age (time 
after initial sonication had been stopped) were used as a qualitative measure of the 
physical stability of the dispersion.  HFA227 formulations containing 2 mgml-1 and 
0.2 mgml-1 PLGA NCs alone, without being formulated in the core-shell particles, 
were also prepared as described above in order to directly compare the quality of the 
dispersion to that with the LA-g-CS shell chemistry. 
 
2.3.8  Aerodynamic characteristics of the formulations. 
           An Anderson Cascade Impactor (ACI, CroPharm Inc.) was used to 
quantitatively assess the aerosol characteristics of the core-shell formulations in the 
propellant HFA227.  The ACI was fitted with an USP induction port and was operated 
at a standard flow rate of 28.3 lmin-1.  Experiments were carried out at 298 K and 
45% relative humidity.  Prior to running the experiment, several shots of the 
formulations were fired to waste.  A commercial actuator (Ventolin HFA®, Glaxo 
Smithkline) was used in all runs.  Shots (a total of 20) with an interval of 10 seconds 
per actuation were fired into the ACI.  The experiments were conducted in triplicate 
(with three independent formulations/canister), and the average of the three runs and 
their standard deviation are reported here.  After each experiment, the apparatus was 
disassembled and each of the stages, along with the actuator and the induction port 
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of the ACI, were thoroughly washed with a known volume of methanol and collected 
separately.  The 6-Coumarin content of the particles was assessed as described 
earlier.  Based on the analysis of the total 6-Coumarin loading onto the core-shell 
particles, we can thus determine the mass of both the PLGA and the LA-g-CS shell 
particles on each stage.  The results are calculated as mass and as percentages.  
The fine particle fraction (FPF), mass median aerosol diameter (MMAD) and 
geometric standard deviation (GSD) were determined from the aerosol studies.  The 
FPF is defined as the percentage of particles on the respirable stages of the impactor 
(stages 3 to terminal filter) over the total particle content (IP to the filter).  Respirable 
fraction (RF) is defined as the percentage of particles on stages 1 to filter, over the 
total particle content.  MMAD is determined by plotting the aerosol particle size vs. 
cumulative percentage less than the size range on a log-probability scale, and 
interpolating for the value at 50 wt% of the aerosol size distribution.  GSD is defined 
as the square root of the ratio of 84.13% over 15.87% particle size distribution from 
the same plot used to obtain MMAD, and it is a measure of the particle size 
distribution.[22]  The single puff dose is obtained by dividing the total mass of the 
formulation fired from each canister to the total number of puffs fired during each run, 
which in this case was 20.  Canisters of dye-loaded PLGA NCs, at a concentration of 
0.2 mgml-1 in propellant, were also prepared.  This concentration was used (instead 
of 2 mgml-1 as core-shell particles), as it corresponds to the concentration of NCs in 
2 mgml-1 core-shell particles.  The aerosol characteristics of these formulations were 
determined using the same procedure as described earlier for the core-shell 
particles. 
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2.4   Results and Discussion 
 
2.4.1 Characterization of the dye-laden PLGA NCs. 
PLGA was chosen as the model polymer to prepare the NCs in this work due 
to its biodegradability, aqueous dispersibility, and its ability to traffic into the cell 
cytosol with relative ease.[39]  Another important property of PLGA-based NCs is 
their ability to sustain the release of therapeutic agents.[37, 39]  This is particularly 
useful in delivering antibiotics and other drugs to tissues where persistent infections 
may exist (as is the case of chlamydial infections).  It has also been shown that 
PLGA NCs delivered intratracheally to mice invoke least inflammation in the lung 
when compared to other chemistries, indicating the benign nature of the polymer in 
vivo.[40] 
           PLGA NCs were prepared by emulsification solvent-evaporation as described 
above.  The NCs were loaded with a fluorescent dye, 6-Coumarin, thus providing for 
a means to follow the localization of the PLGA NCs in the lung airway epithelial Calu-
3 cells.  
 The loading of the dye also demonstrates the ability to encapsulate 
hydrophobic solutes as a potential payload into the PLGA NCs.  The NCs were 
characterized for their size and shape using DLS and SEM, and the results are as 
shown in Figure 2.1.    
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The results indicate the formation of spherical and slightly polydisperse 
particles as expected,[37] with an average diameter of 241 ± 4.7 nm, and a 
polydispersity of 0.13. 
 
2.4.2   Characterization of core-shell particles containing dye-laden PLGA NCs. 
2.4.2a Particle size and morphology. 
           Core-shell particles containing the NCs and an interfacially active co-oligomer 
as the shell were prepared by a modified emulsification-diffusion methodology, as 
previously described by our group.[19]  The central idea of the methodology is that 
an aqueous phase containing the co-oligomer and the solute of interest is first 
emulsified into an organic phase in which water has a considerable solubility.  As the 
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Diameter 
1 µm 
Figure 2.1. Size and morphology of the PLGA NCs as 
determined by dynamic light scattering (DLS) and (inset) 
scanning electron microscopy (SEM). 
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emulsion thus formed is diluted into a larger volume of the organic solvent, the water 
is forced to diffuse out from within the emulsion droplet core and into the continuous 
(organic) phase, causing super saturation of the solute, which leads to nucleation 
and growth of the core, templated by the spherical emulsion droplet.  As the co-
oligomer is interfacially active, it remains at the water-organic interface (of the 
emulsion droplet) during the process.  The co-oligomer, therefore, becomes the 
particle shell.  The outer most portion of the shell (LA) has been designed to be well-
solvated by HFA, and thus to enhance the dispersibility of the particles in the 
propellant.[19, 41]  In the present study, we extend this methodology for the 
encapsulation of water-dispersible particles.  The dye laden PLGA NCs were loaded 
within the core of the LA-g-CS co-oligomer using the same methodology as 
described above, except that the NCs were dispersed in water instead of the drug 
(aqueous solution), as described in the Materials and Methods section.  SEM 
micrographs shown in Figure 2.2 were obtained to confirm the morphology of the 
particles. 
The particles are spherical and polydisperse in nature, with sizes ranging from 
approximately 0.5 µm to 4 µm.  This size range is expected to be appropriate for the 
delivery of particles to the lungs, as they tend to have improved pulmonary 
penetration – the actual average aerodynamic size will be determined as discussed 
later.  The aerosol size can be optimized to target particular region of the lungs, as 
the size and the polydispersity of the particles obtained using such methodology can 
be tuned by varying processing parameters of the emulsification-diffusion 
technique.[19] 
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 A closer examination of the SEM micrographs also indicates the presence of 
some free NCs that were not encapsulated, and some nestled on the surface of the 
polymeric shell.  Some of the PLGA NCs are expected to become trapped at the oil-
water interface during the emulsification diffusion process.  While they are not 
necessarily interfacially active, once adsorbed, the adsorption energy of the particles 
is very high, and they remain attached at the interface.  The adsorption of particles at 
Figure 2.2.  SEM micrographs of the LA-g-CS core-shell particles containing 
the PLGA NCs.  The particles were prepared by the emulsification diffusion, 
at 298 K.  Inset: a high magnification image of the core-shell particles 
showing the corrugated morphology of the particle surface.  The arrows in 
the inset show NCs trapped at the particle surface.  The arrow in main 
micrograph shows a NC that was not encapsulated. 
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the oil-water interface is a well-established emulsion stabilization process, giving rise 
to the so-called Pickering emulsions.[42] 
 
 
 
 
 
 
 
 
 
  
 
 
 
The fluorescent image and TEM micrograph shown in Figure 2.3 and inset, 
respectively, further confirm the encapsulation of the NCs in the core-shell 
morphology as suggested by the fluorescent green micron particles (from the dye 
encapsulated within the NCs), and further by the observation of nanoparticles within 
the micron particles as revealed by the regions with different contrast inside the 
micron particle detailed in the TEM image. 
 The integrity of the NCs after encapsulation within the core-shell particles was 
also evaluated, by determining the size of the NCs before and after the formation of 
10 µm 
100 nm 
Figure 2.3.  Fluorescent field microscope image of the core-shell 
particles containing the fluorescent green dye-laden NCs.  (Inset) TEM 
image of a core-shell particle. 
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the core-shell particles via DLS.  The experiment consisted in adding the core-shell 
particles to either DI water or DMEM (serum-free), and measuring the size of the 
particles in those media so to compare to the results before encapsulation.  DLS 
results show that the size of the NCs remained the same before and after the 
encapsulation within the core-shell particles, indicating that there is no aggregation of 
the NCs, and that the shell breaks down immediately in both water and DMEM, as no 
micron-sized particles could be observed. 
 
2.4.2b Loading of the PLGA NCs within the core of the LA-g-CS microparticles. 
           The loading of the PLGA NCs within the core-shell particles was determined 
gravimetrically, using the solvent extraction technique as described above.  A known 
mass of freshly prepared core-shell particles was dissolved completely in water, thus 
releasing the NCs entrapped within the core, as the oligomer is water soluble.  A 
specific volume of chloroform was added to this aqueous phase and the system 
mixed for several minutes and then allowed to equilibrate.  Since PLGA and 6-
Coumarin are both soluble in chloroform (the co-oligomer is not), this step will ensure 
the complete dissolution of those components into the organic phase.  This 
experiment was repeated in triplicate.  The loading of NCs entrapped within the core-
shell particles was determined to be 10.5 ± 2.1%.  The contents were then 
resolubilized in chloroform and then subjected to HPLC analysis to determine the 6-
Coumarin content.  The results revealed a loading of 0.08 ± 0.02% in weight (to that 
of PLGA). 
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2.4.3 Infection of Calu-3, a Model of the Airway Epithelial Cells, with C. 
         pneumoniae. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calu-3 cells were infected with C. pneumoniae as detailed above.  Figure 2.4 
is a set of fluorescent microscope images at different magnifications which indicate 
the successful infection of the Calu-3 cells.  The infection was confirmed by staining 
the cells with FITC-labeled anti-chlamydial lipopolysaccharide antibody, which 
detects the presence of Chlamydiae in inclusions.  The images shown in Figure 2.4 
were obtained at 72 hpi, and they clearly illustrate high levels of infectivity. 
 
 
(b) (a) 
Figure 2.4.  Fluorescence microscopy images of Calu-3 cells infected with 
Chlamydia pneumoniae captured 72 hours post infection (hpi) at a MOI of 5.  
The inclusions are seen in green and some have been selected (denoted by the 
white arrows).  The cells were fixed with methanol and stained with Chlamydia 
Pathfinder antibody (green).  The original images were obtained at 40x (left)  
and 100x (right) magnification  
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2.4.4 Pulsing and imaging of C. pneumoniae infected Calu-3 cells. 
After infection with C. pneumoniae, the Calu-3 cells were then pulsed (at 72 
hpi) with either the core-shell particles containing the dye-loaded NCs, or the dye-
loaded PLGA NCs alone.  Core-shell particles containing the NCs and bare dye-
laden NCs were pulsed onto Calu-3 monolayers at concentrations of 0.6 mgml-1 and 
0.25 mgml-1, respectively.  Core-shell particles were pulsed at the aforementioned 
concentration as it was found to be non-cytotoxic.  Cellular ATP levels (MTS assay) 
reveal that core-shell particles within the concentration range of from 0.1 to 6 mgml-1 
are non-cytotoxic to Calu-3 cells.  The concentration of NCs was chosen based on 
concentration ranges previously studied to interpret cellular internalization.[37, 43] 
           As a negative control, additional wells of uninfected Calu-3 cells were also 
pulsed with both types of particles.  C. pneumoniae inclusions are slow to develop 
and take about 72-96 hours to completely differentiate to new EBs.[44]  Hence the 
experiments performed on C. pneumoniae-infected cells were performed at 72 hours 
after infection.  Calu-3 cells were chosen for this purpose as they best represent the 
airway epithelium.[5]  Moreover, Calu-3 cells were shown to internalize particles of 
various chemistries supporting the applicability of this particular cell line for our 
study.[45] 
 
 
 
            
 
52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The intracellular localization of the NCs pulsed onto the infected cells was 
monitored under a fluorescent microscope after pulsed cells were fixed with 4% 
paraformaldehyde and counterstained with Evans Blue.  The results at 3 hpp are 
summarized in Figure 2.5 for the NC pulsed as core-shell particle system (Figure 
2.5a) and for the bare NCs (Figure 2.5b).  NCs are observed to be not only within the 
(a) (b) 
10 µm 
10 µm 
10 µm 
Figure 2.5.  Fluorescent microscopy images of Calu-3 cells infected with 
C.pneumoniae and pulsed with (a) NC-laden core-shell particles, and (b) bare 
NCs.  The images were captured using a 40X magnification 72 hours post 
infection (hpi) and 3 hours post pulsing (hpp).  White arrows in the images 
indicate the location of inclusions within the cytosol.  The increased fluorescence 
intensity in (b) is indicative of the higher concentration of NCs when cells were 
pulsed alone (250 µg) compared to the concentration of NCs in cells that were 
pulsed with NCs encapsulated in the core-shell particles (600 µg).  (inset) 100X 
fluorescent field image evidencing the presence of NC (released from the core-
shell particles) within an inclusion. 
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cell cytosol, but also concentrated in the inclusion.  Selected inclusions containing 
NCs are indicated by white arrows. 
           Figure 2.5 indicates that NCs in the core-shell particles and the bare NCs 
were readily internalized by the cells, presumably by fluid phase endocytosis.  The 
images also suggest that the NCs are capable of not only entering the cell cytosol, 
but also readily gain access to the chlamydial inclusions.  The internalization of the 
NCs in non-infected cells was also fast, and observed for both NC alone and NC 
within core-shell particle formulations.  Similar results were observed for repeat 
experiements with other batches of NCs with similar sizes, and with Calu-3 cells 
infected with another chlamydial strain (Chlamydia trachomatis). 
           The strong and localized intracellular fluorescence can be attributed to the 
presence of the (dye loaded) NCs which entered the cells and concentrated in the 
inclusions.  The concentration of free dye is expected to be very small at such short 
times (3hs), as less than 1% leaches out of the NCs after a 24 hour incubation period 
in physiological buffer (PBS, pH 7.4) at 37°C.[37]  This is an important finding and 
suggests the ability of the NCs to gain entry into the chlamydial inclusion can be 
exploited for delivering drugs and therapeutics to sites of this bacterial infection in the 
lungs. 
Cells traffic NCs through a multitude of mechanisms that vary with cell types. 
[13, 43, 46] Some of the salient ones include phagocytosis and endocytosis (either 
fluid phase or receptor mediated).[39, 43]  Most epithelial cell lines have been shown 
to internalize NCs through an endocytic pathway.[43]  This was observed in the case 
of two prominent airway epithelial cell lines.[43, 47]  Although the rate and the extent 
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of uptake can vary, a similar endocytic route can be suggested as a possible route of 
uptake for Calu-3 as well.  While we report the results obtained at 3 hpp, it is worth 
mentioning that the NCs (both bare and from the core-shell ensemble) gained 
access to the cell cytosol within minutes after pulsing (images not shown) both 
infected and uninfected cells.  These results corroborate previous studies that 
suggest that such rapid NP uptake occurs through an endocytic pathway.[37, 43] 
To unambiguously confirm the uptake of the NCs into chlamydial inclusions, 
sections of confocal micrographs of Calu-3 cells infected with C. pneumoniae and 
pulsed with NCs and core-shell particle containing NCs were analyzed.  The results 
are summarized in Figures 2.6(a) and (b).  Inclusions within the cells were selected, 
and the fluorescence intensity of the planes across the inclusion was recorded.  The 
bar graphs insets represent fluorescence intensities normalized by the area being 
observed (area increases towards the equatorial region of the inclusion).  Images of 
selected planes are shown below the plots.  Figure 2.6a represents cells pulsed with 
the core-shell particles containing the NCs and Figure 2.6b depicts the results for 
bare NCs. 
 The quantitative results from the confocal images (fluorescence intensity) 
corroborate the qualitative information obtained from the fluorescence micrographs 
(Figure 2.5).   
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They show that the NCs are located not only within the cytoplasm, but clearly 
gain access and concentrate within the inclusion as well – the inset with normalized 
intensity as the planes cross the inclusion show strong intensity at all planes inside 
the inclusion.  The difference in the fluorescence intensities between the two 
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Figure 2.6. Fluorescence intensity (a.u.) from selected chlamydial 
inclusions vs. plane number across the inclusion obtained from confocal 
micrographs of Calu-3 cells infected with C. pneumoniae (72 hpi) and 3 
hours post pulsing (3 hpp) captured at 40X magnification with (a) PLGA 
NCs formulated within core-shell particles, and (b) bare PLGA NCs.  The 
sets of images shown below the plots represent different planes across 
the selected inclusion.  The inset plots are the fluorescence intensities 
normalized with respect to the threshold area. 
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systems (bare NCs vs. NCs within core-shell particles) can be attributed to lower 
concentration of the NCs pulsed along the core-shell particles compared to the NCs 
alone. 
           One can speculate on the mechanism of access of the NCs onto the 
inclusions based on how such negatively charged particles gain access into the cell 
cytoplasm.  As mentioned earlier, the internalization of PLGA NCs into the cell 
cytosol occurs through an endocytic pathway where the primary endosomes traffic 
the NCs and direct them to a sorting compartment (sorting endosomes) from where 
most NCs are transferred to secondary endosomes.  Under normal circumstances, 
these secondary endosomes will merge with lysosomes to form endo-lysosomes.[37, 
39]  However, chlamydiae inhibit phagosome/lysosome fusion and this may account 
for the observed concentration of NCs in the inclusions, as they do not proceed 
further in the endocytic pathway.[48-49]  It is also important to note that the NCs did 
not gain access to the cell nuclei in neither infected nor uninfected cells, as desired, 
since the target here are the inclusions.  While the details of the internalization 
mechanism, and the fate of the internalized NCs fall outside the scope of this work, 
such studies could help shine light into the effect of several important parameter 
such as NC chemistry and size.[37, 43, 50]  
           This unique characteristic of the NCs can be exploited as a tool for delivering 
therapeutics through the respiratory tract to treat local and systemic disorders 
including chlamydial infections.  However, this can only be accomplished if such NCs 
can be formulated in oral inhalation delivery devices, and efficiently delivered to the 
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lungs.  In the next sections we discuss how this can be achieved using the 
inexpensive and widely used pMDIs. 
 
2.4.5.  Dispersion stability of NC-laden core-shell formulations in HFA 227. 
           Dispersion stability of the PLGA NCs alone and those formulated as core-
shell particles was determined in the propellant HFA227.  The physical stability of the 
dispersion was qualitatively assessed through sedimentation rate experiments at 298 
K and saturation pressure of the propellant.  Particles were weighed, fed into 
pressure proof vials, crimp sealed and then dispersed using a sonicating bath.  The 
formulation stability was monitored as a function of the time after sonication was 
stopped (age of the dispersion).  Digital images of the prepared aerosols at the 
starting point (0 time - insets) and a certain time after the system was dispersed are 
shown in Figure 2.7 –NCs alone are shown as insets. 
The results show that PLGA NCs alone are poorly stable in HFA227  
propellant.  The NC formulation started flocculating copiously soon after (< 1 min) 
removal from the sonicating bath (Figure 7a).  Similar results were observed at 2 and 
0.2 mg NC per ml propellant.  On the other hand, the LA-g-CS shell is clearly 
capable of imparting much superior stability to the core-shell particles containing the 
NCs, and can thus be used as a strategy for dispersing the NC in propellant-based 
pMDIs.  A small creamed layer of flocculated core-shell particles can be seen after 
3h (Figure 7b).  This creamed layer was easily redispersible by simple mechanical 
shaking, indicating that the particles are loosely flocculated and not irreversibly 
aggregated – the same is not true for the NC particles when dispersed alone.  In low 
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dielectric solvents such as HFAs, suspension stability may be achieved via steric 
stabilization, which is largely dictated by the ability of the solvent to solvate the 
stabilizing moieties – in this case the HFA-LA interaction.[19, 51] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
2.4.6. Aerosol characteristics of the NP laden core-shell formulation. 
           An eight stage Anderson Cascade Impactor (ACI) was used to determine the 
aerosol characteristics of the core-shell pMDI formulations containing the NCs.[3]  
Freshly prepared canisters at 2 mg.ml-1 core-shell particles were actuated into the 
ACI, which was held at a constant flow rate.  The particles are deposited on each of 
0 h 3 h 
Figure 2.7. Dispersion stability of PLGA-laden LA-g-CS core-shell particles in 
HFA 227 at 2 mg.ml-1, 298 K, and saturation pressure of the propellant 
mixture.  The images were captured immediately after sonication (0 h) and 3 h 
after mechanical energy input ceased.  (inset) Images of formulations 
prepared using PLGA NCs alone (no shell).  Images were captured at the 
same time points mentioned above, and the formulation was prepared at the 
same particle concentration and also in HFA227 propellant. 
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the eight stages of the ACI, depending on the aerosol particle size, with larger 
particles (higher inertial impaction) being retained on the earlier stages of the 
impactor (from the induction port to stage 2), while the smaller particles find their way 
to the lower stages of the impactor (stages 3-7).[19]  The aerosol characteristics 
(ACI) of the formulation at 0.2 mg.ml-1 NC in HFA227 propellant, in the absence of a 
shell, were also determined.  This concentration range is the nominal NC 
concentration in the ACI study of the core shell formulation, based on the estimated 
10% loading of NCs.  The amount of particles deposited onto the stages was 
determined using prescribed analytical techniques.  The absolute (mass) deposition 
results for both bare NCs and core-shell NCs are given in Table 2.1.  The results 
from Table 2.1 are expressed as percentages and shown in Figure 2.8. 
           Respirable and fine particle fractions (RF and FPF) are two parameters used 
to gauge the efficiency of lung deposition using pMDIs.[52]  A higher FPF denotes 
greater deposition of the formulation in the deep lung.[19, 52]  In addition to these 
parameters, other measures such as MMAD and GSD are relevant in the 
quantification of the aerosol characteristics of pMDIs, and were also determined from 
the ACI studies.[19, 52] 
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Stages 
Total Particle 
concentration (µg) 
(Shell+NCs) 
Concentration 
of NCs (µg) 
AC 72.3 ± 11.2 7.6 ± 9.4 
SP 123.8 ± 10.1 13.0 ± 11.2 
IP 76.8 ± 1.2 8.1 ± 2.6 
Stage 0 (9.0-10.0µm) 43.6 ± 1.9 4.6 ± 1.5 
Stage 1 (5.8-9.0 µm) 78.1 ± 2.6 8.2 ± 1.9 
Stage 2 (4.7-5.8 µm) 48.4 ± 0.2 5.1 ± 1.2 
Stage 3 (3.3-4.7 µm) 84.3 ± 3.8 8.9 ± 0.5 
Stage 4 (2.1-3.3 µm) 180.7 ± 2.0 19.0 ± 0.4 
Stage 5 (1.1-2.1 µm) 114.5 ± 1.0 12.1 ± 1.5 
Stage 6 (0.7-1.1 µm) 74.0 ± 2.6 7.8 ± 1.9 
Stage 7 (0.4-0.7 µm) 19.2 ± 2.4 2.0 ± 1.6 
Filter (0-0.4 µm) 72.3 ± 2.6 0.6 ± 2.7 
Single Puff Dose (µg) 49.4 ± 4.7 4.9 ± 1.4 
RF (%) 72.4 ± 2.2 
FPF (%) 55.2 ± 1.8 
MMAD (µm) 2.1 ± 0.8 
GSD 3.0 ± 1.2 
Table 2.1.  Aerosol characteristics of the core-shell formulation containing 
biodegradable NCs (loaded with 6-Coumarin) in HFA227 at 298 K, saturation 
pressure of the propellant and 2 mgml-1 particle concentration.  The results 
represent the average and deviation of three independent runs (n=3).  RF denotes 
the respirable fraction, FPF, the fine particle fraction, AC = actuator, SP = spacer, 
and IP = induction port.  MMAD and GSD are the mass mean aerodynamic diameter 
and geometric standard deviation, respectively 
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          The impaction tests reveal a RF of 72 % and an FPF of 55% for the NC-based 
core-shell formulation.  The RF and FPF for the bare NC based formulation were 
considerably lower, as expected, at 20.1% and 10.5%, respectively.  A large fraction 
of the NC formulation was found to be entrapped in the actuator when compared to 
the stages of the ACI (vs. the amount found in the core-shell formulation), 
presumably due to the aggregation of the particles in the propellant in the absence of 
the stabilizing shell.  It is also interesting to note that a significant portion of the 
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Figure 2.8.  Aerodynamic characteristics of the core-shell microparticle 
formulation containing the PLGA NCs in HFA 227, at 298 K and saturation 
pressure of the propellant.  Particle concentration was 2 mgml-1 (same as 
in Figure 7)  AC, IP, SP, and F refer to actuator, induction port, spacer and 
filter, respectively.  (Inset) A digital image of the impactor (Andersen 
Cascade Impactor, ACI) used to determine the aerosol fractions. 
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actuated dose in the formulation containing NCs alone was detected in the filter, in 
agreement to the much smaller MMAD - 0.5 µm for NC formulation compared to 2.1 
µm for core-shell formulation. 
           We have shown in the past that particle stability in the propellant correlates 
with the aerosol characteristics of the corresponding formulation; i.e., formulations 
that have good dispersion stability also have good aerosol characteristics, and those 
with poor stability, have poor aerosol characteristics.[21-22]  We have also 
demonstrated that this trend also holds at the particle-particle level (force of 
interaction), as determined by colloidal probe microscopy;[19] i.e., the ability of 
reducing particle-particle interactions as achieved here by the core-shell strategy, 
results in an improved dispersion stability and aerosol characteristics of the 
corresponding formulation.  The experiments above are in agreement with those 
expectations and previous studies, in that the formulations containing NCs alone (not 
within core-shell particles) showed undesirable aerosol characteristics when 
compared to the NC formulation within the core-shell particles, as NCs alone are not 
dispersible in the propellant. 
           While no other NC-based pMDI formulation has been discussed in the 
literature yet, it is instructive to compare and contrast these results with other pMDI 
formulations.  The FPF of 55% obtained here for the core-shell particles compares 
very favorably with Ventolin HFA®, a commercial formulation for asthma and chronic 
obstructive pulmonary disease (COPD) that has a reported FPF of 46%.  An FPF of 
over 74% has been reported by our group from a core-shell formulation 
encapsulating free therapeutics (instead of NCs) – even higher values were achieved 
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with a spacer.[19]  It is worth mentioning that the high FPF observed here may be 
further optimized by controlling the particle preparation parameters and the hardware 
as it is done in the industry.  The proposed core shell formulation had an MMAD of 
2.1 µm and a GSD of 3.0 µm, which was well within the desirable range for 
pMDIs.[19]  
           The aerosol results discussed above, which demonstrate the ability to 
efficiently formulate polymeric NCs in HFA-based pMDIs, suggest this approach to 
be a general strategy for the delivery of therapeutics to and through the lungs using 
pMDI formulations.  Allied with the ability of such polymeric NCs (i) to target 
chlamydial inclusions within airway epithelial cells, as demonstrated in this work, (ii) 
to encapsulate effective carriers for a number of relevant chlamydial therapeutics 
including antibiotics and vaccine candidates,[35, 53] and (iii) recent developments in 
mucosal delivery with polymeric NCs[46, 54] point to the proposed strategy as a 
methodology for treating Chlamydia-related infections in the lung. 
 
2.5   Conclusions 
In this work we demonstrated polymeric NCs can be successfully formulated in 
propellant-based metered-dose inhalers.  Biodegradable polymeric NCs were 
encapsulated within HFA-philic, biodegradable and water-soluble copolymer shells 
by emulsification diffusion.  The core-shell particles thus formed provide for an 
opportunity to efficiently deliver NCs to the lungs, by enhancing their dispersibility in 
the propellant, and by providing the appropriate geometry (aerodynamic size) so as 
to enhance the aerosol characteristics of the corresponding pMDIs (RF of 72%, with 
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an MMAD of 2.3 µm).  In vitro results reveal that NCs from such core-shell 
formulations can be readily internalized by Calu-3 (airway epithelial) cells infected 
with C. pneumoniae, and more importantly, they can gain access to chlamydial 
inclusions.  These results are of great relevance not only for the potential treatment 
of chlamydial infections, but also in the treatment of a host of diseases where the 
regional (to the lungs) or systemic (through the lungs) delivery of drugs can be 
enhanced through the use of tailored polymeric NCs 
 
Note – This work was done with the assistance of Dr. Judith Whittum-Hudson, 
Professor of Immunology and Microbiology, Ms. Mirabela Hali, Ms. Arulselvi 
Anbalagan and Dr.Susan Wykes. 
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Chapter 3 
 
Polymer Nanocarriers for Transport Modulation Across the Pulmonary 
Epithelium: Dendrimers, Polymeric Nanoparticles, and their Nanoblends 
 
3.1   Introduction 
Oral inhalation (OI) is not only the most sensible route for the regional 
administration of drugs to the lungs, but it has also been more recently recognized as 
a potential alternative platform for the systemic delivery of a host of therapeutic 
molecules.[1, 2]  Some of the potential advantages of using the lungs as a portal to 
the systemic circulation include the lower enzymatic activity in the lung tissue,[2, 3] 
which may improve drug bioavailability,[1, 4, 5] and the large absorptive area and 
high vascularization of the alveolar region, which is expected to facilitate the 
transport of therapeutics.[2, 3, 6]  As a matter of fact, literature reports indicate that 
the peak in the systemic circulation of many if not most small molecule therapeutics 
delivered to the lungs via OI is in the order of minutes, or even shorter.[7]  Such fast 
transport rates may actually represent a challenge, as most commercial OI 
formulations in the market today target the lungs, and short residence times may 
require more frequent[8, 9] and higher dosages,[10] which may lead to more 
pronounced side effects.[9, 10]  The reverse problem is also observed in cases when 
the lung epithelium works as an effective (and dominant) barrier to the transport of 
therapeutics that are intended for systemic delivery.[3, 7, 11] 
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             Novel OI formulations that take full advantage of controlled delivery systems 
may help modulate the transport of therapeutics across the lung epithelium, and thus 
improve the effectiveness of existing OI therapies.  Controlled drug delivery may also 
help augment the market share of such a simple and non-invasive route, by 
facilitating systemic administration of therapeutics through the lungs.  Polymeric 
nanocarriers (PNCs) are especially suited within this context.  PNCs may help 
overcome many of the drug delivery challenges facing OI therapies, as cellular 
uptake and transport across the epithelium, the main barriers to the systemic 
circulation,[6, 12-14] may be potentially modulated by carefully designing the 
carriers, as has been demonstrated for other epithelia.[15-18]  Important design 
characteristics of PNCs that may be used to improve the control over the transport of 
therapeutics across epithelial barriers include their architecture (e.g. dendrimer 
nanocarriers (DNCs) vs. polymeric nanoparticles (NPs)),[19-22] size,[23, 24] surface 
charge, and surface chemistry (e.g. presence of targeting or non-fouling 
moieties).[19, 20, 23, 25]  However, while significant attention has been given to the 
transport of PNCs across traditional epithelial barriers,[6, 15, 17, 26] little is known 
on how PNCs interact with the lung epithelium.[27]  Similarly, the ability to deliver 
PNCs to the lungs using portable inhalers has been only recently demonstrated,[28-
30] while a substantial body of work is available in the literature regarding the 
formulation of PNCs for other delivery routes.[15, 21, 31] 
           Based on the challenges and opportunities described above, the goal of this 
work was to investigate the uptake and transport of DNCs across polarized Calu-3 
monolayers, an in vitro model of the lung airway epithelium, and the ability to further 
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modulate the cellular uptake and transport of the DNCs by forming polymeric blends 
between DNCs and polymeric NPs.  Generation 3 (G3), amine terminated, 
poly(amido amine) (PAMAM) dendrimers (G3-NH2) and poly (d,l-lactide-co-glycolide) 
(PLGA) NPs were selected as models in this study due to the extensive literature 
available for these systems as drug delivery carriers.  Transport studies were 
performed across polarized monolayers grown onto porous inserts at the air-
interface culture condition (AIC).  Cellular internalization of the DNCs, polymeric 
NPs, and their blends were determined by flow cytometry, and cell lysis, also on 
polarized cell monolayers.  Another goal of this study was to demonstrate the ability 
to formulate DNCs in portable OI formulations that show aerosol characteristics 
conducive to enhanced deep lung deposition.  Core-shell structures containing the 
DNCs were prepared, and the aerosol characteristics of corresponding formulations 
in pressurized metered-dose inhalers (pMDIs) quantitatively determined. 
 
3.2   Materials 
Carboxyl-terminated PLGA (COOH-PLGA, 50:50, MW 31.3 - 45.0 KDa) was 
purchased from Birmingham Polymers (Birmingham, AL).  G3 PAMAM dendrimer 
(G3-NH2), containing 32 surface groups (MW 6,909 Da), fluorescein isothiocyanate 
(FITC), glutaraldehyde (25%), Triton-X-100 (reagent grade), Bovine Serum Albumin 
(BSA), Osmium tetroxide (OsO4, 4% in water), penicillin-streptomycin (100 U/mL, 
AB), poly(vinyl alcohol) (PVA, 87-90% hydrolyzed), Alcian Blue, Trypan Blue, DPX® 
mounting media, N-Hydroxysuccinimide (NHS), N,N'-dicyclohexylcarbodiimide 
(DCC), and dialysis membranes (SpectraPor, MWCO 1 kDa) were all procured from 
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Sigma.  Ethylenediamine was purchased from Fluka.  Deionized (DI) water with a 
resistivity of 18.0 MΩcm (NanoPURE Diamond, Barnstead) was used in all 
experiments.  BCA® protein assay was purchased from Pierce.  Phosphate Buffered 
Saline (PBS, 10X) was purchased from Fisher Scientific and was diluted to 1X using 
DI water.  Hank’s Balanced Salt Solution (HBSS 1X, pH 7.3) supplemented with 
0.01M HEPES was prepared.  Rabbit Anti ZO-1 (Mid) primary antibody (product # 
A11010), Alexa Fluor® 546 labeled goat anti-rabbit IgG (product # 402200), 4’, 6-
diamino-2-phenylidole diacetate (DAPI) and the cell viability assay, MTT (Vybrant® 
cell proliferation assay kit), were purchased from Molecular Probes.  Transwell® 
inserts (Corning, 0.4 µm pore size, polyester, 0.33 cm2), cell culture flasks (75 cm2), 
24 well culture plates, coverglass slides (18 mm2), and 96-well flat bottomed culture 
plates (Cellstar), and trypsin supplemented with 0.25% ethylene diamine tetraacetic 
acid (EDTA)  were purchased from VWR.  Dulbecco’s Modified Eagle’s Medium 
(DMEM, product # 10569) was procured from Invitrogen.  Fetal Bovine Serum (FBS, 
non-heat inactivated) was purchased from Atlanta Biologicals.  Metering valves were 
kindly provided by Valois (DF30) and 3M (EPDM Spraymiser).  Pressure proof vials 
(5 mL, 6800318) were purchased from West Pharmaceutical Services.  Pharma 
Grade (>99.99% purity) hydrofluoroalkane, 1,1,1,2,3,3,3-heptafluoropropane 
(HFA227) was a gift from Solvay Fluor und Derivate GmbH & Co.  2H,3H-
perfluoropentane (Vertrel XF, HPFP) was purchased from TMC Industries.  
Glutaraldehyde was diluted from 25% to 2.5%, and osmium tetroxide diluted to 1% 
using DI water prior to their utilization.  G3-NH2 dendrimers were dried in vacuum 
overnight to remove methanol prior to usage.  Anhydrous dimethylsulfoxide (anh. 
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DMSO) and anhydrous dichloromethane (anh. DCM) were obtained from EMD 
chemicals.  All other chemicals used in this work were procured from EMD, were of 
analytical grade, and were used as received, unless otherwise noted. 
 
3.3   Methods. 
3.3.1 Conjugation of FITC to G3-NH2.   
Conjugation of FITC to G3-NH2 was performed according to a procedure 
described earlier.[32]  Briefly, a known mass of dendrimer was dissolved in PBS (5 
mL).  A known mass of FITC (concentration < 5 mg·mL-1) was solubilized in acetone 
and reacted with the aforementioned solution of G3-NH2 under darkness for 24 
hours, resulting in the FITC-conjugated G3-NH2 (G3-NH2-FITC).  The organic phase 
was evaporated by gently sparging nitrogen, and the remaining contents from the 
flask were transferred to a dialysis bag and dialyzed extensively against DI water for 
48 hours, with periodic changing in DI water every 6h, to remove any unreacted 
FITC.  The contents of the dialysis bag were then transferred to a centrifuge tube, 
flash frozen using liquid N2 and lyophilized (Labconco Freezone) for 48 hours to 
obtain the final product.  The presence and the extent of FITC conjugation onto the 
dendrimer was ascertained by 1H-NMR (DMSO-d6 Varian 400 MHz). 
 
3.3.2 Preparation of G3-NH2-FITC-loaded PLGA nanoparticles (NPs).   
  Loading of the G3-NH2-FITC into the NPs to form the nanoblends was 
accomplished using a modified version of the double emulsion solvent evaporation 
technique.[33]  Briefly, 0.9 mg of the FITC-labeled dendrimer was dissolved in 50 µL 
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of DI water.  The aqueous solution was emulsified over an ice bath with 80 mg of 
PLGA dissolved in 6 mL of an organic mixture containing ethyl acetate and acetone 
(4:1 ratio) using a sonicating probe (OmniRUPTOR 250, Omni Inc.) set at 50W 
power for 2 minutes.  The primary emulsion formed was added dropwise to 5 mL of 
an ice-cold, 5% PVA solution under heavy vortexing (3000 RPM).  The secondary 
emulsion formed was emulsified over an ice bath using the probe set to the same 
power, for another 1min.  The emulsified mixture was diluted in about 150 mL of 
chilled 1% PVA solution and stirred overnight to evaporate the organic solvent.  The 
NPs were recovered by centrifugation (26000×g for 60 minutes at 4°C, Sorvall 
Legend X1R) and washed thrice with DI water to remove residual PVA.  The washed 
NPs were redispersed in DI water, flash frozen in liquid N2 and lyophilized for 36h to 
obtain the final product.  The recovered G3-NH2-FITC loaded NPs (the nanoblend) 
were characterized for size, surface charge and morphology using the Zetasizer 
Nano (Malvern) (dynamic light scattering (DLS), and zeta potential), and scanning 
electron microscopy (SEM).  For DLS, 2 mg of NPs were gently dispersed in 1.5 mL 
of 1X HBSS using a probe sonicator over an ice bath.  For SEM, a few drops of the 
aforementioned dispersion were deposited on the surface of a cover glass and 
subsequently evaporated overnight.  The cover glass was then sputter coated with 
gold for 25 seconds (Ernst Fullam) and imaged using SEM (Hitachi S-2400) at a 
voltage of 25 kV. 
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3.3.3 Loading efficiency of the G3-NH2-FITC into PLGA NPs.   
Loading efficiency of the FITC conjugated PAMAM dendrimers from the NPs 
was determined using fluorescence spectroscopy.  5 mg of the G3-NH2-FITC loaded 
PLGA NPs was dissolved in 2 mL methylene chloride.  The organic phase was then 
contacted with an equal volume of 1X HBSS and the mixture was subject to 
vortexing for 1 minute at 3000 rpm followed by extraction (LabQuake, Thermo 
Fisher) overnight under gentle mixing.  The aqueous phase was isolated after 
extraction and subjected to fluorescence spectroscopy (Synergy Mx, Biotek 
Instuments, λex 490 nm and λem 520 nm).  The readings obtained were compared 
against a previously prepared calibration curve of the G3-NH2-FITC to quantify the 
extent of the conjugate in the NPs.  This procedure was done in triplicate, and the 
value reported here is an average of the three independent preparations of 
dendrimers loaded NPs. 
 
3.3.4 Controlled release studies of the G3-NH2-FITC from the NPs.   
The sustained release of the G3-NH2-FITC from the PLGA NPs was 
performed in 1X HBSS maintained at 37°C.  5 mg of the G3-NH2-FITC-loaded PLGA 
NPs (ca. 50 µg G3-NH2-FITC) were incubated in 5 mL of buffer maintained at 
constant temperature (37°C) in a water bath.  At predetermined times, the 
suspension was centrifuged (26000× g, for 30 min at 4°C) and 200 µl of the HBSS 
was sampled from the supernatant.  The amount of the G3-NH2-FITC released was 
estimated by fluorometry, as described in the previous section.  An equal volume of 
fresh HBSS was added back to the release media in order to compensate for the 
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buffer removed.  The system was then redispersed and replaced back into the water 
bath for further sampling.  The release profile is presented as a cumulative estimate 
of the G3-NH2-FITC conjugate released over a period of 24h.  The release of G3-
NH2-FITC from the NPs in presence of mucus laden HBSS was also evaluated.  
Synthetic regular mucus was prepared according to a methodology in literature and 
was diluted in the ratio 1:1000 in HBSS.[34]  The ratio 1:1000 (Mucus:HBSS) was 
estimated by determining the volume of mucus on confluent Calu-3 monolayers 
seeded in the insert, which was calculated based on the thickness of the mucosal 
layer in the airways estimated to be 8 µm and the surface area of the insert to be 
0.33 mm2.[35]  The release studies were conducted as described for the release in 
HBSS.  The measurements were conducted in triplicate, and the values reported 
here are averages of three independent runs. 
 
3.3.5 Preparation of FITC-conjugated PLGA NPs.   
FITC was conjugated to PLGA according to a procedure detailed in the 
literature.[36]  Briefly, COOH-PLGA (200 mg, 5 µM) was solubilized in anh. 
dichloromethane (DCM, 5 mL) and allowed to react with DCC (1.5 mg, 7 µM) and 
NHS (1 mg, 7 µM) overnight in order to activate the terminal carboxyl group on 
PLGA.  The dicyclohexylisourea (DCU) formed as a precipitate was filtered, and the 
resulting product was allowed to react with ethylenediamine (1 mg, 16 µM) in DCM in 
order to convert the succinimidyl ester group on PLGA to primary amine.[36]  The 
product obtained was purified by precipitating in diethyl ether, and the resulting solid 
was dried under vacuum.  This amine terminated PLGA was allowed to react with 
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FITC (2.2 mg, 6 µM) overnight in anhydrous DMSO (5 mL).  The resulting product 
was purified by dialysis against water, and lyophilized to recover the final product.  
The polymer thus prepared was characterized using 1H-NMR to ascertain the 
conjugation of FITC to the polymer backbone – carboxyl group.  NPs of the resulting 
polymer (FITC-conjugated PLGA) were prepared using emulsification solvent 
evaporation technique as detailed earlier.  The NPs recovered were characterized for 
size and surface charge as described in previous sections. 
 
3.3.6 Cell culture.   
The human airway epithelial cell line, Calu-3, was purchased from the 
American Type Culture Collection (ATCC).  Cells from passages 35-45 were used in 
the transport experiments.  Calu-3 cells were plated in 75 cm2 culture flasks, in 
DMEM supplemented with 10% FBS and 1% AB, and allowed to grow to confluence.  
Once the confluence of the monolayer in the culture flasks was ascertained visually 
they were subcultured and reseeded in Transwell® inserts at a density of 0.5×106 
cells per well, and allowed to proliferate in a humidified atmosphere maintained at 
37°C and 5% CO2.  The cells were grown initially under liquid culture conditions 
(LCC) for 48h, after which the medium on the apical side was removed and the cells 
were allowed to grow under an air interface culture (AIC).  The culture medium on 
the basolateral side was replaced every two days, and the integrity of the Calu-3 
monolayer was ascertained by determining its transepithelial electrical resistance 
(TEER).  The measurements were conducted using an electrovoltohmmeter (EVOM, 
WPI Inc.,) equipped with chopstick electrodes.  TEER of the monolayer was 
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monitored every day until the values peaked to a high value and leveled, indicating 
that the monolayer had reached confluence.  Additional techniques, including 
electron microscopy and immunocytochemical analysis were employed to ascertain 
the presence of tight junctions and to confirm monolayer integrity. 
 
3.3.7 Electron microscopy and immunocytochemistry.   
Confluent Calu-3 monolayers were subjected to SEM to visually ascertain the 
morphology of the cell monolayers.  Fixing and staining of the cells was done 
according to a procedure enlisted in the literature.[37]  Once the confluence of cell 
monolayers was confirmed by TEER, select inserts were isolated and incubated in a 
1:1 mixture of 2.5% glutaraldehyde (in DI water) and cell culture medium for 5 
minutes at room temperature.  The inserts were gently rotated in this medium during 
incubation.  The mixture was replaced with the fixative, 2.5% glutaraldehyde, and 
was incubated for 30 minutes at room temperature.  The cells were then stained with 
a 1% solution of OsO4 for a period of 90 minutes after which they were washed in 
increasing gradients of ethanol (20%, 40%, 60%, 80% and 100% all v/v), each for a 
period of 10 minutes.  The dehydrated monolayers were lyophilized for a period of 
48h, sputter coated with gold (Ernst Fullam) and imaged using SEM (JEOL, JSM-
6510LV-LGS ) at 25 kV. 
           Alcian Blue stain was used in confirming the secretion of glycoproteins on the 
surface of Calu-3 cells.  Confluent Calu-3 monolayers were isolated and were 
washed with HBSS after which they were incubated for a period of 20-30 minutes in 
1% Alcian Blue (in 3% Acetic acid) at room temperature.  After incubation, the 
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staining reagent was removed from the apical side, and the monolayers were 
washed with excess HBSS until the rinsate ran clear.  The membrane from the 
inserts were carefully removed and mounted on microscope slides using DPX 
mountant, and imaged using an optical microscope (Diaphot 300, Nikon). 
           Immunocytochemical staining was conducted on confluent Calu-3 monolayers 
to detect and confirm the presence of the Zona Occludens (ZO-1) protein that 
populates the tight junctions of confluent Calu-3 monolayers.[37, 38]  The procedure 
was performed according to the protocol prescribed by the manufacturer.  Briefly, 
select monolayers, whose TEER values had peaked and leveled were washed with 
1X PBS twice and were fixed in a 4% solution of paraformaldehyde for 20 minutes at 
room temperature.  The fixed monolayers were washed with PBS and permeabilized 
with 0.5% Triton-X-100 solution containing 1% BSA (blocking agent), in HBSS for a 
duration of 30 minutes.  The permeabilizer was removed and cells were washed well 
with PBS, and subsequently incubated for 60 minutes in a 6% BSA solution in HBSS 
to block non-specific interactions.  The cells were then incubated in Rabbit Anti ZO-1 
(Mid) primary antibody (5 µg·mL-1) dissolved in the blocking agent for 45 minutes 
followed by another 45 minute incubation in an Alexa Fluor® 546 labeled goat anti-
rabbit IgG in blocking solution.  The cells were washed with PBS and counterstained 
with DAPI (0.1 µg·mL-1in DI water), mounted on glass slides using DPX mounting 
media and stored at 4ºC overnight.  The stained monolayers were observed using a 
fluorescent microscope (Zeiss Axiocam mRM, Carl Zeiss) to visually ascertain the 
presence of ZO-1.  The images were captured using the software, Axiovision (Zeiss). 
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3.3.8 Cytotoxicity Studies.   
The viability of Calu-3 cells in presence of G3-NH2-FITC and G3-NH2-FITC 
loaded NPs was estimated using the MTT assay, according to a protocol outlined by 
the manufacturer.  Briefly, Calu-3 cells were seeded at a density of 10,000 cells per 
well in 96-well culture plates, and allowed to grow for a period of 24h.  Cells were 
then washed twice with HBSS and the medium was replaced with 100 µL of HBSS 
containing varying concentrations of either G3-NH2-FITC or the NPs containing the 
conjugates.  The cells were allowed to incubate in the test solutions for a period of 
7h.  This duration was selected as it was 2 hours longer than the time utilized for the 
transport experiment.  After the duration of the test period, cells were washed thrice 
with 1X HBSS and incubated at 37ºC in 100µL of HBSS containing 20 µL of MTT 
solution for a period of 4h.  The incubation was followed by replacing 75 µL of the 
solutions in the wells with 50 µL of DMSO and allowing the cells to stand for 10 
minutes in order to dissolve the formazan crystals.  The well plates were read at an 
absorbance of 540 nm using a plate reader (Synergy Mx, BioTek Instruments).  Cell 
monolayers exposed to only 1X HBSS were used as controls.  Cell viability was 
determined by comparing the absorbance values of cells exposed to G3-NH2-FITC 
and G3-NH2-FITC loaded into NPs to that of the control. 
 
3.3.9 In-vitro transport, cellular uptake, and mass balance studies 
3.3.9a Transport. 
           Transport of bare G3-NH2-FITC and G3-NH2-FITC from blends with the 
polymeric NPs was determined across confluent Calu-3 monolayers using a strategy 
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similar to that reported in the literature for therapeutics and other probe 
molecules.[39, 40]  Once an acceptable in vitro epithelial barrier was established as 
described above, the permeability experiments commenced.  Prior to starting the 
transport studies, the medium on the apical and basolateral sides were replaced with 
warm 1X HBSS and the monolayers were allowed to equilibrate at 37ºC for a period 
of 45 minutes.  The TEER of the monolayer was recorded, after which the PNCs 
were pulsed onto the cell monolayers in 0.2 mL HBSS solution.  For the case of bare 
G3-NH2-FITC, the 0.2 mL HBSS solution contained 25 µg of dendrimers.  For the 
case of the dendrimer-NP blends, the 0.2 mL HBSS solution contained 3 mg of NPs.  
The NP concentration was selected based on the loading of the G3-NH2-FITC – so 
as to correspond to a total mass of dendrimer of 25 µg.  These experiments 
guarantee the same mass/molar concentration of dendrimer in both systems.  The 
basolateral side (receptor compartment) was fed with 0.6 mL fresh 1X HBSS.  The 
transport across the cell monolayer to the basolateral side was monitored over a 5h 
period.  At predetermined times, inserts were transferred to wells containing fresh 1X 
HBSS in the receptor compartment and the transport study was continued.  This was 
done in order to maintain sink conditions during the duration of the experiment.  The 
amount of G3-NH2-FITC that traversed onto the basolateral side was quantified by 
fluorescence spectroscopy (λex 485 nm λem 520 nm).  The apparent permeability 
(Papp) was determined according to equation (3.1). 
 
                                                                                                                                (3.1) 
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Where F is the flux (rate of cumulative mass of G3-NH2-FITC transported), A is the 
area of the insert (0.33 cm2) and Co is the initial concentration of G3-NH2-FITC on 
the apical side of the insert.  F was calculated by plotting the cumulative mass of G3-
NH2-FITC transported as a function of time, and corresponds to the slope from the 
resultant curve.[37] 
 
3.3.9b Cellular uptake and mass balance. 
Cellular uptake was determined using two approaches.  Here we report the 
procedure for the uptake determined from the cell lysate.  This is an absolute 
determination (total concentration of the species of interest), and was used to 
perform an overall mass balance with respect to the amount of the dendrimer.  In the 
next section we discuss cellular uptake determined by flow cytometry.  The 
concentration of G3-NH2-FITC and G3-NH2-FITC encapsulated in the NPs into Calu-
3 cells was quantified at the end of the transport experiments – at the 5h time point.  
After completion of the transport studies, the apical media was removed and stored 
under darkness at 4ºC.  The cell monolayers were washed with ice-cold HBSS to 
arrest uptake and remove non-bound NPs and conjugates.  The particles washed 
during this rinse were also collected and accounted for as non-internalized.  The 
amount of G3-NH2FITC in the fluids collected was measured by fluorescence 
spectrometry as described in earlier sections.  For bare G3-NH2-FITC, the apical fluid 
collected was centrifuged (1500 rpm, 6 minutes) and directly read using a 
fluorometer, whereas for the dendrimer-NP blends, the apical fluid laden with NPs 
was contacted with organic solvent (methylene chloride) to break down the polymeric 
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matrix and release the dendrimer.  The mixture was allowed to stand until the 
organic and the aqueous phases separated.  The aqueous phase was subsequently 
analyzed for the conjugate released as detailed above.  The monolayers were 
subsequently lysed by allowing them to stand in 2% triton-X-100 in HBSS for 24 h 
under darkness.[41]  In case of bare G3-NH2-FITC, lysed cell monolayers were 
centrifuged (800 rpm, 5 min) and the supernatant was analyzed for the G3-NH2-FITC 
using fluorometry (λex 485 nm and λem 520 nm, Synergy Mx, Biotek Instruments).  In 
case of the G3-NH2-FITC loaded into NPs, the lysate was centrifuged (800 rpm, 5 
minutes), the supernatant separated and contacted with methylene chloride to 
dissolve the internalized NPs and extract the G3-NH2-FITC into the aqueous phase.  
After a 24h extraction, the aqueous phase was analyzed for G3-NH2-FITC using 
fluorometry.  The results were normalized with respect to the total protein content 
using BCA protein assay, according to the protocol given by the manufacturer.  By 
determining the concentration of the G3-NH2-FITC in the apical side of the 
monolayer, the concentration that was internalized within the cell, and the amount 
transported onto the basoleteral side, a mass balance of the G3-NH2-FITC could 
thus be performed. 
 
3.3.9c Flow Cytometry. 
           Flow cytometry analysis was conducted on polarized Calu-3 cells according to 
methodology detailed in the literature, with some modifications.[42, 43]  Calu-3 cells 
(passages 35-45) were seeded at a density of 1 x 106 cells per well in 24-well plates, 
and allowed to grow to confluence.  The monolayer confluence was confirmed by 
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staining select wells for ZO-1 and subjecting them to fluorescence spectrometry as 
detailed earlier, a day before commencing the uptake studies.  The presence of ZO-1 
protein suggested that the cells were confluent.  Prior to pulsing G3-NH2-FITC or 
NPs loaded with G3-NH2-FITC, the cell monolayers were incubated with 1X HBSS 
(at 37ºC) for a period of 30 minutes.  The cells were then incubated with: (i) G3-NH2-
FITC; or (ii) NPs loaded with G3-NH2-FITC; or (iii) FITC-PLGA NPs in HBSS for 
varying time periods (5h, 4h, 3h, 2h, 1h, 30 minutes and 15 minutes).  Care was 
taken to ensure that the concentration of G3-NH2-FITC was same for both systems.  
The concentration FITC-PLGA was the same as that of NPs loaded with G3-NH2-
FITC.  After incubation for a specified duration, the test solutions were removed and 
the cell monolayers were washed thrice with ice-cold HBSS.  The extracellular 
fluorescence was quenched with trypan blue (0.25% w/v in HBSS), and the 
monolayers were washed again, before being subjected to trypsinzation (trypsin 
supplemented with 0.25% EDTA).  The detached cells were centrifuged (1200 rpm, 6 
minutes) to obtain the cell pellet which was subsequently resuspended in 1 mL of 
fresh HBSS and analyzed using a flow cytometer (BD LSR II (BD Biosciences, San 
Jose, CA), with the samples excited with a Coherent Sapphire laser (488 nm) and 
detected through a 530/30 bandpass filter (FITC).  Only viable cells were gated for 
fluorescence analysis.  As controls for G3-NH2-FITC, 1X HBSS was utilized, whereas 
for NP system, blank PLGA NPs were used.  At least, 6000 events were counted for 
each condition.  All experiments were repeated / performed independently by two 
different investigators in our laboratories, with three wells each time, 4 weeks apart 
from each other.  The results shown here are thus averages of 6 wells.  The cellular 
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entry was expressed in percentages as a function of time by plotting the mean 
fluorescence intensity (MFI) values of cells gated for FITC from histograms sourced 
from the FACS data.  In addition, the rate of cellular entry was also plotted as a 
function of time, by normalizing the MFI data with respect to the 5h MFI values, 
which were set at 100%. 
 
3.3.10 Preparation and characterization of G3-NH2-FITC loaded core-shell  
           particles.   
           Synthesis and characterization of a biodegradable co-oligomer, oligo(lactide) 
grafted chitosan (OLA-g-CS) that forms the shell encapsulating the G3-NH2-FITC 
has been documented in detail elsewhere.[44]  The CS was depolymerized from 310 
kDa to a MW of about 1 kDa according to procedure described in the literature, with 
a degree of deacetylation of 77% as estimated by 1H-NMR.[44]  Ring opening 
polymerization was used in grafting lactide chains onto the degraded CS backbone.  
The resulting co-oligomer had a MW of 1.7 kDa, with at least 3 OLA chains (8 LA 
units, 21% graft percentage) onto each CS backbone as determined using 1H-
NMR.[30]  Preparation of G3-NH2-FITC loaded core-shell particles was 
accomplished via emulsification diffusion.  Briefly, 30 mg of the co-oligomer was 
dissolved in 0.9 mL DI water and to this solution 1.2 mg of the dendrimer was added.  
This aqueous solution was emulsified with 19 mL of ethyl acetate in a bath sonicator 
(VWR P250D, 180 W) for 8 minutes at 17°C.  The resulting water in oil emulsion was 
quickly added to a large volume of ethyl acetate (200 mL).  The high solubility of 
water in ethyl acetate causes it to migrate from the dispersed droplet phase into the 
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bulk phase.  Being interfacially active,[44] the co-oligomer resides at the interface, 
templating the G3-NH2-FITC as spherical particles with a core-shell morphology, 
where the co-oligomer becomes the shell and dendrimers the core.  Core-shell 
particles thus formed were collected by centrifugation (Sorvall Legend X1R, 5000 
rpm, 20 mins), air dried and stored in a desiccator prior to usage.  The particles were 
characterized for shape and size using DLS and SEM.  A known amount (2 mg) of 
particles was dispersed in 1.5 mL of HPFP at 18ºC in a bath sonicator and subject to 
DLS analysis.  A small quantity of the dispersion was deposited onto cover glass 
slides, dried in a light stream of air, and sputter coated with gold for 40s prior to 
imaging them under SEM (Hitachi S-2400) at 25 kV. 
           The loading of the dendrimer conjugates in the core of the particles was 
determined using fluorescent spectroscopy.  A known mass of the particles (3 mg) 
containing the G3-NH2-FITC and the water-soluble shell was dissolved in a known 
volume (3 mL) of HBSS.  The resulting solution was analyzed using fluorescence 
plate reader at excitation and emission wavelengths of 495 and 520 nm respectively 
(those corresponding to FITC) and compared against a previously prepared 
calibration curve of the G3-NH2-FITC to quantify their loading. 
 
3.3.11 Physical stability of G3-NH2-FITC loaded core-shell particles in HFA 
           propellant.  
            A known mass of the core-shell particles containing the G3-NH2-FITC was 
loaded into pressure proof glass vials (West Pharma, 6800318), and crimp sealed 
using metering valves (DF30, Valois).  The propellant was fed into the pressure proof 
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vials using a manual high pressure pump (HiP 50-6-15) and a home-made aerosol 
filler.  The volume of HFA added was such that the final concentration in the vial was 
2 mgmL-1.  The formulation was gently agitated in a low intensity sonicating bath 
(VWR P250D set to 180W) between 16 and 18°C for a few min to break up larger 
aggregates.  Digital images of the dispersion were captured immediately after 
ceasing the mechanical energy input, and later at predetermined times.  The physical 
stability of the dispersion was qualitatively estimated as a function of the dispersion 
age.  As a comparison, bare G3-NH2-FITC was also formulated in pMDIs (0.15 
mg·mL-1) as described above for core-shell particles, and its dispersion stability also 
evaluated as a function of time. 
 
3.3.12 Aerodynamic properties of G3-NH2-FITC core-shell formulations.   
           An eight stage Andersen Cascade Impactor (ACI, Copley Scientific) operating 
at a flow rate of 28.3 Lmin-1 was used to evaluate the aerosol characteristics of the 
G3-NH2-FITC loaded core-shell formulations.  Formulations of G3-NH2-FITC alone 
were also tested for comparison.  The studies were carried out at room temperature 
and 52% relative humidity.  Freshly prepared canisters of the formulations were 
dispersed with the help of a sonicating bath maintained at 18°C for 30 minutes.  
Several shots of the formulation were fired to waste prior to subjecting them to the 
impaction experiments.  20 shots were then fired into the ACI at an interval of 10s 
between each actuation.  After the study, the amount of dendrimer deposited on the 
actuator (Ac), the induction port (IP) and each of the stages of the ACI was estimated 
by rinsing the stage plates in 20 mL of 1X HBSS overnight, and subjecting the 
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resulting solution to fluorometry.  Three independent runs (different canisters) were 
conducted, and the results reported here are averages of those runs.  In addition to 
the fine particle fraction (FPF), other relevant aerosol properties including the mass 
median aerodynamic diameter (MMAD), and geometric standard deviation (GSD) 
were also determined from the ACI results. 
 
3.4   Results and Discussion 
3.4.1 Synthesis and characterization of G3-NH2-FITC, and FITC conjugated  
         PLGA.   
FITC was tagged onto dendrimers in order to allow their detection during 
transport and uptake studies.  FITC conjugation to G3-NH2 was accomplished by 
linking the isothiocyanate group of FITC to the amine group of G3-NH2.[45]  
Characterization of the prepared G3-NH2-FITC was done using 
1H-NMR.  The NMR 
spectrum of the prepared conjugates, along with the reaction scheme is shown in 
Figure 3.1. 
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        A singlet observed at 2.19 ppm can be attributed to the methylene (–CH2-) 
protons of G3-NH2.  This peak was used as an internal standard to estimate the 
extent of FITC conjugation, and was set at 120(H) protons.[46]  Multiplets between 
7.82-8.22 ppm can be attributed to the carbamate (-NH-) peaks of the G3-NH2.  The 
presence of FITC can be confirmed by the appearance the multiplet at 6.42-6.61 
ppm, attributed to the aromatic protons (4H) on FITC.[47]  The ratio of the integral 
area of the signals between 6.42-6.61 to the integral area of the methylene protons 
of the G3-NH2, weighted by the respective number of protons gives the number of 
FITC molecules per G3-NH2, in this case determined to be 1.7.  FITC conjugated 
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Figure 3.1.  1H-NMR (400 MHz, d6 DMSO) spectra of the G3-NH2-FITC.  The 
singlet at 2.19 ppm can be attributed to the methylene peak of G3-NH2.  This peak 
was used as the internal standard, and was set to 120 protons.  The multiplets 
between 6.82-6.51 ppm denote the aromatic protons on the FITC molecule.  
Multiplets between 8.22-7.82 ppm denote the carbamate –NH protons.  (Inset) 
Scheme depicting the synthesis of the G3-NH2-FITC. 
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PLGA was synthesized so as to evaluate the rate of cellular uptake of PLGA NPs 
and to compare with the uptake results of the dendrimer-NP blends as discussed 
below.  The conjugation was also characterized by 1H-NMR.  The presence of 
multiplet peaks between 6.5 and 6.7 ppm can be attributed to the presence of FITC 
(spectrum not shown), which was conjugated to the carboxyl group (converted to a 
primary amine) on the PLGA terminus.   
 
3.4.2 Loading of G3-NH2-FITC onto PLGA NPs, characterization of the NPs and  
         release of the dendrimers from the polymeric nanoblends.   
Loading moieties into biodegradable polymeric matrices can lead to sustained 
release of the encapsulate over extended periods of time.[48]  Sustained and 
controlled release of therapeutics from the NPs is an effective methodology to 
ensure retention and prolonged therapeutic effect at the target site, and has further 
relevance in the delivery of high potency, and/or more costly drugs such as 
chemotherapeutics.[48, 49]  Such strategies have also been demonstrated for large 
therapeutics such as biomacromolecules, with molecular weight and hydrophilicity 
similar to that of DNCs investigated in this work.[50, 51]  Incorporating dendrimer 
conjugates within polymeric NPs (blends) can potentially augment the capabilities of 
the dendrimers and polymeric nanocarriers as potent drug delivery vehicles, by 
providing an avenue for further control of the release and transport of the DNCs 
across biological barriers, and consequently that of the therapeutic cargo conjugated 
to the dendrimer.  Additionally, these NPs can act as protective depots for fragile 
molecules that may be conjugated to the dendrimers, thereby ensuring greater 
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retention of their activity.[52]  The encapsulation of dendrimers in polymeric NPs can 
also be used to mediate the interaction of the dendrimers with both extra and 
intracellular barriers present in the lung epithelia.  As drugs and other moieties are 
grafted onto DNCs, the surface chemistry of the carriers is affected, which may also 
impact their interaction with both intra and extracellular barriers.[49, 53]  The 
encapsulation of the dendrimers into NPs may thus serve as a strategy for the 
transport of different dendrimer nanocarriers. 
The double emulsion solvent evaporation technique was employed to load the 
G3-NH2-FITC onto the NPs.[33, 48]  The particles formed were lyophilized and 
characterized using SEM and DLS. A representative SEM micrograph (10000X) of 
the NPs and the size distribution as determined by DLS (as inset) is shown in Figure 
3.2(a).  DLS experiments were conducted in 1X HBSS as the medium, which is the 
same solvent medium used in the uptake and transport experiments. 
           . 
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The particle size as determined by DLS was 175±28 nm, with a polydispersity 
of 0.08.  SEM images indicated that the particles formed were smooth spheres with 
an average size of 221±35 nm, as determined with the ImageJ software (v1.4, NIH).  
The zeta potential of the particles was found to be -10.1±2.4 mV.  The loading of the 
G3-NH2-FITC into the NPs was estimated using fluorometry.  A known mass of the 
NPs recovered after lyophilization was dissolved in a known volume of methylene 
chloride to break down the polymeric matrix and release the G3-NH2-FITC.  The 
organic phase was then mixed with an equal volume of 1X HBSS to extract the G3-
Figure 3.2.  (a) SEM micrograph of the G3-NH2-FITC-loaded PLGA NPs 
prepared using double emulsion solvent evaporation technique. (inset) Size 
distribution of the G3-NH2-FITC-loaded PLGA NPs as determined by dynamic 
light scattering (DLS); (b) Sustained release profile of G3-NH2-FITC from PLGA 
NPs in 1X HBSS (pH 7.3) and mucus containing 1X HBSS (pH 7.4) measured at 
37ºC.  (Inset) Illustration indicating release of the G3-NH2-FITC from PLGA NPs.  
Error bars that do not show are smaller than symbol sizes.  Results reported here 
are the average of three independent runs. 
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NH2-FITC released from the NPs into the aqueous phase, which was subsequently 
estimated using fluorometry as described earlier.  The amount of G3-NH2-FITC was 
then estimated by comparing the fluorescence of the extract to a previously 
constructed calibration curve of the conjugate.  The amount of G3-NH2-FITC loaded 
into the NPs was determined to be 7.8±1.2 µg per mg NPs.  This average is an 
estimate of three independent runs (different batches of NPs).  The overall 
encapsulation efficiency of the G3-NH2-FITC into the NPs was found to be 10±1.8%.  
The relatively low loading of the G3-NH2-FITC into the NPs can be attributed to the 
hydrophilicity of the dendrimer, which enhances the rapid partition of the G3-NH2-
FITC to the external aqueous phase during the dilution procedure, as observed for 
other drugs and biomacromolecules such as proteins and peptides.[49, 54, 55]  The 
NPs of FITC conjugated PLGA had a size of 245 ± 40 nm as determined by DLS, and 
a zeta potential of -12±3.1 mV. 
There have been a few studies in the literature that have reported the 
formulation of dendrimers into particulate carriers.[56, 57]  Most of those studies have 
focused on the encapsulation of G3-NH2-plasmid DNA complex (dendriplexes) into 
PLGA microparticles.[57]  One of the important findings from those studies was the 
ability to sustain the release of these dendriplexes from the polymeric core over 
extended periods of time, suggesting that formulating dendrimer conjugates into 
polymeric matrices can be a potential strategy to further enhance their efficacy as 
drug delivery agents.[56]  To the best of our knowledge, there have been no previous 
articles reporting the encapsulation of dendrimers into polymeric NPs. 
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Release studies of the G3-NH2-FITC from the polymeric matrix were 
conducted in 1X HBSS, the medium in which the transport experiments were to be 
conducted, as described in the earlier sections.  Additionally release studies were 
conducted in mucus laden HBSS, in order to simulate an environment that the NPs 
will encounter in the vicinity of the cell milieu and understand the impact of the 
surroundings on the G3-NH2-FITC release.  These experiments were conducted in 
triplicate.  The release studies were conducted for a period of 24h, with supernatant 
removed and tested at periodic time points for the released conjugates.  A plot of 
cumulative release G3-NH2-FITC from PLGA NPs as a function of time is shown in 
Figure 3.2(b).  It is observed that a sustained release of G3-NH2-FITC can be 
achieved from the NPs within the time span investigated, with about 24% of the 
conjugate being released into the buffer by 24h.  A similar release profile was also 
exhibited by the NPs when the studies were conducted in the mucus dissolved buffer.  
In order to put these release studies in perspective, it would be instructive to compare 
the results to compounds of similar size as the DNCs that have been encapsulated 
into PLGA NPs, with PLGA of similar molecular weight.  Interestingly, insulin (MW 
5808 Da) loaded into PLGA (MW 50 kDa) NPs exhibited a similar release profile as 
the G3-NH2-FITC reported in this work.[58]  However, in our work, we observed a 
more subtle, sustained release of the conjugates during the initial times as opposed 
to a sudden burst release, which has been reported for the aforementioned and 
several other systems.[59, 60]  This can be attributed to the relatively low loading 
efficiency of the conjugates within the NPs, and the MW of the polymer.[54]  The 
effect of lower loading of encapsulates into NPs on the release characteristics has 
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been extensively reported in literature.[61]  For instance, PLA NPs containing varying 
payloads of savoxepine, a potent antipsychotic compound, displayed dual release 
profiles.  An initial burst and faster release characteristics were observed for NPs with 
higher encapsulated payloads, while those with lower drug contents displayed little or 
no burst release, and considerably slower release profiles.[62]  This behavior was 
also observed for a protein, Bovine Serum Albumin (BSA) loaded into PLGA 
microspheres.[63]  Another factor that could possibly influence the release 
characteristics of G3-NH2-FITC from the polymeric matrix is the presence of surface-
associated PVA, which is usually present on the smaller NP surface, and which has 
been shown to hinder the diffusion of encapsulated compounds from within the 
NPs.[63]  This is an important observation, as sustained-release profiles of moieties 
from polymeric matrices is expected to be primarily governed by diffusion processes 
during the early stages of release.[63] 
 
3.4.3 Cytotoxicity of G3-NH2-FITC and G3-NH2-FITC loaded NPs on Calu-3 
 cells.   
 The cytotoxicity of the conjugates and the dendrimer-NP blends were tested 
on Calu-3 cells.  Cell viability was determined using the MTT assay as described in 
Methods.  The cell viability results are plotted as a function of the concentration of 
G3-NH2-FITC and of the dendrimer-NP blend, and are shown in Figure 3.3.  The 
results reported here are those for a period of 7 h, as transport studies conducted in 
this work lasted 5h – see transport result below. 
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            The results show that neither the bare conjugate dendrimer nor the conjugate 
formulated as NPs induced any appreciable cytotoxicity on Calu-3 cells within the 
concentration ranges and the duration investigated.  It has been well established that 
cytotoxicity of dendrimers are concentration, charge and generation dependent, with 
cationic dendrimers of higher generations exhibiting greater cell kill than their anionic 
and lower generation counterparts.[15, 64]  As there have been no previous  
 
cytotoxicity studies of G3-NH2-FITC onto Calu-3 cells, it would be appropriate to 
compare our results to studies performed on Caco-2 cells, which is a colon cancer 
cell line that exhibits certain characteristics somewhat similar to Calu-3 (possess 
microvilli on the apical surface and form tight epithelial junctions).[20, 65]  
Experiments conducted on Caco-2 cells show that G3–NH2-FITC are non-toxic up to 
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Figure 3.3 Viability of Calu-3 cells upon exposure to varying 
concentrations of (a) G3-NH2-FITC; and (b) G3-NH2-FITC-loaded PLGA 
NPs.  Viability determined by MTT assay (n=4), after 7h of exposure. 
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a concentration of 10 µmol (~69 mg) per mL, which is much higher than the 
concentration range investigated in this work.[66]  The combination of G3-NH2-FITC 
and PLGA NPs did not exert any toxic effect on the cell monolayers within the 
concentration tested either, as shown in Figure 3.3b.  This is not surprising, as 
previous cell viability studies on Calu-3 cells have reported that PLGA NPs did not 
induce any pronounced cytotoxic effects even at 48h after exposure for 
concentrations of up to 5 mg of NPs per mL.[67, 68]  The non-toxic nature of the G3-
NH2-FITC loaded NPs suggests that the encapsulation of dendrimer conjugates 
within NPs may possibly also be seen as a viable strategy to alleviate the potential 
toxicity associated with higher concentrations and / or high dendrimer generation, 
and their corresponding conjugates.  The encapsulation of dendrimers in NPs may 
also alleviate issues regarding to the solubility of dendrimer nanocarriers in 
physiological environment in cases when their surface is modified with hydrophobic 
therapeutics. 
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3.4.4 Characterization of the Calu-3 monolayers for transport studies.   
            
           
 
 
 
 
 
 
 
 
        
 
 
 
 
The human airway epithelial cell line Calu-3 was used to assess the 
permeability and uptake of the G3-NH2-FITC and G3-NH2-FITC encapsulated into 
PLGA NPs.  Calu-3 is a well-differentiated and characterized cell line derived from 
human bronchial sub mucosal glands.[27]  Besides producing tight junctions, Calu-3 
is one of the few respiratory cell lines capable of expressing many important 
characteristics of the bronchial epithelium in vitro, viz. production of airway surface 
liquid, mucin excretion, cilia, and other immunologically active substances that make 
0 2 4 6 8 10 12
0
100
200
300
400
500
600
 
 
T
E
E
R
 (
Ω
⋅
Ω
⋅
Ω
⋅
Ω
⋅c
m
2
)
Days
Figure 3.4.   Variation in transepithelial electrical resistance (TEER) 
across Calu-3 monolayers (n=12) grown in Transwell® inserts (0.4 µm 
pore size and 0.33 cm2 area) under an air-interface culture (AIC) as a 
function of time.  The TEER values were obtained after equilibrating 
the apical chamber with the culture medium for 30 minutes.  The 
TEER reported here was corrected for the resistance of the blank 
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Calu-3 an appropriate candidate for elucidating tracheobronchial permeability in 
vitro.[27, 37] 
Calu-3 cells were plated at a density of 0.5×106 cells per insert, in DMEM 
supplemented with 15% FBS and 1% antibiotics as described earlier.  The cells were 
grown under a liquid-covered culture for 48 hours, after which the medium in the 
apical compartment was removed and the cells were allowed to grow under AIC.  It 
has been shown that when grown at AIC, Calu-3 cells exhibit a greater resemblance 
to the native epithelium (microvilli/cilia, mucins and other relevant glycoproteins), and 
hence that particular method of culture was employed in this study.[37] 
The TEER of the Calu-3 monolayers was measured to ascertain their 
confluence.[37]. A plot of the TEER afforded by the cell monolayer as a function of 
time (days in culture) is shown in Figure 3.4.   The TEER of the Calu-3 monolayers is 
seen to increase steadily above baseline by day 5, and to reach confluence by day 8.  
The values leveled by day 11, indicating that the monolayer had reached the level of 
confluence required to conduct the transport studies.[37, 38]  These results compare 
favorably with the results reported in the literature for Calu-3 cells cultured under AIC, 
which are deemed confluent for TEER values peaking beyond ca. 300 Ω·cm2,[37, 69] 
values which are dependent to some extent to the culture conditions and cell 
passage.[70] 
In addition to determining the TEER of the monolayers, immunocytochemical 
(IC) analysis and electron microscopy studies were conducted to visually ascertain 
the presence of tight junctions and morphology of the confluent Calu-3 monolayers.  
In this work, IC analysis and electron microscopy experiments were performed a day 
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prior to commencement of the transport studies.  The cell monolayers were prepared 
for both studies as detailed in the methods section.  Figure 3.5 (a) is a representative 
electron micrograph of a Calu-3 monolayer fixed and stained with osmium tetroxide, 
and reveals that the confluent Calu-3 monolayers displayed some of the requisite 
morphology possessed by confluent Calu-3 viz. microvilli (filled white arrows). 
IC analysis was performed on the cell monolayers to detect the presence of 
Zona Occludens Protein - 1 (ZO-1), which is a major protein expressed in the tight 
junctions of confluent Calu-3 cells.[70]  The presence of the protein was detected by 
staining the fixed cells with an anti-ZO-1 antibody labeled with Alexa Fluor® 546.[37]  
The nuclear stain, DAPI, was utilized as a counterstain.  A representative fluorescent 
microscope image of the fixed and stained Calu-3 monolayer is shown in Figure 
3.5(b). The presence of orange boundaries (denoted by the yellow arrows) around 
the cells can be attributed to the expression of ZO-1 protein.  Calu-3 cells when 
cultured under AIC have been shown to secrete a greater amount of glycoproteins 
(mucins) on their surface,[37] which can be detected by staining the cell surface with 
Alcian Blue.[37, 70]  Figure 3.5(c) is an optical microscope image captured after the 
cells were stained with Alcian Blue and fixed.  The heavy blue staining on the 
monolayer surface (open black arrows) is an indicator of the presence of mucosal 
glycoproteins on Calu-3 cultures grown under AIC.  The observations reported here 
are in agreement with those reported in earlier studies characterizing confluent Calu-
3 monolayers.[38, 70]  Once the monolayers were characterized and their 
morphology ascertained, they were subject to transport experiments, which are 
discussed next. 
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3.4.5  In-vitro transport and uptake.  
In-vitro transport of bare G3-NH2-FITC and those loaded into NPs were 
conducted on confluent Calu-3 cell monolayers for a period of 5h.  A summary of the 
Papp (y1 axis) results as a function of time for bare G3-NH2-FITC, and those 
Figure 3.5.  (a) Representative SEM micrograph of Calu-3 monolayers grown 
under an air-interface culture (AIC).  Monolayers were isolated once the TEER 
values peaked and leveled.  Cell monolayers were fixed and stained with osmium 
tetroxide, and dehydrated in increasing gradients of ethanol after which they 
were lyophilized.  White arrows indicate the presence of microvilli on the 
monolayer surface.  (b) Fluorescent microscope image of Calu-3 monolayers 
showing the presence of tight junctions (yellow arrows) populating the cell 
periphery.  Red arrows indicate the location of the nuclei (stained with DAPI - 
blue).  Cells were seeded at a density of 0.5×106 per well and were grown under 
AIC.  The cells were stained for the tight junctional protein, Zona Occludens-1 
(ZO-1) labeled with Alexa Fluor® 546 dye (orange) and counterstained with DAPI 
for nuclei.  (c) Optical microscope image of a Calu-3 monolayer stained with 
Alcian blue, indicating the presence of glycoproteins (mucins, unfilled black). 
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formulated as blends within PLGA NPs across Calu-3 is shown in Figure 3.6. The y2 
axis in the plot denotes the cumulative mass of G3-NH2-FITC transported (in 
percentage) across the cell monolayer as a function of time after pulsing. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
At the end of the 5h time point, the Papp of the G3-NH2-FITC across Calu-3 
was found to be 1.4 × 10-7 cms-1.  About 1.7% of the conjugates had traversed 
across the monolayer within 5h.  An increase in the Papp value from 0.7 to (a peak of) 
2.8 × 10-7 cm·s-1 was observed at 2h, followed by a subsequent decrease to 1.4 × 10-
7 cm·s-1 by at the end of the experiment, indicating the presence of an ‘activation’ 
time for transport.  This coincides with a minimum in the TEER, which may indicate a 
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preference with regards to transport route.   On the other hand, for the system 
comprised of G3-NH2-FITC formulated as blends with the PLGA-NPs, no transport 
was observed within the duration of the experiment.  Slow release of the conjugates 
(low concentration of the G3-NH2-FITC in the donor chamber) from the NPs is 
expected to help mediate the transport of the DNCs across the monolayer.  From the 
sustained release studies discussed above, it is estimated that only ca. 5% of the 
encapsulated conjugate is released from the polymeric matrix within 5h.  Because the 
concentration of the DNCs is expected to impact their permeability,[20] the 
encapsulation of the dendrimer within the  NPs is expected to impact (reduce) the 
rate of transport.  Moreover, the NPs themselves are not expected to be transport 
across the Calu-3 monolayer, further reducing the potential for transport of the 
DNCs.[40] 
Cell monolayers incubated with bare G3-NH2-FITC and G3-NH2-FITC loaded 
PLGA NPs were lysed after the transport experiments so as to quantify cellular 
uptake.  The results indicated that 16±1.7% of the bare G3-NH2-FITC (0.08 nmol) 
and 19±2.1% (0.1 nmol) of the G3-NH2-FITC from the NPs were internalized into the 
cells during the study.  It is quite interesting to observe that the dendrimer 
internalization seems to be greater with NPs compared to free dendrimers.  A mass 
balance of the dendrimers was accomplished by quantifying the contents of the 
apical chamber for G3-NH2-FITC after the completion of the transport studies, and 
combining those values with those obtained from analyzing the contents internalized 
into cells and the contents transported across to the basolateral side.  The total 
amount recovered from these analyses (for both systems) was 85% - out of the total 
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pulsed onto the cells.  In comparison, earlier translocation studies conducted on 
Calu-3 cells utilizing polymeric NPs of similar size as those discussed here reported 
an internalization of 11%, with a recovery of up to 93%.[40]  The lower recovery could 
be attributed to losses associated with the fraction of carriers that may be bound to 
the cell surface despite washing – that fraction will settle down along with the cell 
debris during the centrifugation.   Losses may also arise due to adsorption of 
particles to other surfaces, and also quenching of the fluorophore. 
While no previous results for internalization or transport of dendrimers across 
Calu-3 cells have been reported yet, it is interesting to put the results of this work in 
perspective by comparing with other cell types.  The transport of G3-NH2-FITC 
across Calu-3 cells is observed to be qualitatively different than that reported for 
Caco-2 cells, where no apparent maximum in permeability has been reported.[20, 71]  
However, the magnitude of the Papp of the G3-NH2-FITC across the Calu-3 
monolayer was observed to be similar to that reported across Caco-2 monolayers, 
which was ca. 0.8 × 10-7 cm·s-1 at 150 min.[71]  While these numbers seem to be in 
agreement, caution should be exercised when drawing such comparisons, as factors 
including cell type, donor chamber concentration, and duration of the study can 
greatly influence the overall rate of transport.[15, 72]  For instance, in the 
aforementioned studies, typical donor concentrations employed were at least 0.1 
mM, which is considerably larger compared to this study (3.2 nmol).  The similarities 
in these numbers at such dramatically different concentrations of the nanocarriers 
highlight the potential impact of the cell type.  For instance, at concentrations of 0.1 
mgmL-1 G3-NH2-FITC dendrimers had Papp values of 5.5 × 10
-7 cm·s-1 across Madin-
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Darby canine kidney cells (MDCK).[73]  These values were markedly different when 
compared to what was observed for both Caco-2 and Calu-3 cells.  Another factor 
that can also influence the permeability of G3-NH2-FITC is the donor chamber 
concentration and incubation time.[15, 17, 71]  For Caco-2 cells, at two different 
donor concentrations of 10 mM and 1 mM, the Papp values were determined to be 
2.7× 10-7 cm·s-1  and 0.6× 10-7 cm·s-1, respectively.[71]  In another study, transport of 
G2-NH2 (generation 2 dendrimers) studied on MDCK cells at increasing donor 
chamber concentrations from 50 µg to 300 µg resulted in ca. 4-fold increase of the 
Papp values.[73]  These studies highlight the dependence of Papp on the initial donor 
chamber concentration.  To put things in perspective, a comparison of the Papp values 
can be also made against some of the most common paracellular and transcellular 
markers.  FITC-dextran, a common paracellular marker, of similar MW (10 KDa) was 
reported to have an Papp value of ca.  2 ×10
-7 cm·s-1 across Calu-3 monolayers 
cultured under AIC – similar to what was observed in this case, while small lipophilic 
compounds that primarily traverse across Calu-3 monolayers via transcellular route, 
have much higher permeabilities, with Papp in the range of 10
-5 to 10-6 cm·s-1 [37, 74] 
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TEER measurements were used to understand the impact of the nanocarriers 
onto the monolayer integrity.  The results for G3-NH2-FITC, NP containing G3-NH2-
FITC, and NPs alone are shown in Figure 3.7.   From the plot, a marked reduction 
(~60% of control) in the TEER of the Calu-3 cell monolayers incubated with G3-NH2-
FITC was observed.  Similar results have been reported when studying the transport 
of dendrimer conjugates across Caco-2 cell lines,[75] where a strong association 
between paracellular transport (through the cellular tight junctions) and TEER 
reduction was proposed.  The integrity of the tight junctions populating the cell 
monolayers has been shown to be altered in the presence of positive charges such 
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Figure 3.7.  Variation in TEER of Calu-3 monolayers as a function of 
time, upon incubation with bare G3-NH2-FITC, bare PLGA NPs, and 
NPs loaded with G3-NH2-FITC.  Results are reported as % reduction 
in TEER compared to control (cells incubated in blank HBSS). (n=4) 
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as the amine surface groups of G3-PAMAM dendrimers.[76]  Our experiments 
revealed that replacing the G3-NH2-FITC laden media with culture medium after 5h 
resulted in the revival of TEER to 80% of the control after 3 days – we stopped the 
experiments at that time, but it is possible that further TEER recovery could be 
observed after that time period.  This is an important finding as these results, coupled 
with the lack of cytotoxicity on Calu-3 cells within the concentration ranges tested, 
reaffirm the potential of G3-NH2 dendrimers as drug carriers for lung delivery. 
The TEER reduction was also evaluated for the cell monolayers incubated 
with G3-NH2-FITC loaded NPs.  The studies revealed that there was no significant 
reduction in the TEER values of the cells incubated with the G3-NH2-FITC loaded 
NPs compared to that of the control.  The same observation was recorded for blank 
PLGA NPs pulsed onto Calu-3 cells.  These results agree with earlier studies where it 
has been shown that PLGA NPs incubated on Calu-3 and on other epithelial cells did 
not alter the TEER, suggesting that the NPs do not interfere with the tight junctional 
integrity.[41, 77]  An impact on the TEER seems to correlate well with the ability of 
the nanocarrier to transport across the monolayer. This is also clearly a concentration 
dependent effect, as when the dendrimers are released in small concentrations from 
the NPs, they do not to significantly affect the TEER, and are also not transported 
across the monolayer either. 
 
3.4.6 Uptake studies with FACS. 
Flow cytometry was employed in order to quantitatively determine the extent of 
internalization of bare G3-NH2-FITC, G3-NH2-FITC loaded NPs and PLGA-FITC NPs  
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Figure 3.8 (a) Cellular entry of G3-NH2-FITC, G3-NH2-FITC loaded PLGA NPs, 
and PLGA-FITC NPs into Calu-3 as a function of time, as determined by FACS - 
mean fluorescence intensity values (MFI).  The results shown here are averages 
of 6 replicates for each system, with at least 6000 events counted per system;  (b) 
Rate of cell entry vs. time obtained by recasting MFI values relative to their 
cellular uptake at 5h;  (c) Effect of cell polarization on the cellular entry of G3-NH2-
FITC.  The error bars represent standard deviation (n=6 wells per time point; 6000 
events for each well). 
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into polarized Calu-3 cells as a function of time.  These results are highly 
complementary to the quantification of dendrimer concentration in the cell lysate 
discussed above.  The results above provide an internalized amount based on an 
absolute scale - % out of total pulsed into the apical side of the insert, which is 
obtained at a single time point – at the end (5h) of the experiment.  The FACS results 
on the other hand provide a relative scale of the extent of the internalization, where 
the kinetics of cellular uptake is emphasized.  In the FACS work we also include a 
study with the PLGA-FITC NPs, which was run at the same concentration as the NP 
blend with dendrimer.  This extra system was added in order to decouple the effect of 
NP internalization to that of the internalization of the FITC-dendrimer released from 
the NPs into the medium during the experiment, as discussed in more detail below.   
For each system, at least 6000 events were counted.  The results of the mean 
fluorescent intensity (MFI) values obtained from FACS for each system (G3-NH2-
FITC, G3-NH2-FITC loaded NPs and PLGA-FITC NPs) are summarized in Figure 3.8 
as a function of time.  The results from Figure 3.8a are recast in Figure 3.8b as a 
percentage relative to the total internalization at 5h (which was set as 100%) in order 
to better understand the rate of cellular entry.[42]  Note that this is done in spite of 
the fact that not all curves seem to have leveled off at that time, but nonetheless it will 
prove useful in this discussion.  The results in Figure 3.8c serve to highlight the effect 
of monolayer polarization on cellular uptake - the uptake results for a selected system 
(G3-NH2-FITC) are summarized in Figure 8c for polarized vs. non-polarized Calu-3 
monolayers. 
113 
 
 
 
A sustained increase in cellular uptake, followed by a subsequent leveling off 
was observed in the case of G3-NH2-FITC nanocarriers – Figure 3.8a. The leveling 
off in the cellular uptake was consistent with previous studies, where a similar trend 
with respect to the uptake of FITC-conjugated cationic dendrimers was observed on 
A549 cells.[42]  This phenomenon was attributed to the fact that cationic dendrimers 
are typically internalized via adsorptive endocytosis, mediated by the presence of 
negatively charged proteoglycans on the cell membrane.[42]  The uptake kinetics for 
this mode of internalization follows a curvilinear pattern likely due to saturation of 
membrane binding sites.  A similar observation was also reported in B16f10 
melanoma cells.[78]  Interestingly, the internalization for cationic dendrimers in A549 
cells leveled off within an hour after pulsing.[42]  However, in this work, we observed 
a more gradual leveling off in the rate of internalization, with ca. only 60% being 
internalized after 1h – Figure 3.8b.  This could possibly be attributed to differences in 
dendrimer generation and cell type, as both can influence cellular uptake.[15, 79]  
Another factor that could have potentially affected the rate of internalization is that, 
different from A549 cells, Calu-3 cells express mucins, which are negatively charged 
proteins that may interact with the dendrimers via electrostatic interactions, effectively 
hindering their transport to the cell surface.[80] 
When compared to the G3-NH2-FITC nanocarriers, the NPs (FITC-PLGA NPs) 
are seen to be internalized at a much lower rate – Figure 3.8b.  It has been 
previously reported that particles in the size range of 30 nm diffuse unhindered 
across mucosal layers, while larger particles diffused at a much slower pace.[80]  It 
seems, therefore, that despite their positive charge, G3-NH2-FITC, being much 
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smaller than NPs, traverse the mucus layer at a much faster rate compared to what 
has been observed for NPs.  It is also interesting to observe that there seems to be 
an induction period in terms of the internalization of the NPs, which was not observed 
for the free dendrimers.  After an initial internalization, very little in terms of NPs 
seems to be taken up between 1 and 3h, when the rate of internalization starts 
increasing again.  Even after 5h, the trend in the uptake curve appears to suggest 
that NPs continue to be internalized.  This could be potentially related to the difficulty 
in diffusing through the mucosal layer at early times, as discussed above, but the 
ability of those particles to eventually traverse the mucus layer and to start being 
subsequently internalized. 
The G3-NH2-FITC-NP blends internalized at a rate similar to that of the FITC-
PLGA NPs in the first 30 min of experiments, after which the rate of internalization 
more closely resembled that of the free G3-NH2-FITC – Figure 3.8b.  These results 
suggest that initial dendrimer internalization happened mostly as a blend (within the 
NPs).  Different from the G3-NH2-FITC, the uptake of PLGA NPs into the cell milieu is 
mostly expected to occur via internalization mechanisms distinct to those of positively 
charged dendrimers (at least how it is mediated at the cell surface), such as 
pinocytosis or clathrin-mediated endocytosis, owing to the negative charge and size 
of NPs.[81]  This may help explain the variation in the rate of uptake when compared 
to that of bare G3-NH2-FITC.  However, after 1h, even when the release of the 
dendrimer from the NPs is relatively small at ca. 1.5%, the internalization of (free) 
dendrimers released from the NPs, and not as blends, seem to take over the 
internalization process.  It is interesting to see that even after 5h, the internalization 
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process does not seem to have leveled off, different from the case of free 
dendrimers.  This may be due to the fact that the internalization of the NPs increase 
at later times – after an induction period as discussed for the FITC-PLGA NPs.  The 
increasing presence of free dendrimer released from the NPs is also likely to 
contribute to the fact that the curve seems to not level off at 5h. 
Given that the same mass/molar concentration of dendrimer is added to the 
system for both free dendrimer and dendrimer encapsulated within the NPs 
(dendrimer in the blends), the MFI for the respective curves shown in Figure 8a can 
be directly compared.  The dual mode of uptake of the dendrimer when formulated as 
blends (within the NPs as a blend, and as free dendrimer) seems to facilitate the 
internalization of a greater amount of dendrimer into the cell, thus effectively 
preventing the saturation seen in the case of free dendrimer.  This is especially 
attractive as a drug delivery strategy as one can control not only the rate of delivery, 
but also the total cellular uptake.  The ability to enhance uptake may be achieved by 
eliciting different endocytic pathways as can be done by varying the surface 
characteristics of nanocarriers,[64, 81] and this is currently under investigation. 
Another important aspect of the FACS study was to elucidate the effect of 
Calu-3 polarization on cellular uptake.  Polarized Calu-3 cells are expected to form 
tight junctional monolayers and exhibit all requisite morphological features inherent to 
them,[82] which also includes a different composition of the apical and basolateral 
membrane.[83]  Because cellular uptake is surface-mediated, the composition of the 
apical side of the membrane is expected to impact uptake.  Calu-3 was cultured to 
form polarized monolayers as described in the earlier sections.  In case of the non-
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polarized cells, the cells were seeded at the same density in 24-well plates and 
allowed to proliferate for a period of (only) 4 days prior to pulsing them with the G3-
NH2-FITC, when the cells were determined to be non-confluent.  A plot of the MFI as 
a function of time for both non-polarized and polarized cells is shown in Figure 3.7c.  
From the figure, a marked increase in cellular uptake was observed for the non-
polarized Calu-3 cells, with no signs of saturation in internalization by 5h, in sharp 
contrast to the results observed for the polarized layer.  The results thus emphasize 
the relevance in performing the internalization studies on polarized monolayers. 
In summary, the transport and internalization results described above suggest 
that the G3-NH2-FITC can not only be effectively transported across Calu-3 
monolayers, but also efficiently internalized in the cell milieu.  The results also show 
that further mediation in terms of both cellular uptake into Calu-3 cells, and transport 
across the respective monolayers may be achieved by blending the DNCs within 
polymeric NPs.  In the sections that follow, we present a strategy to formulate 
dendrimer nanocarriers into propellant-based OI formulations (pressurized metered-
dose inhalers, pMDIs), with aerosol characteristics conducive to the deep lung 
deposition.  Together with a recent publication from our group that demonstrate the 
ability to formulate polymeric NPs in pMDIs,[28, 30] the results demonstrate the 
potential in using the nanocarriers discussed here as platforms for the delivery of 
therapeutics to the lungs for local or systemic delivery. 
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3.4.7 Preparation and characterization of G3-NH2-FITC loaded core-shell  
         particles.   
Given the fact that the dendrimer nanocarriers are highly positively charged, 
we expected them not to be easily dispersible in the low dielectric HFAs.[84, 85]  
Another potential issue in formulating the nanocarriers in propellant-based inhalers 
that needed to be considered is the fact that the optimum size of the aerosol particles 
for deep lung deposition (a few microns in diameter)[3] falls far outside the size of the 
dendrimer nanocarriers (a few nanometers in diameter).  These will be considered in 
more detail in the discussion that follows.  In this section we present a particle 
engineering technology that was pursued to formulate the dendrimer nanocarriers as 
micron-sized particles with enhanced physical stability in the propellant HFA, as an 
attempt to address the concerns mentioned above. 
Loading of G3-NH2-FITC into core-shell particles was accomplished via a 
modified emulsification-diffusion methodology.[28, 44]  OLA-g-CS is a water soluble 
co-oligomer that has been shown to aid in the formation of stable particle dispersions 
in propellant HFAs due to the presence of ester groups, which have been shown to 
be highly HFA-philic.[86]  A representative SEM micrograph of the G3-NH2-FITC 
loaded core-shell particles is shown in Figure 3.9.  The size distribution of these 
particles as determined by DLS in a model HFA (HPFP, which is liquid at ambient 
conditions) is shown as an inset in the same figure 3.8. 
The SEM micrograph indicates the formation of smooth, fairly polydisperse 
(but with a single peak) particles.  The average size of the particles was determined 
to be 1.0 ± 0.2 µm, with a polydispersity of 0.3.  The geometric size range of the 
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particles formed here is well within the range prescribed for efficient deep lung 
deposition of inhaled aerosols.[2]  The encapsulation efficiency of the G3-NH2-FITC 
was determined using fluorometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        The loading of G3-NH2-FITC in the core-shell particles was determined to be 
0.06 ± 0.01 mg of dendrimer per mg co-oligomer, which corresponds to an 
encapsulation efficiency of 37±5%.  While we have not attempted to encapsulate the 
G3-NH2-FITC-loaded NPs in such core-shell particles, we have recently 
demonstrated the applicability of similar methodology in the encapsulation of 
polymeric NPs containing a fluorescent probe, which is of similar size and surface 
Figure 3.9. SEM micrograph of the G3-NH2-FITC-loaded core-shell particles 
prepared via emulsification-diffusion. (Inset)  Size distribution of G3-NH2-FITC-
loaded core-shell particles prepared using emulsification diffusion, as 
estimated by DLS, in HPFP, a model (liquid at ambient conditions) propellant 
HFA. 
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characteristics, and thus expect that strategy to be also applicable to the to the G3-
NH2-FITC-loaded PLGA NPs.[28] 
3.4.8 Physical stability of G3-NH2-FITC loaded core-shell particles in 
 HFA227. 
           The stability of freshly prepared G3-NH2-FITC loaded core-shell particles and 
bare G3-NH2-FITC dispersions in HFA227 was assessed by visually ascertaining the 
rate of sedimentation of the formulations as a function of time.  Digital photographs 
were captured at predetermined times after the mechanical energy for dispersing the 
particles ceased, in order to assess the quality of the dispersions.  Images captured 
at t=0h and t=2h are shown in Figure 3.10.  The physical stability of formulations 
prepared using bare G3-NH2-FITC are also shown as insets.  The concentration of 
the core-shell particles was 2 mg·mL-1 (corresponding to 0.14 mg of the conjugate).  
A similar concentration of the G3-NH2-FITC (0.15 mg.mL
-1) was utilized for the bare 
formulation. 
From the images, as expected, the dispersions formulated using the core-shell 
particles are seen to possess superior physical stability when compared to the bare 
G3-NH2-FITC formulation.  The bare G3-NH2-FITC formulated in the propellant 
creamed within a few seconds, and remained as aggregate, even after further 
mechanical energy input.  For the core-shell formulation, creaming of the particles 
due to gravitational forces was observed - these are micron particles compared to the 
nanometer-sized dendrimers.  These particles form loose aggregates that can be 
easily broken up and redispersed by simple manual agitation, indicating that the 
particles did not irreversibly flocculate. 
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3.4.9. Aerosol characteristics of G3-NH2-FITC loaded core-shell 
          particles.   
           Cascade impaction studies were conducted using an ACI in order to 
quantitatively assess the aerosol quality of the pMDI formulations, and the effect of 
the proposed particle engineering technology.  ACI is an in vitro testing device 
comprised of 8-stages, with each stage representing a region of the lung, as 
benchmarked by in vivo and in vitro studies.[44, 87]  Actuating the formulation  
 
 
 
0 h  2 h 
0 h 0.5 h 
Figure 3.10.  Dispersion stability of G3-NH2-FITC formulated as core-shell 
particles in HFA 227 at 2 mg.mL-1, 298 K, and saturation pressure of the 
propellant mixture.  The digital images were obtained as soon as the 
mechanical energy input for dispersing the system was halted, and as a 
function of time after that.  (Inset) Formulations prepared using bare G3-
NH2-FITC at 0.15 mg.mL
-1 concentration. 
121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1  Aerodynamic characteristics of the G3-NH2-FITC-loaded core-shell and bare 
G3-NH2-FITC formulations in HFA227 at 298 K and saturation pressure of the 
propellant.  The particle concentration was 2 mgmL-1 for the G3-NH2-FITC-loaded core-
shell formulation and 0.15 mgmL-1 (corresponding to G3-NH2-FITC mass loading in the 
core-shell particles) for bare G3-NH2-FITC formulation.  The mass reported is that of the 
G3-NH2-FITC.  The average and deviation were obtained from three independent runs 
(n=3).  FPF  = fine particle fraction, AC = actuator, and IP = induction port.  MMAD and 
GSD are the mass mean aerodynamic diameter and geometric standard deviation, 
respectively. 
Stages 
G3-NH2-FITC concentration  
(Core-shell) (µg ± s.d) (n=3 
runs) 
G3-NH2-FITC concentration 
(bare) (µg ± s.d) (n=3 runs) 
AC 2.4 ± 1.6 1.4 ± 0.5 
IP 25.2 ± 7.8 2.1 ± 0.8 
Stage 0 (9.0-10.0µm) 4.7 ± 1.9 0.4 ± 0.1 
Stage 1 (5.8-9.0 µm) 9.2 ± 7.1 - 
Stage 2 (4.7-5.8 µm) 3.5 ± 1.5 - 
Stage 3 (3.3-4.7 µm) 16.7 ± 3.5 - 
Stage 4 (2.1-3.3 µm) 15.3 ± 1.3 - 
Stage 5 (1.1-2.1 µm) 11.6 ± 2.6 - 
Stage 6 (0.7-1.1 µm) 3.3 ± 2.1 - 
Stage 7 (0.4-0.7 µm) 2.0 ± 1.2 - 
Filter (0-0.4 µm) 6.4 ± 4.7 3.2± 1.3 
Single Puff Dose (µg) 4.7 ± 0.7 - 
FPF (%) 55.1 ± 5.2 - 
MMAD (µm) 3.0 ± 0.4 - 
GSD 2.5 ± 0.1  
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through the device under vacuum at a constant flow rate deposits the particles (free 
dendrimers or core-shell particles containing the G3-NH2-FITC) on different stages 
depending on the aerosol size - larger aerosol particles are retained on the earlier 
stages of the impactor, while the smaller ones are retained in the later stages.[88]  
The amount of the G3-NH2-FITC deposited on these stages was quantified by 
fluorometry, and relevant aerosol properties, including the FPF, MMAD and GSD 
were determined.  FPF (fraction on stages 3-F of the ACI) is a measure of the 
efficiency of deposition in the deep lungs.  MMAD is defined as the median of the 
airborne particle mass distribution with respect to the aerodynamic diameter.  MMAD 
is always accompanied by GSD, which characterizes the variability of the particle 
size distribution.[88] 
The ACI results for both the core-shell and the bare G3-NH2-FITC formulation 
are summarized in Table 3.1, and recast as a % in Figure 3.11.  The figure in % is 
easier for visualization and comparison of the different formulations, but does not 
contain the raw information required for the various calculations.  Therefore, we 
include both figure and table.  The values reported here are averages of three 
independent experiments obtained with three different canisters, with 20 actuations 
per canister. 
The FPF for the formulation with the G3-NH2-FITC loaded core-shell particles 
was 55±5%.  We also achieved a high recovery efficiency for this formulation - mass 
collected relative to the estimated amount delivered based on the formulation 
concentration and reservoir volume - 80±8%.  In comparison, the bare G3-NH2-FITC 
formulation had a very poor recovery efficiency (ca. 5%), making a reliable estimation 
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of the FPF and other aerosol properties impractical.  The low recovery for the 
formulation with free dendrimer can be attributed to the fact that the system is not 
well dispersed within the canister, and other losses due to perhaps the small sizes of 
the dendrimers. 
 
 
 
 
 
            
 
 
 
 
 
 
 
 
From what was collected, a large fraction was detected in the induction port 
and filter regions of the actuator, indicating the aggregation and erratic dispersion of 
these carriers within the propellant.  These results further corroborate our earlier 
hypothesis, where, through a combination of sedimentation rate experiments and 
colloidal probe microscopy,[44, 84] we have shown that there is a direct correlation 
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Figure 3.11.  Anderson Cascade impaction results of the G3-NH2-FITC 
formulated (a) as core-shell microparticles, and (b) as bare G3-NH2-FITC in 
HFA 227, at 298 K and saturation pressure of the propellant.  Particle 
concentration was 2 mgmL-1 for the core-shell preparation while the 
concentration for the bare G3-NH2-FITC formulation was 0.15 mgmL
-1.  AC, 
IP and F refer to actuator, induction port, and filter, respectively. 
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between the physical stability of the formulations in the propellant, and the 
corresponding aerosol characteristics.[44]  The aerosol properties of the G3-NH2-
FITC core-shell formulation compare favorably with those of commercial pMDI 
formulations containing dispersed crystals of small molecular weight therapeutics.[44, 
89]  For instance, Ventolin HFA®, a commercial formulation for asthma and chronic 
obstructive pulmonary disease (COPD) reported an FPF of 46% under the same 
conditions – note we have not attempted to optimize the FPF through changes in 
hardware nor particle size/distribution, when we would expect to achieve even larger 
FPFs.[44]  The MMAD and GSD of the core-shell formulation, was calculated to be 
3.0 µm and 2.5 µm, respectively, which is in good agreement with values required for 
enhanced deposition to the deep lungs.[3] 
These results suggest that G3-NH2-FITC formulations with good aerosol 
characteristics can be prepared using the proposed particle engineering strategy.  
Such platforms have thus the potential to be utilized to treat local ailments of the 
lungs, or in the treatment of systemic disorders through careful carrier design – 
transport modulation, as discussed above. 
 
 
 
 
 
 
 
125 
 
 
 
3.5   Conclusions. 
 
In this work we demonstrate that the internalization and transport of G3-NH2-
FITC across a model of the pulmonary epithelium can be modulated by forming 
nanoblends of G3-NH2-FITC with PLGA.  The kinetics of internalization of the blends 
is very different from that of the free dendrimers.  While saturation in cellular uptake 
is observed in the case of free G3-NH2-FITC, the same is not seen for the solid NP 
blends containing the dendrimers, within the time frame of the experiments – 5h.  
Another interesting feature observed is that while there seems to be an induction 
period over which the uptake of the NPs is slow, as expected due to the larger size of 
the NPs, the presence of a mucus layer covering the Calu-3 cells, and the negative 
surface charge of the NPs, the total uptake of the dendrimers blended into the NPs 
increases at later times, and ends up being larger than the loading of free dendrimers 
at 5h - and it does not seem to have reached saturation at that time.  These results 
thus indicate that the formation of nanoblends may help overcome saturation, and 
thus enhance cellular uptake, by exploring alternative internalization mechanisms.  
The formulation of dendrimers as nanoblends is also seen to be very efficient in 
preventing the transport across the monolayer, as seen by a decrease in the 
apparent permeability from 10-7 cm.s-1 for the free dendrimers, to zero for dendrimers 
formulated as nanoblends.  It is also relevant to mention that, within the concentration 
range investigated in this work, both the dendrimer and nanoblends were seen to be 
fairly non cytotoxic to Calu-3 cells.  These results are particularly exciting as 
dendrimers have been suggested as effective drug delivery carriers for several 
chemotherapeutics, biomolecules, imaging agents and other relevant high potency 
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drugs.  These results, combined with the ability to efficiently formulate free 
dendrimers or solid NPs (our previous work) in pMDIs, highlight the potential of these 
nanocarriers for the OI delivery of a range of therapeutics for the treatment of 
regional and systemic diseases. 
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Chapter 4 
 
PEGylated Dendrimer Nanocarriers for Transport Modulation  
Across the Pulmonary Epithelium 
 
4.1. Introduction. 
Oral inhalation (OI) is not only the preferred mode of administration of 
therapeutics intended for the regional delivery to the lungs, but it has been also 
recognized as a promising route for the non-invasive targeting to the systemic 
circulation – through the lungs.[1, 2]  Systemic delivery through the lungs is facilitated 
due to its large surface area, low proteolytic activity, and a thin cellular barrier, 
characteristics that may enhance the bioavailability of therapeutics, and provide fast 
access to those molecules to the bloodstream.[2, 3]  Several recent clinical trials of 
OI formulations dealing with therapeutics intended to the systemic circulation attest to 
this potential.[4-6] 
Polymeric nanocarriers (PNCs) may be successfully explored in combination 
with OI formulations for the controlled and targeted local delivery of therapeutics to 
the lung tissue, and to modulate the transport of drugs across the airway epithelia.  
Such advancements hold great promise in the delivery of both small molecules and 
biomacromolecules for the treatment of medically relevant diseases such as lung 
cancer, tuberculosis, COPD, and asthma, among others.[7-13]  
The ease at which the size, morphology and surface chemistry of PNCs can 
be tailored is perhaps the most attractive feature of such drug carriers, as those 
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properties can be used to modulate the interaction of the nanocarriers with intra and 
extracellular barriers, and to selectively target desired cell populations, and even 
specific cellular organelles.[7, 14, 15]  Given these potential advantages, there are 
tremendous opportunities in combining the development of innovative OI formulations 
for the regional and systemic delivery to an through the lungs using PNCs. 
Dendrimer nanocarriers (DNCs) represent a particularly interesting class of 
polymeric nanocarriers (PNCs) as they are especially suited to tackle the many 
challenges that exist in the development of carriers for the delivery of drugs to and 
through the lungs.  DNCs are hyperbranched synthetic molecules with high 
monodispersity, and multivalency at the surface that allows the facile attachment of a 
range of moieties, including therapeutic and imaging agents.[9, 16-18]  This surface 
polyfunctionality can be exploited to tailor the DNCs with functional groups that can 
be used to modulate (i) the rate and mechanism of cellular uptake, and (ii) the extent 
of permeation across unyielding extra and intracellular barriers populating the lung 
epithelium,[16, 19, 20] and thus optimize the carrier for either local or systemic 
deliver.  The tethering of poly (ethylene glycol) (PEG) to the surface of DNCs is a 
particularly relevant strategy in this case as PEGylation to PNCs has been shown to 
minimize the carrier toxicity,[18, 21] improve transport across extracellular 
barriers,[14, 22] decrease non-specific interactions, including with serum proteins 
(opsonization),[23] lung surfactant[24] and constituents of the mucosal tissues,[25] to 
improve systemic circulation,[23, 26]  and to influence the mechanisms of cellular 
transport and uptake.[16, 21] 
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The goal of this study was to investigate the effect of PEGylation on the 
interaction of DNCs with in vitro and in vivo models of the pulmonary epithelium.  
Generation 3 (G3) poly(amido amine) (PAMAM) dendrimers with varying surface 
density of PEG (MW 1000 Da, G3NH2-nPEG1000) were synthesized, characterized, 
and their toxicity evaluated on a model airway epithelial cell line, Calu-3.  Transport 
studies of the synthesized conjugates were conducted across polarized Calu-3 
monolayers cultured under an air-interface.  Rate of cellular uptake was followed by 
flow cytometry, and the total cellular uptake quantified using cell lysis, also on 
polarized cell monolayers.  The pharmacokinetic parameters of selected conjugates 
were investigated upon lung delivery (pharyngeal aspiration) to BALB-C mice so as 
to assess the potential of PEGylation to mediate the transport of the DNCs across the 
pulmonary epithelium. 
 
4.2  Materials. 
Amine-terminated, generation 3 (G3) poly(amido amine) (PAMAM) dendrimer 
(G3NH2), with 32 surface groups, and 6882 Da as determined by MALDI (mass 
reported by the vendor is 6909 Da), poly(ethylene glycol) monomethyl ether (mPEG, 
Mn 1000 Da), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-
Hydroxysuccinimide (NHS), potassium tert butoxide, ethyl bromoacetate, fluorescein 
isothiocyanate (FITC), Bovine Serum Albumin (BSA), Trypan Blue (0.4%), Trypsin 
supplemented with 0.25% EDTA (for flow cytometry), osmium tetroxide (OsO4), and 
Triton-X-100 were all purchased from Sigma (St.Louis, MO), and used as received 
unless otherwise specified.  G3NH2 dendrimers were dried in vacuum for 24 hours to 
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remove traces of methanol before the reaction.  mPEG was purified by dissolving the 
raw compound in chloroform, and drying the resulting solution over anhydrous 
magnesium sulfate.  The final product was obtained by filtering and then evaporating 
the sample in a rotavapor.  Samples were stored in a desiccator prior to usage.  
Anhydrous dimethylsulfoxide (DMSO) was purchased from Acros.  Deionized water 
(DI water) with a resistivity of 18.2 MΩcm2 was used in all experiments.  Hanks’ 
balanced salt solution (HBSS, 1X) supplemented with 0.01 M (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) (HEPES) was prepared according to a procedure 
detailed elsewhere.[27]  Human bronchial epithelial cell line Calu-3 (HTB-55) was 
purchased from ATCC (Manassas, VA).  Tissue culture flasks (Greiner BioOne, 75 
cm2), 24 (Corning Costar) and 96 well plates (Greiner BioOne), Transwell Inserts 
(#3470 - polyester membrane, Corning, 0.33 cm2, 0.4 µm pore size) were all 
purchased from VWR.  Dulbecco’s Modified Eagle’s Media (DMEM) and trypsin 
(TRYple™ express) were obtained from Invitrogen.  Fetal Bovine Serum (non-heat 
inactivated) was procured from Atlanta Biologicals (Atlanta, GA).  Rabbit anti ZO-1 
(Mid) antibody, Alexa Fluor 546 goat anti-rabbit IgG (H+L), and 4´,6-diamidino-2-
phenylindole, dilactate (DAPI, dilactate) were purchased from Molecular Probes.  All 
antibodies were diluted a 100 times in phosphate buffered saline (5 g, PBS, pH 
7.4), supplemented with 6% (w/v) BSA (to prevent non-specific binding of the 
antibody) prior to usage.  DPX mounting medium was obtained from Fluka.  MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay was purchased 
from Life Technologies, and was utilized as per the protocol detailed by the 
manufacturer.  BCA protein assay was purchased from Pierce (Evanston, IL).  
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Microscope slides and cover glass slides (18 mm2) were obtained from Fisher.  All 
glassware was washed thoroughly in water and dried under vacuum prior to usage.  
All other chemicals used were purchased from Fisher and EMD, were of HPLC 
grade, and used as received unless otherwise noted. 
All animal experiments were conducted in accordance to the Institutional 
Animal Care and Use Committee at Wayne State University.  Seven week old, male 
Balb/c mice weighing between 20-25 g were purchased from Charles River Inc.  All 
animals were allowed to acclimatize for a week prior to experimentation and were 
housed in a pathogen free environment in HEPA filtered cages.  Animals had access 
to food and water ad libitum.  Isoflurane was purchased from VetOne.  Heparin 
sodium salt was purchased from Sigma and dissolved in sterile saline to make a 10 
U/ml final concentration. 
 
4.3.  Methods. 
4.3.1. Synthesis and Characterization of Carboxylic acid-terminated mPEGs 
(cmPEG).   
cmPEG was synthesized according to a procedure described in the 
literature.[28]  Purified mPEG (0.018 mmol) and potassium tert-butoxide (0.089 mol) 
were dissolved in 150 mL of tert-butanol at 40°C.  Ethyl bromoacetate (0.045 mol) 
was subsequently slowly added to this solution.  The contents were reacted for a 
period of 2h, after which the tert-butanol was evaporated.  The residue recovered 
was dissolved in 1M sodium hydroxide (to hydrolyze the ester), and the solution was 
allowed to stand at room temperature for 2h, after which the pH of the solution was 
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adjusted to 2 using 4N HCl.  The cmPEG obtained was extracted into chloroform 
(200 mL), and the extract was washed with water, and dried over anhydrous MgSO4.  
The resulting product was characterized using 1H-NMR (Varian 400 mHz), and 
MALDI-TOF (Ultraflex, Bruker Daltonics).  The sample for MALDI analysis was 
prepared by mixing 2 µl of 1 mgml-1 solution of the PEG compound in a 1:1 (v/v) 
acetonitrile-water mixture with an equal volume of 2,5-dihydrobenzoicacid (DHB) 
matrix (10 mg·ml-1 in the same solvent mixture, 1:1 AcN:water).  2 µl of this mixture 
was spotted and evaporated to dryness on a stainless steel MALDI target plate (MTP 
384, Bruker Daltonics).  A mass spectrum was generated in the linear mode using a 
nitrogen laser at 20 kV.  The mass of the compound was determined by comparing 
the resulting spectra against a compendium of calibrated peptide standards using 
FlexAnalysis™ software (Bruker Daltonics). 
 
4.3.2. Conjugation of PEG grafts and FITC to G3-NH2.   
Conjugation of PEG to G3-NH2 was accomplished by reacting the carboxyl-
terminated end of the cmPEG to the amine surface group of G3NH2 via EDC-NHS 
coupling reaction, with minor modifications.[29]  Labeling of FITC to the G3NH2 
surface and the PEGylation were done in a one pot synthesis, using a procedure 
similar to that detailed in the literature.[30-32]  A series of G3NH2 with varying graft 
densities of PEG 1000 Da (G3NH2-nPEG1000, where n is the number of PEG 1000 
grafts) was prepared and characterized.  Appropriate molar ratios of EDC and NHS, 
which depended on the desired extent of PEG surface density, were added to a 
stirred solution of G3NH2 (150 mg, 21 µM) in anhydrous DMSO (3 mL), and the 
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mixture was stirred for 4 hours.  This was followed by the addition of appropriate 
molar ratios of cmPEG and FITC (dissolved in 1 mL DMSO) dropwise to the reaction 
under stirring.  The reaction mixture was allowed to stir for a period of at least 4 days 
in case of low PEG graft density, and for up to two weeks for the higher PEG 
densities.  The contents from the flask were then transferred to a dialysis tube 
(Fisher, MWCO 12000 Da), and were dialyzed against DI water for 48h to remove 
any unreacted FITC, EDC, NHS and cmPEG.  The final product was recovered by 
snap freezing the contents from the dialysis bag, and freeze drying the resulting 
product for 48h.  Product yields were ca. 60%.  Dendrimer conjugates were 
characterized by light scattering for size and zeta potential (ζ) using a Malvern 
Zetasizer, and by 1H-NMR, and MALDI-TOF.  DLS was performed by dissolving 1.5 
mg of the purified conjugate in HBSS and analyzing the resulting sample.  The size 
reported here is an average of 4 runs with 10 counts for each run.  For 1H-NMR 8 mg 
of the freeze dried G3NH2-nPEG1000 was dissolved in d-DMSO (Cambridge 
Isotopes).  The sample for MALDI-TOF analysis was prepared as described in the 
earlier section.  Synthesis of FITC labeled G3NH2 with no PEG was accomplished by 
reacting appropriate molar amounts of FITC dissolved in DMSO with G3NH2 
overnight in DMSO (5 mL).  The resulting product was purified dialyzed (MWCO 1000 
Da) against DI water for 48h, and the product was recovered by freeze drying. 
 
4.3.3. Culture of Calu-3 Cells. 
Calu-3 cells, derived from human bronchial airway epithelium, between 
passages 36 and 50, were used as models to study the transport and internalization 
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of dendrimers conjugates.  Cells were plated in 75 cm2 culture flasks in medium 
comprising of Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% 
FBS and 2% antibiotic (AB, penicillin-streptomycin) solution.  The medium was 
exchanged once every two days.  Cells were split at a ratio of 2:3 when they attained 
ca. 90% confluence. 
 
4.3.4. Cytotoxicity of G3NH2-nPEG1000 conjugates.  
Cell viability of G3NH2-nPEG1000 conjugates was determined using the MTT 
assay (Promega) as described in the literature.[33]  The assay was prepared as per 
the protocol given by the manufacturer and stored at -20°C prior to use.  Cells were 
plated at a density of 10,000 cells per well, in 96 well plates, in DMEM supplemented 
with 10% FBS and 2% AB.  Cells were allowed to attach and grow for a period of 
24h, after which they were washed thrice with 1X PBS, and replenished with serum-
free medium containing the G3NH2-nPEG1000 conjugates at varying concentrations.  
The cells were incubated in the conjugate laden media for a period of 24h, after 
which the medium was removed, the cells washed thrice with 1X PBS and incubated 
in MTT assay at 37°C for 4h, after which 75 µl of the media was removed and the 
wells were incubated in 50 µl of DMSO for 10 minutes in order to dissolve the 
insoluble formazan crystals.  Cell monolayers were subjected to UV analysis at a 
wavelength of 540 nm using a plate reader (Molecular Devices, CA) to assess the 
extent of their cell kill.  As a positive control, untreated cells were used and the total 
cell kill was determined by comparing the absorbance of the treated cells with their 
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untreated counterparts.  The results expressed here are cell viability averages of 5 
wells for each concentration. 
 
4.3.5. Cell Culture for Transport Studies. 
 For transport experiments, cells were seeded on the apical compartment of 
Transwell® cell culture supports at a density of 0.5×106 cells·cm-2.  The inserts were 
then positioned onto 24 well plates containing 0.6 mL of medium on the basolateral 
side of the insert.  To the apical side, 0.2 mL of culture medium was added.  The cells 
were incubated at 37°C and 5% CO2 atmosphere, and grown in a liquid-covered 
culture (LCC) for 2 days.  The medium in the apical compartment was then removed, 
and the cells were allowed to grow in an air-interfaced culture (AIC).  The medium in 
the basolateral compartment was replaced every two days, and the cells continued to 
grow under AIC.  Transepithelial electrical resistance (TEER) measurements were 
conducted using Chopstick electrodes (STX-2) and an EVOM voltohmmeter (World 
Precision Instruments, Florida) in order to ascertain the monolayer confluence.  The 
apical (where the monolayer is cultured) and the basolateral chambers were fed with 
appropriate volumes of fresh warmed culture media and the inserts were returned to 
the incubator for equilibration for 30 minutes.  The monolayer resistance was 
measured after equilibration, and the true monolayer resistance was calculated by 
subtracting the EVOM reading of the cell-free culture insert from the reading obtained 
from cell-laden insert, and normalizing for the surface area of the support.  The TEER 
values reported in this study represent the average resistance of monolayers cultured 
in 16 separate Transwell® inserts. 
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4.3.6. Electron Microscopy of Cell monolayers.  
.  Once the peak TEER values were attained, some of the cell monolayers 
were subject to scanning electron microscopy (SEM) in order to evaluate their 
morphological features.  The monolayers for SEM were prepared according to a 
procedure described in the literature.[34]  Briefly, the monolayers were fixed in a 1:1 
ratio of culture medium and 2.5% glutaraldehyde (fixing solution) in DI water.  The 
fixing medium was added to both the apical and basolateral sides of the insert, and 
the insert was gently rotated for 5 minutes.  Subsequently, the medium-fixative 
mixture was aspirated and replaced with 100% fixing solution (2.5% glutaraldehyde) 
for 1 hour.  The fixed cell monolayers were bathed in 1% (w/v) OsO4 in water for 2 
hours.  The cells were then dehydrated by washing in a series of increasing gradients 
of ethanol (20, 40, 60, 80 and 100% ethanol for 8-10 minutes each) and lyophilized 
(LabConco FreeZone) for 36h.  Cell monolayers thus prepared were carefully 
removed from the insert and mounted onto aluminum stubs using adhesive carbon 
tapes.  They were sputter-coated (Ernst Fullam, NY) with gold for 30s, and imaged 
using an SEM (Hitachi S-2400) at 22kV. 
 
4.3.7. Immunocytochemistry.  
Immunocytochemistry was performed on confluent Calu-3 monolayers in order 
to visualize the presence of tight junctional protein, ZO-1 according to the protocol 
detailed by the manufacturer.[35]  Select monolayers, with appropriate TEER values 
(values peaked and leveled) were sequestered and washed with PBS to remove 
traces of culture media.  The washed cell monolayers were fixed in 4% 
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paraformaldehyde (in PBS) for a period of 20 minutes.  The fixed cells were washed 
thrice with PBS (5 minutes each time), and permeabilized with 0.2% triton X-100 in 
PBS for 30 minutes.  The permeabilized monolayer was further washed with PBS 
and blocked using 6% BSA for 30 minutes to prevent non-specific antibody 
binding.[36]  This procedure was followed by incubation of the cells for 60 minutes in 
Rabbit anti ZO-1 antibody at 37°C.  The cells exposed to the primary antibody were 
washed thrice with PBS, and were incubated for 60 min in Alexa Fluor 546 goat anti-
rabbit IgG, the secondary antibody, at 37°C.  The cell layer was washed thoroughly 
with PBS, and counterstained with DAPI (0.5 µg·ml-1 in DI water) for 30 minutes at 
room temperature.  The cell culture support membranes from the Transwell® inserts 
were carefully removed and mounted onto glass slides using DPX mounting media, 
and sealed using cover slides.  The slide was stored at 4°C overnight prior to 
observation under a fluorescence microscope (Zeiss Axiocam MR, Carl Zeiss) to 
visualize the presence of tight junctions. 
 
4.3.8. Epithelial Permeability of the Dendrimer Conjugates Across Calu-3 
Monolayers Seeded in Transwell® Inserts.   
Transport experiments were conducted once the cell monolayers reached 
confluence and the TEER values peaked (around day 15).  The TEER of the cell 
monolayers was measured prior to starting the experiments.  The culture media in 
the inserts was replaced with warm 1X Hank’s Balanced salt solution (HBSS) at both 
the apical and basolateral chambers, and the cells were allowed to equilibrate for 30 
min.  After that, the HBSS on the side was removed, and replaced with HBSS 
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containing a known molar concentration (25 nmol) of FITC-conjugated G3NH2-
nPEG1000 of varying PEG surface density (n).  In order to maintain sink conditions, 
the inserts were moved to a well containing fresh HBSS (1X) at predetermined times, 
and a known volume of HBSS from the basolateral side of the spent insert was 
removed and analyzed for the FITC-conjugated dendrimer using a fluorescence 
spectrometer (Perkin Elmer LS50B) in order to determine the extent of transport of 
dendrimer from the apical onto the basolateral (A  B) side.  The apparent 
permeability (Papp) from AB, which indicates the ease of flow of the dendrimers 
nanocarriers across the monolayer, was calculated according to Equation 4.1: 
 
Papp  =  F  /  (ACo)     (4.1) 
 
where F is the flux, or rate of change of cumulative mass transported, A is the 
area of the insert and Co  is the initial concentration of G3NH2-nPEG1000 in the 
donor (apical) compartment. 
Dendrimer-free HBSS incubated on the apical side of the insert was used as 
control.  Recording of TEER was accomplished (as described earlier) at every single 
time point of basolateral sampling to determine the effect of G3NH2-nPEG1000 
incubation on the tight junctions of Calu-3 monolayers.  After completion of the 
experiments, samples from the apical side were removed and stored for further 
analysis.  Select cell monolayers (from each condition) were washed twice with 
HBSS and were replenished with the growth medium on the apical side to estimate 
the revival of TEER after completion of the permeability experiments. 
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For mass balance studies, after each time point, selected inserts were chosen 
(n=3 for each conjugate), and the dendrimer-laden buffer in the apical chamber was 
removed and analyzed to estimate the extent of dendrimer remaining after 
internalization and transport.  The extent of transport of the conjugate onto the 
basolateral compartment was estimated as mentioned in the earlier part of this 
section.  For quantifying the internalized conjugates, cell monolayers were first 
washed with cold HBSS to arrest uptake.  Subsequently the monolayers were lysed 
using 2% triton-X-100 overnight and the lysate was analyzed for the internalized 
conjugates using fluorometry.  The resulting lysate was centrifuged to isolate the cell 
debris, and the supernatant was analyzed for the FITC-labeled PEGylated dendrimer 
using fluorometry.  The dendrimer uptake was normalized to the cellular protein 
content using BCA assay, according to the protocol described by the 
manufacturer.[37]  Summation of the mass internalized, mass transported and the 
mass remaining on the apical side was compared against the initial mass pulsed to 
obtain the overall mass balance. 
 
4.3.9. Cellular Internalization via Flow Cytometry.   
Cellular internalization experiments using flow cytometry were conducted on 
polarized Calu-3 monolayers according to procedure detailed in the literature, with 
slight modifications.[32]  Calu-3 cells were plated at a density of 1×106 cells per well 
in a 24-well plate in DMEM as described in earlier sections, and allowed to proliferate 
to confluence for a period of 8-10 days, with the monolayer periodically checked for 
confluence by staining the cells for tight junctional protein, ZO-1 and ascertaining its 
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presence through fluorescence microscopy.  Once the monolayer integrity was 
confirmed, the cells were subject to uptake studies.  Prior to commencing 
internalization studies, the cells were incubated for a period of 30 min in warm 1X 
HBSS.  This was followed by incubating the acclimatized monolayers of Calu-3 with 
25 nmol of G3NH2-nPEG1000 (in 0.5 mL HBSS) of varying surface densities of PEG, 
for varying durations (5h, 4h, 3h, 2h, 1h, 0.5h and 0.25h).  After lapse of the 
incubation period, the conjugate laden media was carefully aspirated, and the cell 
monolayers were washed thrice with cold HBSS.  The extracellular fluorescence was 
quenched using 0.2% Trypan Blue, washed again with HBSS, and the cells 
trypsinized (trypsin supplemented with 0.25% EDTA) and subjected to centrifugation 
(1200 rpm, 6 minutes) to recover the cell pellet.  The cell pellet thus recovered was 
resuspended in 1 mL fresh 1X HBSS and subjected to flow cytometry (BD LSR II, BD 
Biosciences, San Jose, CA) with a coherent sapphire laser (488 nm) and detected 
through a 530/30 bandpass filter (FITC).  For analysis, at least 5000 events were 
counted, and only viable cells were gated for fluorescence analysis.  1X HBSS was 
used as controls for the conjugates.  The extent and rate of cellular entry was 
determined by plotting the mean fluorescence intensity (MFI) values as a function of 
time.  The results reported here are averages of 6 wells for each conjugate. 
 
4.3.10. Administration of Dendrimers to mice.   
Pulmonary administration of the G3NH2-nPEG1000 of varying surface 
densities of PEG 1000 Da was performed using the pharyngeal aspiration technique.  
Briefly, the mice were anaesthetized by inhalation of 2.5% v/v isoflurane, and placed 
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on a slant board with the back resting on the board, and partially suspended with a 
rubber band by their incisors.  The tongue was held gently in extension and the 
G3NH2-nPEG1000 solution was placed in the pharynx region by means of a micro 
syringe.  The tongue was continuously held in extension until several breaths had 
elapsed.  Once the entire dosage (100µl) had been administered, the mice were 
returned to their housing and monitored for rapid recovery.  This method has been 
validated in comparison to intratracheal administration, and allows for greater lung 
deposition and higher dose-dose consistency.[38]  For intravenous administration, 
100µl the G3NH2-nPEG1000 solution was injected into the tail vein.  The solutions of 
G3NH2-nPEG1000 were prepared in sterile normal saline, and a dose of 200 µg (in 
100 µL) was given to all study groups. 
 
4.3.11. Blood Sampling and Lung Harvesting.  
After administration of the solution of G3NH2-nPEG1000 to mice, blood 
samples were collected at pre-determined time points (0.5, 1, 3, 6, 12, 24, 48, and 96 
hours, and then at 1, 2, 3, and 4 weeks) from each animal.  At each time point, 60 µl 
of blood was extracted via the tail vein into tubes containing 20 µl of heparin.  The 
blood sample was centrifuged at 5000 rpm for 30 s, and plasma was collected.  
Plasma sampled was analyzed for FITC fluorescence (Synergy, BioTek Instruments) 
and the G3NH2-nPEG1000 was determined by comparing the fluorescence values to 
a previously constructed calibration curve.  At the terminal time point, blood was 
collected by cardiac puncture, and the lungs were excised.  Whole lung tissues were 
homogenized, followed by extraction with 3N sodium hydroxide for a period of 72h in 
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darkness and analyzed for FITC fluorescence to determine total residual mass of 
G3NH2-nPEG1000 within the lungs.[8] 
 
4.3.12. Pharmacokinetic Analysis.  
The area under the curve (AUC) for G3NH2-nPEG1000 after intravenous 
administration (AUCiv) and after pulmonary administration (AUCp) was calculated 
using OriginPro software (OriginLabs).  The clearance (Cl) was calculated using the 
following equation: 
Cl = Doseiv / AUCiv      (4.2) 
where Doseiv is the dose administered intravenously. 
The absolute bioavailability after pulmonary administration (F) of the G3NH2-
nPEG1000 was calculated using the equation: 
F = (AUCp  / AUCiv )  (Doseiv / Dosep)  100    (4.3) 
where AUCp is the area under the curve after pulmonary administration, and  Dosep is 
the dose administered to lungs.  
The rate of absorption (Ro) of dendrimers after pulmonary administration was 
calculated using the total clearance after intravenous administration, and considering 
the plasma concentration-time profiles analogous to infusion at constant rate using 
the equation: 
Ro  =  Css    Cl       (4.4) 
where the steady state concentration (Css) for each experimental group was 
determined individually from peak concentrations following pulmonary administration. 
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4.3.13. Statistical Analysis.   
Statistical analysis of the data was performed by one-way ANOVA and 
student’s t-test using OriginPro (Origin Labs).  Probability values of p<0.05 were 
deemed significant. 
 
4.4. Results and Discussion. 
4.4.1. Synthesis of FITC-labeled G3NH2-nPEG1000.   
There are many potential advantages in PEGylating dendrimer nanocarriers 
for drug delivery applications.  The literature show that PEGylation reduces the 
cytoxicity of amine-terminated PAMAM.[16] PEGylation has also show to improve the 
aqueous solubility of dendrimers,[39] which is particularly relevant when conjugating 
hydrophobic therapeutics to the carriers, and has also been shown to enhance 
circulation times upon systemic administration.[40]  PEGylation of nanocarriers in 
general, can also potentially favor their transport across extracellular barriers of the 
respiratory epithelium, as they may facilitate transport across the mucosal layer lining 
the airways, and reduce the interaction between the nanocarrier and the surface fluid 
of the alveolar region.[14] 
FITC-labeled G3NH2, with varying surface densities of PEG1000 (G3NH2-
nPEG1000), were synthesized as described above.  The resulting products were 
characterized by MALDI, 1H-NMR and FT-IR - spectra provided in Supplementary 
Material.  The first step in the process was the conversion of monomethoxy PEG 
(mPEG) to the carboxyl terminated PEG (cmPEG).  An increase in the MW, with a 
distinct change in the MW distribution pattern as evidenced by the MALDI spectrum 
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(Figure S1a) was observed.  The conversion from mPEG to cmPEG was also 
confirmed by the absence of a peak at in the 1H-NMR spectrum of cmPEG 4.6 ppm 
(H from –OH in mPEG), and the appearance of a peak in the FTIR spectra at 1735 
cm-1, from the stretching band of the carbonyl moiety unique to cmPEG – Figure 
S1b,c.[27] 
FITC was conjugated to the G3NH2 surface according to a strategy described 
in the literature, with a target of 2 FITC per G3NH2.  The conjugation was 
accomplished through the formation of thiourea bond between FITC and G3NH2,[41] 
and was performed in a one pot synthesis along with the cmPEG conjugation.  
Conjugation of cmPEG at various surface densities to G3NH2 was accomplished 
through EDC-NHS chemistry, by coupling the –NH2 group of the G3NH2 to the –
COOH on the cmPEG.  The resulting products (G3NH2-nPEG1000) were purified by 
dialysis of the contents of the reaction vessel against DI water.  The G3NH2-
nPEG1000 were characterized using 1H-NMR (DMSO-d6) and MALDI-TOF - Figures 
S2-S5.  The grafting density of PEG1000 was varied by controlling the molar ratio of 
cmPEG to G3NH2, and the reaction time. 
The singlet signal originating at 2.17 ppm in the 1H-NMR spectra of the 
G3NH2-nPEG1000 (Figure S2(a)-S5(a)) can be attributed to the methylene protons 
next to the carbonyl groups of the dendrimer.[42]  The presence of the PEG moiety 
can be ascertained by the presence of broad peaks occurring between 3.3 to 3.6 
ppm, which is attributed to the protons of the CH2CH2O repeat unit, and the signal 
due to the terminal -CH3 group of PEG at 3.23 ppm.[42, 43]  The number of PEG 
moieties attached to the G3NH2 surface was determined by comparing the integral 
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values of the –CH3 peak at 3.23 ppm, to that of the methylene peaks of the 
dendrimer at 2.18 ppm (set at 120 protons – internal standard).[42]  The multiplet 
peaks between 6.5-6.8 ppm can be attributed to the aromatic protons of FITC.[44]  
From those results, the number of PEG1000 surface groups on the dendrimers 
conjugates was calculated to be to be 5, 13 and 25, and those of FITC were on 
target, and determined to be between 1.5-2.0.  A summary of the conjugates 
synthesized in this work, along with their characteristics, including the number of 
PEG1000 and FITC grafts, their MW, size, and surface charge is provided in Table 
4.1. 
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@ Average no of PEG units conjugated per PAMAM molecule estimated using 1H-NMR 
spectra of the compound in DMSO-d6 
* Estimated from the MALDI MW distribution using DHB as matrix using FlexAnalysisTM 
software. 
**Provided by the manufacturer 
# n=4 
X As determined by 1H-NMR  
 
The MW of the commercial PAMAM dendrimer obtained from Sigma was 
determined to be 6882 Da, which was in good agreement with the value 6909 Da 
provided by the manufacturer.  The average MW of the compound was determined 
NMR MALDI*
 
Compound 
nPEG
@
 MW nPEG MW 
Size±s.d
#
 (nm) 
ζ ±s.d
#
 
(mV) 
nFITC
X
 
G3-NH2  0 6909
**
 0 6882 2.9±1 +21±4.8 0 
G3-NH2-0PEG 1000 0 8076 0 7660 3.6±0.5 15.5±5.3 2 
G3-NH2-5PEG 1000 5 13805 4 11403 4.8±0.9 1.09±0.4 1.5 
G3-NH2-13PEG 1000 13 23586 9 18160 5.5±1.4 -1.41±0.8 1.7 
G3-NH2-25PEG 1000 25 38267 23 34015 7.9±1.0 -4.7±1.2 2 
Table 4.1.  Compilation of MW, size distribution and zeta (ζ) potential estimation 
of FITC linked G3-NH2-nPEG 1000 conjugates determined using 
1H- NMR and 
MALDI, and DLS analysis respectively.   MW reported here was determined by 
processing the MALDI spectra obtained using flexAnalysis™ software (Bruker 
Daltonics).  DLS measurements were conducted in HBSS (pH 7.4) and room 
temperature.   
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from the major peak of the MALDI spectra.  MW of G3NH2-0PEG1000 was 7660 Da 
– an increase in MW of 778 Da when compared to pure G3-NH2.  This indicates the 
presence of 2 FITC molecules per dendrimer – each new FITC conjugate is 390 Da.  
The MW for the other G3NH2-nPEG1000 was 11,403 Da, 18,160 Da and 34,015 Da, 
respectively.  With the knowledge of the MW of cmPEG, also from MALDI, and that of 
the G3NH2-nPEG1000, the number of PEG1000 surface groups was thus determined 
also determined from MALDI.  Those results are also included in Table 1, and can be 
compared to the results from 1H-NMR.  While the numbers estimated by NMR and 
MALDI are similar, it is interesting to note that there is an underestimation of the MW 
(ca. 10-15%) in the case of MALDI, when compared to that of NMR.  This behavior is 
similar to that observed in the literature.[43]  We believe the NMR numbers better 
represent the actual number of grafts,[42, 45] and we will thus refer to those numbers 
from now on. 
Light scattering was used to ascertain the size and surface charge of the 
conjugates.  The results are also included in Table 1.  The size of G3NH2 and G3-
NH2-0PEG1000 (just FITC-conjugated PAMAM) was determined to be 2.9 and 3.6 
nm, respectively.  These values are in good agreement with those reported in the 
literature of 3.2 nm and 3.6 nm, respectively.[46]  Furthermore, a similar increase in 
size of ca. 0.6 nm has been reported when FITC was conjugated onto G4-PAMAM 
dendrimers.[47]  With the increase in PEG1000 surface density, a gradual increase in 
hydrodynamic diameter from 3.6 nm (0 PEG) to ca. 8 nm (25 PEG) was observed.  
While a direct comparison cannot be made owing to lack of literature pertaining the 
DLS analysis of G3NH2-nPEG1000, several studies have been published reporting a 
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similar increase in size of dendrimers upon grafting their end groups with PEG of 
varying MWs.[21, 40, 48]  The increase in size reported here is observed to be within 
the size range reported in the case of G3-polylysine dendrimers (diameter of 
unmodified dendrimers ca. 2.8 nm) that were grafted with 32 surface groups of 
PEG750, with a reported size of ca.6.7 nm.[40]  In another study, PEG of MW 3400 
Da was tethered to the surface of G3 NH2 and DLS analysis reported a size increase 
of 3.4 nm for a PEG surface coverage of 3.4.  The   increase in the size reported in 
this that is relatively higher, perhaps due to the presence of longer PEG chains.[49]  
Our results are also in line with the results reported for G3NH2–PEG2000, where a 
diameter of ca. 12 nm has been reported at 99% surface coverage.[43]  This value is 
higher than what we observed, but this increase is to be expected given the higher 
density and MW of PEG grafted on the dendrimer surface in that case.  In another 
study, G4NH2 with 50% PEG density and PEG with MW of 5000 Da was reported to 
have a size of ca. 13 nm,[48] further reaffirming that the conjugates synthesized in 
this work seem to fall within the expected size range. 
A gradual decrease in the surface charge of the conjugates from +15.5 mV 
(G3NH2-0PEG1000) to -4.7 mV (G3NH2-25PEG1000) was observed upon increase 
in PEG density.  Shielding of the positive charges in the dendrimers was actually 
observed even at the lowest PEG density, as the addition of 5PEG1000 decreased 
the surface charge to +1.1 mV.  This drastic decrease in surface charge has also 
been reported in previous studies.  For instance, in the case G4.5 dendrimers, 
addition of 1 PEG (MW 750 Da) moiety onto the dendrimer surface resulted in a 
change in surface charge from -56 mV to -39 mV.[21]  Similarly, a significant 
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reduction in surface charge was also reported in case of G-NH2 conjugated with PEG 
5000 Da.  A 50% surface coverage of PEG resulted in a decrease of ca. 11 mV, from 
+16.6 to +6.2 mV.  That study also reported a graduate change of surface charge 
upon PEGylation as reported here.[48]  Upon tethering 76-128 –NH2 surface groups 
of G6 polylysine dendrimers with PEG MW 5000, a drastic reduction in charge was 
observed from ca. +20 mV to as low as ca. -6.5 mV.[40]  These results provide 
valuable insight into the impact of linking PEG onto the surface charge of cationic 
dendrimers and further validate our observations. 
The fact that PEGylation has such a dramatic impact in the size and surface 
charge of the dendrimers are of great relevance, as those characteristics of the 
nanocarriers are expected to also impact the rate, extent and mechanism of cellular 
uptake,[19, 32, 46, 50, 51] and their transport across epithelial barriers.[21, 52]  For 
instance, addition of PEG (MW 2000 Da) to G5NH2 surface at varying densities did 
not alter the uptake of the conjugates into NIH 3T3 cells, while the uptake of G4.5 
dendrimers with just one PEG (MW 750 Da) on its surface increased its uptake into 
Caco-2 cells compared to the bare dendrimers.[21, 53]  Transport of macromolecules 
and nanocarriers with the size range discussed here (which are of the order of size 
comparable to biomacromolecules) across the nano-sized, negatively charged tight 
junctional complex domains that exist in epithelial barriers, have been shown to be 
affected by their size and charge density.[52, 54-56] PEGylation of G3NH2 is thus 
also expected to provide opportunities to modulate transport across the pulmonary 
epithelium.  It has been shown that PEGylated dendrimers can interact and 
subsequently open tight junctions of Caco-2 cells even at low PEG surface density 
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and relatively low concentrations.[21]  In general, it has been reported that 
hydrophilic compounds are predominantly transported paracellularly across epithelial 
barriers,[21, 57, 58] and that this process is cell dependent[21, 51, 59, 60].  In the 
sections that follow we will demonstrate that the rate and extent of internalization into 
and transport of G3NH2 nanocarriers across models of the pulmonary epithelium can 
be modulated upon PEGylation. 
 
4.4.2. Cytotoxicity of G3NH2-nPEG1000 on Calu-3 cells.   
Cytotoxicity of G3NH2-nPEG1000 was evaluated on Calu-3 cells as described 
above.  A summary of the cell viability results as a function of molar concentration of 
G3NH2-nPEG1000 is shown in Figure 4.1. 
As a general trend, G3NH2-nPEG1000 had no appreciable inhibitory potential 
at concentrations below 0.01 µmol, with cell viabilities largely maintained at above 
80%.  While a 30% cell kill was observed for G3-NH2-0PEG1000 at a concentration 
of 1 µmol, over 90% of cells exposed to the PEGylated conjugates were viable at the 
same concentration.  Further increase in concentration resulted in a reduction in cell 
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viability for all conjugates, except G3NH2-25PEG1000.  The IC50 (minimum inhibitory 
concentration required to kill 50% of viable cells) for G3NH2-0PEG1000 was 
estimated to be ca. 55 µmol.  On the other hand, within the concentrations 
investigated, none of the PEG terminated conjugates had exerted a 50% cell kill at 
24h incubation.  Based on the observed trend, the IC50 for G3NH2-5PEG1000 and 
G3NH2-13PEG1000 can be estimated to be greater than 100 µmol.  Cells incubated 
in G3NH2-25 PEG1000 had a viability of greater than 85% even at 100 µmol. 
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Figure 4.1.  Viability of Calu-3 cells by MTT assay after incubation in 
G3NH2-nPEG1000 conjugate laden media for a 24 h.  Cells incubated 
in serum-free culture medium (DMEM) were used as control.  Results 
denote mean ± s.d (n=5).  * denotes statistically significant data 
(p<0.05) w.r.t control (G3NH2-0PEG1000). 
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While no prior work on the effect of dendrimers on viability of Calu-3 cells has 
been reported in the past, it is worth comparing and contrasting the results from this 
work with literature on other relevant epithelial models. It has been observed that 
Caco-2 cells exposed to G4NH2, dendrimers with no surface modification, had an 
IC50 of 0.12 mM.  Upon adding 4 PEG moieties to its surface, the concentration at 
50% cell kill dramatically increased to 0.8 mM.  The increased cell viability in 
presence of PEGylated dendrimer is thought to be due to the shielding of the positive 
–NH2 groups by PEG, as the cationic nature of –NH2 groups is considered to be the 
primary cause for cytotoxicity.[14, 35, 53]  Similarly, an increase in the concentration 
for 50% cell kill of over 60 µmol was reported in the case of  NIH 3T3 cells exposed 
to G5NH2 dendrimers, where 51 of the surface groups was modified with PEG 2000 
Da, when compared to unmodified G5-NH2.[19]  Cytotoxic evaluation of PEGylated 
G4NH2 PAMAM (16 and 32 surface amino groups PEGylated) dendrimers on B16 
murine melanoma cells indicated that over 50% of the cells were alive even after 48h 
exposure to the highest concentration of conjugate - 100 M, while their non-
PEGylated counterpart had a very low IC50 of 1.95 M, reaffirming the improved 
toxicity profile of PEGylated dendrimers.[42]  The benign nature imparted by 
PEGylation of cationic dendrimers has also been documented on various other cell 
lines.[14, 54, 55] 
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4.4.3. Culture of Calu-3 cells, SEM and Immunocytochemical (IC) Analysis.   
.  The human airway epithelial cell line Calu-3 was used as an in vitro model to 
determine the effect of PEGylation on the permeability and uptake of G3NH2-
nPEG1000.  Calu-3 is a well-differentiated and characterized cell line derived from 
human bronchial submucosal glands.[63]  Besides forming tight junctions, Calu-3 
cells have also been documented to possess many salient characteristics of the 
bronchial epithelium, viz. airway surface liquid, cilia, production of mucins and other 
immunologically active substances that make this cell line an appropriate candidate 
for elucidating tracheobronchial permeability and uptake in vitro.[63, 64]  In order to 
ensure that the cell monolayers are of requisite morphology for the transport studies, 
they were characterized via electrophysiological measurements (TEER), SEM, and 
immunocytochemistry. 
AIC culture was adopted as Calu-3 is known to exhibit all salient features of 
native epithelium when allowed to proliferate under AIC.[34, 65]  The cultures 
became confluent 6 days after culture under AIC.  Monolayer confluence was 
evaluated by periodically recording their TEER.  A plot of the epithelial resistance 
afforded by the cell monolayer as a function of time (days in culture) is shown in 
Figure 4.2 (a).  Under AIC, the TEER values of the cultured Calu-3 monolayer 
increased above the baseline values after about 5 days in culture, and peaked by 
day 11 at ca. 305 Ωcm2.  TEER values between ca. 300 and 350 Ωcm2 are 
considered to be an indicator of attainment of monolayer confluence and formation of 
tight junctions.[34, 64, 65] 
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Figure 4.2. (a) Increase in transepithelial electrical resistance (TEER) of Calu-
3 cells cultured under AIC on 0.33 cm2 transwell inserts as a function of time.  
Data mean ± s.d (n=16).  (b) SEM micrographs showing the morphology of 
AIC cultured Calu-3 cell monolayers, imaged once TEER values peaked and 
stabilized (day 15).  Bar represents 20 µm.  (Inset) A magnified SEM image of 
Calu-3 cell monolayer indicating the presence of microvilli (Open arrows).  Bar 
represents 5 µm.  (c) Representative XY-2D sections of confluent Calu-3 
monolayers captured using a confocal microscope at 40X magnification.  
Monolayers were fixed with 2% paraformaldehyde and stained for ZO-1 (white 
arrows), a tight junctional protein.  Cell monolayers were also counterstained 
with DAPI (blue; red arrows) to show the location of the nucleus.  Size bar 
indicates 20 µm.  (d) Optical micrograph of a Calu-3 monolayer stained with 
the mucosal stain, Alcian blue indicating the presence of glycoproteins on the 
cell surface (yellow arrows). 
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Prior to beginning the transport experiments, once the TEER values peaked, 
immunocytochemical (IC) analysis and electron microscopy studies were conducted 
to visually ascertain the presence of tight junctions and morphology of the confluent 
Calu-3 monolayers.  The cell monolayers were prepared for both studies as detailed 
in the methods section.  Figure 4.2(b) is a representative electron micrograph of a 
Calu-3 monolayer fixed and stained, and represents the nature of the monolayer at 
the time transport experiments commenced.  In the same figure, as an inset, a higher 
magnification image of the monolayer is also shown.  The presence of microvilli 
populating the surface of Calu-3 cells can be clearly observed from the electron 
micrograph.  A closer inspection of the inset in Figure 2(b) reveals the presence of 
cilia (filled yellow arrow).  Furthermore, we also observed the presence of mucus on 
the cell surface through electron microscopy (image not shown), another confirmation 
that the cell monolayer cultured under AIC possessed the requisite morphology 
mimicking the tracheobronchial epithelium. 
IC analyses were also performed on confluent Calu-3 monolayers prior to 
commencing transport experiments.  Studies were conducted to detect the presence 
of ZO-1 proteins, which are expressed in the tight junctions of confluent Calu-3 
cells.[63, 64]  The presence of the protein was detected by staining the fixed cells 
with an anti-ZO-1 antibody labeled with a fluorescent dye, Alexa Fluor® 546.  The 
cells were counterstained with the nuclear stain, DAPI.  Representative images 
(fluorescent microscope) of the fixed and stained Calu-3 cells monolayer is given in 
Figure 4.2(c).  The clear orange patterns observed along the periphery of the 
individual cells of the monolayer can be attributed to the presence of ZO-1 - denoted 
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by the white arrows.  The presence of dark blue (red arrows) within the cell milieu 
indicates the nuclei of the cells.  Alcian Blue stain was utilized to detect the presence 
of glycoproteins on the surface of the Calu-3 monolayer.  An optical image of a 
monolayer stained with Alcian Blue is shown in Figure 2(d).  The distinct blue layer 
blanketing the cell surface (indicated by yellow arrows) can be attributed to the 
presence of mucosal glycoproteins.  The results reported here with respect to 
monolayer characterization agree with observations reported in the literature.[64]  
Through a combination of TEER, IC and SEM it can be concluded that the 
monolayers are confluent and have appropriate morphology, and can thus be utilized 
for transport experiments, which are detailed in the section that follows. 
 
4.4.4 In vitro Transport of G3NH2-nPEG1000 across Polarized Calu-3 
Monolayers.   
In this section we discuss the effect of PEGylation on the transport of G3NH2-
nPEG1000 conjugates across confluent Calu-3 monolayers cultured under AIC.  The 
results are summarized in Figures 4.3 and 4.4.  Figure 4.3 depicts the effect of PEG 
density on the apparent permeability (Papp) of the nanocarriers.  Papp is a parameter 
that represents the ease with which compounds are transported across epithelial 
barriers.[34] 
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Our results indicate that the Papp of the G3NH2-nPEG1000 nanocarriers across 
Calu-3 monolayers increases with increasing PEG1000 density.  The Papp for G3NH2-
0PEG1000 was determined to be 1.2×10-7 cm·s-1, while that for G3NH2-25PEG1000 
was tenfold greater, at 14×10-7 cm·s-1.  The Papp values for the all conjugates 
containing PEG1000 moieties were determined to be statistically significantly 
(p<0.05) different compared to the Papp of the conjugate with no PEG (G3NH2-
0PEG1000). 
Figure 4.3.  Effect of PEGylation density on the apparent permeability (Papp) of 
G3NH2-nPEG1000 conjugates across confluent Calu-3 monolayers.  Papp 
values reported here were determined at the 5 hour time point after incubation 
of the cell monolayers with the conjugates.  Data represents mean ± s.d (n=4).  
25 nmol of conjugates in 1X HBSS was pulsed on the apical side.  * denotes 
statistically significant data (p<0.05) with respect to control (nPEG=0). 
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In Figure 4.4, the cumulative mass of the conjugate transported from the 
apical to the basolateral side (AB) of the insert is shown as a function of time.  At 
5h, only ca. 1% of the G3NH2-0PEG1000 had been transported to the basolateral 
side.  With conjugation of PEG1000 to the G3NH2 surface, an increase in the rate of 
mass of conjugate transported was observed, with a maximum of ca. 12% for 
G3NH2-25PEG1000.  All the PEGylated conjugates viz., G3NH2-5PEG1000, G3NH2-
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Figure 4.4.  Effect of PEGylation on the cumulative mass of the G3NH2-
nPEG1000 conjugates transport across confluent Calu-3 monolayers 
(Apical  Basolateral) as a function of time.  Error bars denote s.d (n=4).  
Error bars not showing are smaller than symbol size.  25 nmol of 
conjugates in 1X HBSS was pulsed on the apical side.  * denotes 
statistically significant data (p<0.05) with respect to control (nPEG=0). 
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13PEG1000 and G3NH2-25PEG1000 had statistically significant increases in the 
mass transported (p<0.05) compared to that seen for G3NH2-0PEG1000, at all times, 
as shown in Figure 4.4. 
In order to evaluate the effect of the PEGylation of the conjugates on the tight 
junctions, changes in electrophysiological behavior were monitored by recording the 
TEER during the course of the transport experiments.  The results are summarized in 
Figure 4.5.  From the plot, it is evident that G3NH2-nPEG1000 had a pronounced 
effect on the tight junctional properties of the monolayer.  A gradual reduction in the 
TEER of Calu-3 monolayers was observed during the course of the transport 
experiments, with all conjugates reducing the TEER of the monolayers to ca. 30% of 
the original value that of cells incubated in HBSS only.  This phenomenon was 
somewhat reversible, as upon re-incubating the monolayers with culture media in the 
absence of the conjugates, the TEER values returned to ca. 80% of their original 
value within 3 days of incubation, as seen in Figure 4.5. 
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A similar reduction in TEER has been also reported in the case of Caco-2 
cells, upon incubation with PEG-surface modified G3NH2 and G4NH2.[55]  The 
presence of conjugates resulted in a decrease in TEER down to 20% of the original 
value, but re-incubation in dendrimer-free medium also restored the TEER back to 
original levels by 24-48h. 
Figure 4.5.  Effect of PEGylation density of the G3NH2-nPEG1000 conjugates (in 
1X HBSS (pH 7.4)) on the TEER values of AIC cultured Calu-3 cells as a function 
of time.  Values shown in the plot are denoted as % of control, which is TEER of 
Calu-3 incubated in 1X HBSS before the start of transport experiments.  The 
recovery of TEER after the transport experiments is also shown in the plot.  The cell 
monolayers were washed after the transport studies and re-incubated in DMEM 
and the TEER was monitored with time. 
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Transport of surface-modified dendrimers across epithelial monolayers is 
highly dependent on the size, surface charge, the chemistry of functionalities 
attached to the surface, and the cell type.[18, 21, 56]  Previous studies have 
suggested that dendrimers transport across monolayers via a combination of 
transcellular (through the cell milieu) or paracellular (through the tight junctions) 
routes.[18, 21]  Most transport studies of PAMAM have focused on cell lines in the 
context of oral delivery, however, with Caco-2, IPEC-J2 and Madin-Darby Kidney 
cells being the primary in vitro models.[18, 59]  To the best of our knowledge, the 
permeability characteristic of PEGylated G3NH2 conjugates (or any dendrimer) has 
not been evaluated on cell culture models relevant to the pulmonary epithelium. 
Conjugation of a lipid, lauroyl chloride, to G3NH2 surface increased Papp 
across Caco-2 monolayers by a factor of 2.5 from ca. 2×10-6 cm·s-1 to ca. 5×10-6  
cm·s-1 within a 3h time period, possibly due to the permeation enhancing effects of 
the lipid chains.[46]  Similarly, increasing the surface coverage of FITC to G4NH2 
also had a considerable impact on its transepithelial transport with enhanced 
permeability of the conjugates across Caco-2 monolayers reported after 2h.  The 
increase in transport was attributed to a higher degree of tight junctional 
modulation.[55]  In another study, addition of polyamines (ornithine and arginine) 
onto the G4NH2 surface also improved the permeability of the conjugates across 
Caco-2 and IPEC-J2 cell monolayers after 3h, possibly due to a combination of 
polyamine transporter system aiding in the active uptake of the conjugates, and a 
passive transport through the tight junctions due to charge mediation.[56, 66] 
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In this work we observed that as the surface density of PEG increases, the 
transport of G3NH2-nPEG1000 across the Calu-3 polarized monolayer also 
increased.  Because all G3NH2-nPEG1000 impact the tight junctions to the same 
extent, at least as probed by the ionic mobility across the epithelial barrier (TEER), 
we argue that this enhanced transport for G3NH2-nPEG1000 with higher number of 
graft PEGs, compared to those with lower PEG density does not reflect a permeation 
enhancement effect.  The fact that all G3NH2-nPEG1000, irrespective of size and 
surface charge affect the TEER to the same degree is, to some extent, surprising, as 
tight junctional proteins are negatively charged and have gaps of the order of 0.8-2 
nm depending on cell type.[54]  One would have expected, therefore, that the smaller 
and more positively charged dendrimers would have exerted a greater influence on 
TEER.  Interestingly, it has been shown that tethering of 1 or 2 chains of PEG (MW 
750 Da) onto G3.5 and G4.5 dendrimers (hydroxyl terminated dendrimers) decreased 
the transepithelial permeability of the conjugates across Caco-2 monolayers after 2h 
incubation, possibly due to relatively lower levels of interaction of PEG modified 
conjugates with the tight junctions of Caco-2.[21]  However, the trend observed here 
indeed seems to be somewhat universal for positively charged polymers, as PEG 
modified chitosan, a linear polymer with –NH2 groups (MW PEG 1900 Da), also 
reduces the TEER of Calu-3 - down to 40% of the initial value.[52]  It was suggested 
that the reduction in the TEER could be due to the higher equivalent concentrations 
of chitosan in the conjugates in combination with the unsubstituted amine groups of 
the PEG modified chitosan backbone.[52] 
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Another interesting observation was the rapid increase in the transport of 
G3NH2-25PEG1000 within the first hour when compared to the other conjugates (ca. 
1.4% compared to ca.0.3% in case of G3-NH2-5 PEG 1000).  The presence of PEG 
on nanocarrier surfaces (in that particular case of solid nanoparticles) has been 
shown to impart stealth like properties to them thereby facilitating their rapid transport 
across mucosal barriers.[22, 25]  Combining the results discussed above, with the 
fact that internalization of the carriers within Calu-3 cells decreases upon PEGylation 
(discussed below), one could argue that a fast transport across the mucosal layer, 
and decreased interaction with and internalization within Calu-3 cells may provide an 
opportunity for the more densely PEGylated nanocarriers to achieve enhanced 
transport across the monolayer.  Of course this assumes a dominant paracellular 
transport, which seems plausible given the information, but has not been determined 
in this work.  These studies are ongoing in our laboratory. 
 
4.4.5 Cellular Uptake and Flow Cytometry.  
The effect of PEGylation on the extent of cellular uptake of the G3NH2-
nPEG1000 conjugates onto polarized Calu-3 monolayers was also determined.  
Cellular internalization was evaluated by cell lysate and flow cytometry.  The cell 
lysate results at the end point of transport studies (5 h) are plotted as % uptake in 
Figure 4.6. 
At the end of the transport studies (5h time point), ca. 10% of the G3NH2-
0PEG1000 was internalized into Calu-3.  In contrast, PEGylated conjugates had 
reduced internalization.  The total internalized amount (mass basis relative to 
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the amount of dendrimer added in the beginning of the transport study) for G3NH2-
5PEG1000, G3NH2-13PEG1000 and G3NH2-25PEG1000 was 6%, 2.2% and 1.7%, 
respectively.  These results, combined with the determination of the amount of 
dendrimer left in the apical side of the insert at the end of the transport studies, and 
the cumulative amount collected on the basolateral side also at 5h, allowed us to 
perform an overall mass balance study.  The results yielded a total average recovery 
of ca. 80% for all conjugates.  The ca. 20% not recovered, could be attributed to 
factors including the presence of conjugates bound to cell surface that remain 
Figure 4.6.  Effect of PEGylation density of the G3NH2-nPEG1000 
conjugates on the % uptake into Calu-3 at t=5h, as measure in the cell 
lysates.  Values represent mean ± s.d (n=4).  Statistical significance with 
respect to control (p<0.05) denoted by *. 
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adhered to cell debris after lysis, and the adsorption of conjugates to surfaces of the 
inserts and wells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. (a) Effect of PEGylation density on the cellular uptake of the 
G3NH2-nPEG1000 conjugates into polarized Calu-3 cell monolayers as 
a function of time, as determined by flow cytometry.  Data represents 
mean ± s.d (n=6).  Statistical significance with respect to control 
(p<0.05) denoted by *. (b) Effect of cell polarization of Calu-3 on the 
uptake of G3NH2-0PEG 1000 
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In addition to determining cellular uptake through cell lysis, internalization of 
the conjugates was monitored as a function of time utilizing flow cytometry.  The 
results of the study are summarized in Figure 4.7(a).  The studies were conducted on 
polarized Calu-3 monolayers as detailed before.  Proliferation of Calu-3 till 
polarization is essential as it facilitates the formation of tight junctions thereby 
providing a more accurate representation of the true airway morphology.[67]  Figure 
4.7(a) is a plot of the mean fluorescence intensity (MFI) as a function of time. 
From the plot, it is observed that the cellular uptake is reduced as the PEG 
number on the G3NH2 surface increases, in agreement with what was observed from 
the cell lysate experiments.  However, here we also obtain the kinetics of the 
process.  The maximum cellular uptake was observed for G3NH2-0PEG1000, whose 
uptake saturates by the 5h time point, as evidenced by the leveling off of the MFI 
values.  This trend in cellular internalization for G3NH2-0PEG1000, can be attributed 
to the typical trafficking mechanism of cationic dendrimers, that are believed to be 
taken up by charge mediated endocytosis, facilitated by the presence of negatively 
charged proteoglycans on cell surface.[32]  However, for the PEGylated compounds, 
the rates of internalization were gradually reduced with the increase in PEG density 
with G3NH2-25PEG1000 and G3NH2-13PEG1000 having similar (lowest) rates of 
uptake.  Additionally, it is interesting to note that the saturation in uptake observed in 
the case of the non-PEGylated dendrimer was not seen for the PEGylated carriers, 
suggesting that PEGylation may be in altering the route of internalization into Calu-3.  
The surface functionalities of dendrimers has been shown to affect not only the rate 
and amount of internalization, but also the endocytic mechanism upon which 
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internalization takes place.[18, 21, 32, 68]  PEGylation of the conjugates results in 
the shielding of charges, which minimizes the interaction of the conjugates with cell 
surface, resulting in reduced surface adsorption that would subsequently lead to 
endocytosis.[21]  For instance, in an earlier study involving partial PEGylation of 
G4NH2 conjugates, an increase in surface coverage of PEG 5000 Da resulted in a 
significant decrease in the cellular uptake in B16F3 cells, as quantified by flow 
cytometry. It was observed that this reduction had a definite correlation to the zeta 
potential of the conjugates reiterating the impact of surface charge and surface 
functionality on cellular uptake.[48]   Previous works have also shown that 
conjugation of PEG 750 Da to the surface of G3.5 PAMAM dendrimers reduced 
interaction with Caco-2 cell surface.  Interestingly, the same study reported that 
addition of same PEG moiety to G4.5 dendrimers increased cellular uptake, 
suggesting that an ideal charge density may be required for promotion or reduction of 
dendrimer trafficking into the cellular milieu.[21] 
Uptake experiments reported here were conducted on polarized, well 
differentiated monolayers of Calu-3.  Polarized Calu-3 monolayers form tight 
junctions and exhibit morphological features native to pulmonary epithelium.[63]  The 
importance of cell polarization in the cellular uptake of the G3NH2 in Calu-3 cells was 
evaluated, and the results shown in Figure 4.7(b), where the uptake results in 
polarized cells are contrasted with non-polarized monolayers.  Non-polarized cells of 
Calu-3 were able to internalize G3NH2-0PEG1000 to a much greater extent 
compared to the polarized cells as evidenced by a five fold increase in the MFI 
values for the non-polarized cells.  Another interesting observation to note from this 
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figure is the lack of saturation in the uptake of the conjugate exposed to the non-
polarized cells when compared to the polarized Calu-3 monolayers.  The effect of 
Calu-3 polarization was also observed in other independent studies where it was 
reported that well formed, polarized airway epithelial cells were infected to a lesser 
extent with Pseudomonas aeruginosa and Chlamydia trachomatis compared to their 
non-polarized counterparts.[67, 69]  These results suggest that it would be prudent to 
conduct cellular uptake studies of moieties on polarized, well characterized cell 
monolayers in order to understand the true extent and kinetics of internalization. 
Through the collective set of experiments comprising in vitro transport and 
cellular uptake assessed by cell lysis and flow cytometry, transport and TEER, we 
can gauge the impact of PEGylation on the transport and uptake of G3NH2-
nPEG1000 across and into Calu-3 monolayers.  The results showcased through 
these studies, suggest that by suitably tailoring the surface of G3NH2 with PEG1000, 
once can achieve a great deal of modulation in both transport and cellular uptake of 
dendrimer nanocarriers across and into such a relevant model of the pulmonary 
epithelium.  The results obtained here also suggest that conjugation to PEG can 
impart other beneficial characteristics to the G3NH2 nanocarriers, by reducing their 
toxicity and assisting in overcoming extracellular barriers present in the pulmonary 
epithelium, such as the mucosal layer. 
These results can be utilized to guide the design of polymeric nanocarriers for 
controlled and targeted local or systemic delivery of therapeutics to (regional delivery) 
and through (systemic circulation) the lungs.  Carriers with reduced transport and 
enhanced cellular internalization are potential candidates for the regional targeting of 
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drugs to the lungs, while those that rapidly transport across the pulmonary 
epithelium, are potential candidates to target the systemic ailments. 
While in the previous sections we evaluated the feasibility of using PEGylation 
to modulate the transport of G3NH2 nanocarriers across the pulmonary epithelium 
using an in vitro model, in the section that follows we evaluate the effect of 
PEGylation on the transport of G3NH2-nPEG1000 across an in vivo model of the lung 
epithelium, by determining the pharmacokinetic (PK) behavior of selected 
nanocarriers upon inhalation administration to Balb/c mice. 
 
4.4.6. In vivo Pharmacokinetic (PK) Evaluation of G3NH2-nPEG1000.   
The plasma concentration-time profile for the G3NH2-nPEG1000 dendrimer 
conjugates with n = 0, 13 and 25, following administration by pharyngeal aspiration 
and intravenous route, are shown in Figure 4.8(a) and (b).  The PK parameters 
calculated from plasma concentration versus time profiles from both routes of 
administration (Figure 4.8(a) and (b)) are shown in Table 4.2: 
The results demonstrate that the dendrimers with the highest degree of 
PEGylation (25PEG) show the highest plasma concentration at all time points.  The 
other two dendrimer systems have significantly lower plasma concentrations as 
compared to the other G3NH2-nPEG1000 dendrimers.  After pharyngeal aspiration of 
the G3NH2-25PEG1000 conjugate, a peak plasma concentration of ca.4.4 µg was 
reached at 3h, and stays constant for about 24h after, and then starts to slowly 
decrease, with dendrimer remaining in plasma at the end of 1 week.  In contrast, 
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G3NH2-0PEG1000 and G3NH2-13PEG1000 had significantly lower peak plasma 
concentrations at ca.0.2 and 0.4 µg respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8.  Mean plasma concentrations of G3NH2-nPEG1000 conjugates 
detected by fluorometry after (a) pulmonary administration in mice (n=6 for 
each condition) as a function of time.  (b) after intravenous (i.v.) 
administration in mice (n=3).  In both cases, blood samples were collected 
from the tail vein using the tail bleeding method.  Statistical significance with 
respect to control (p<0.05) denoted by *. 
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Among the conjugates, G3NH2-25PEG1000 had the highest peak plasma 
concentration upon i.v administration, when compared to both G3NH2-0PEG1000 
and G3NH2-13PEG1000.   The conjugate G3NH2-0PEG1000 had intermediate 
clearance.  Css results indicate that among the conjugates, the greatest amount 
detected in plasma was that for G3NH2-25PEG1000. 
 
 
 
 
 
 
 
 
 
 
 
The PK results, to some extent, agreed with the in vitro transport studies.  For 
instance, the relatively large rate of absorption seen for G3NH2-25PEG1000 and 
G3NH2-13PEG1000 in vivo (compared to G3NH2-0PEG1000), agreed with the in 
vitro observation pertinent to the apical to basolateral transport of G3NH2-nPEG1000 
across Calu-3 monolayers that increased with an increase in PEG density, with the 
greatest enhancement seen for G3NH2-25PEG1000.  However, different from in vivo 
results, the extent of G3NH2-13PEG1000 transport in vitro was markedly different.  
Dendrimer Cl (ml/min) Css (ng/ml) Ro (ng/min) 
G3NH2-0PEG1000 0.40 ± 0.004 477.09 ± 63.9 193.22 ± 27.93 
G3NH2-13PEG1000 7.99 ± 0.1 189.73 ± 11.14 1517.79 ± 112.0 
G3NH2-25PEG1000 0.14 ± 0.01 4596.9 ± 1434.8 639.88 ± 232.1 
Table 4.2.  Pharmacokinetic parameters for the G3NH2-nPEG1000 upon 
administration to the lungs.  The clearance (Cl) was determined from the data 
of intravenous administration studies of the same carriers.  Css = steady state 
concentration; and Ro = rate of absorption.   
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It is interesting to note that for the G3NH2-13PEG1000 dendrimer, Ro is more 
than 2-fold higher than that for dendrimer with 25 PEG, and more than 7-fold higher 
than that for non-PEGylated dendrimer.  From this observation, G3NH2-13PEG1000 
dendrimer would be expected to have higher plasma concentration over the other 
two systems.  However, the dendrimer with G3NH2-25PEG1000 has the highest 
plasma concentration at all times.  This is most likely due to the fact that the 
clearance for G3NH2-13PEG1000 dendrimer is 57 times higher than that for G3NH2-
25PEG1000 dendrimer.  Therefore, the 13 PEG dendrimer is very rapidly cleared 
from the systemic circulation despite its high absorption from the lungs.  On the other 
hand, though the Ro for G3NH2-25PEG1000 dendrimer is less than that for G3NH2-
13PEG1000 conjugate, the clearance is drastically lower than that for 13 PEG 
dendrimer, thus resulting in an extended blood circulation time for 25 PEG 
dendrimers. 
It is well established that PEG acts to increase the circulation time of carriers 
in the systemic circulation by way of increasing the hydrophilicity of the carrier and 
reducing opsonization, drastically reducing uptake by the reticuloendothelial system 
(RES).[16, 31]  While there have been several studies delineating the 
pharmacokinetics of PEGylated dendrimers upon oral and i.v administration, to the 
best of our knowledge, this is the first study evaluating the PK of PEGylated PAMAM 
conjugates upon pulmonary administration.  Pharmacokinetics of PEGylated poly-L-
lysine dendrimers administered intravenously to rats, revealed that conjugates with 
MW>30 KDa exhibited longer circulation times with higher peak plasma 
concentrations, when compared to the low MW counterparts (<20 KDa), an 
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observation that was echoed in this study as well.[40]  In another study, PEGylated 
PAMAM dendrimers (G4 and G5, MW ca.160 KDa and 284 KDa respectively) 
tethered with different MW of PEG (2KDa and 5 KDa), injected to mice were reported 
to be detected in blood even after 24h, while the acetylated counterparts of the 
conjugate was largely observed in the kidney.[70] 
  In the absence of data with respect to translocation of dendrimers from the 
lung to the systemic circulation upon pulmonary delivery, it would be wise to put 
these results in perspective with respect to other nanocarriers whose translocation 
has been evaluated upon lung administration.  Less than 0.5% of polystyrene (PS) 
nanoparticles (NPs) with 20 nm diameter was detected in blood after a week upon 
pharyngeal aspiration to rat lungs - 70-80% of NPs recovered from the lung after a 
week.[38]  Along similar lines, intratracheal instillation of anionic PS-polyacrylate NPs 
to rats resulted in over 2% of the conjugate being detected in the lymph nodes within 
the first hour, while over 40% was detected in the rest of the body.[71]  Solid lipid 
nanoparticles have shown to be rapidly eliminated from rat lungs upon endotracheal 
administration, and are observed to immediately localize (within minutes) in axillary 
and inguinal lymph nodes.[72]  PEGylated PLGA NPs of ca.200 nm in diameter were 
shown to remain in C57BL6 mice for as long as 11 days after intranasally 
administered, as evidenced by live body imaging.[73] 
The G3NH2-25PEG1000 dendrimer conjugate, due to its low clearance, has 
the highest plasma concentrations, and it remains in systemic circulation for longer 
than the other two systems.  G3NH2-13PEG1000 dendrimer has a slightly higher 
plasma concentration as compared to the non-PEGylated dendrimer after pulmonary 
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administration.  It is interesting to note that the non-PEGylated dendrimer has a 
higher plasma concentration as compared to 13 PEG dendrimer after i.v. 
administration (Figure 4.8b).  This is likely a result of the clearance being signficantly 
higher for the 13 PEG dendrimer as compared to the non-PEGylated dendrimer.  
However, the G3NH2-25PEG1000 dendrimer has the highest plasma concentration 
among the three dendrimer systems, likely a result of extended plasma circulation by 
RES evasion.[31, 40] 
When considering the PK of the dendrimer systems after both pulmonary and 
intravenous exposure, these results suggest that PEGylation of dendrimer surface 
has a significant effect on their pulmonary translocation.  PEGylation up to a certain 
degree (13 PEG in this case) enhances the rate of absorption of the dendrimers 
across the lungs, whereas a higher PEGylation (25 PEG) improves the absorption 
across the lungs in addition to increasing the circulation time and concentration of the 
dendrimers in the systemic circulation post absorption from the lungs. 
 
4.5. Conclusions. 
 In this work we determined the effect of PEGylation onto DNCs, on their 
interaction with in vitro and in vivo models of the lung epithelium.  The cellular uptake, 
transport and pharmacokinetics of G3NH2 dendrimers conjugated with PEG 1000 Da 
at various surface densities (5, 13 and 25 PEGs per G3NH2 molecule) were studied.  
Cell viability studies conducted on Calu-3 cells revealed that PEGylation improved 
cell survival rate, with over 90% of the cells viability at concentrations as high as 100 
µmol when incubated with G3NH2-25PEG1000 for 24 hours.  In contrast, only 30% of 
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cells incubated with G3NH2-0PEG1000 survived at the same concentration.  In vitro 
transport studies conducted on polarized Calu-3 monolayers revealed an increase in 
transport of G3NH2-nPEG1000 with increasing PEG density.  As much as 14% (w/w) 
of G3NH2-25PEG1000 are transported from the apical to the basolateral side of the 
monolayer at 5h.  On the other hand, only 1% of G3NH2-0PEG1000 is transported 
within the same time.  PEGylation also resulted in modulation of cellular uptake, as 
evidenced by flow cytometry and cell lysis studies, where PEGylation of DNCs was 
seen to decrease cellular uptake.  This observation, in conjunction with the 
observation that the TEER of the monolayers is reduced during the transport studies 
suggests that the PEGylated conjugates could be traversing paracellularly.  Peak 
plasma concentrations as high as 4.5 µg was detected for G3NH2-25PEG1000 by 3h, 
while G3NH20PEG1000 and G3NH2-13PEG1000 had very low peak plasma values 
to the tune of 0.2 and 0.4 µg, respectively corroborating what the in vitro transport 
studies.  These results combined suggest that surface modification of G3-NH2 with 
appropriate surface densities of PEG can aid in modulation of transport and uptake of 
the nanocarriers in lung epithelium.  These results are promising since the 
incorporation of versatile drug delivery vehicles like dendrimers can open up new 
avenues within the realm of pulmonary delivery to target not only local disorders, but 
also diseases of systemic relevance. 
Note – PK studies was done with the assistance of Dr. Josh Reineke, Asst. 
Professor, Department of Pharmaceutical Sciences and Mr. Abdul Mohammad 
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Chapter 5 
 
Pulmonary Inflammatory Response of a Versatile Chitosan-based Co-oligmeric 
Excipient for Pressurized-Metered Dose Inhalers 
 
5.1. Introduction 
Portable oral inhalation (OI) devices, such as such as pressurized metered-
dose inhalers (pMDIs) and dry powder inhalers (DPIs), have tremendous relevance in 
the treatment of pulmonary disorders.[1-6]  Such platforms have been also 
recognized as potential candidates for the delivery of therapeutics intended for 
systemic circulation, in this case to be delivered non-invasively through the lungs.  
They both have advantages and disadvantages,[1, 2, 6, 7] and it seems that the ideal 
scenario would be to offer patients and doctors the option to use either platform, in a 
way to achieve maximum efficiency based on a series of factors, including disease 
condition and age of the patient.[2, 8, 9]  One major formulation challenge in the case 
of pMDIs is the fact that the hydrofluoroalkane (HFA) propellants utilized in those 
devices are somewhat hydrophobic and lipophobic at the same time,[5, 10, 11] and 
as a result, are not good solvents for most therapeutics of interest.[5, 11-14]  One 
then often needs to resort to dispersion-based formulations in pMDIs,[5, 13, 15, 16] 
but the design of dispersants is also no easy task.[3, 17, 18] 
We have developed a versatile biodegradable excipient that is capable of 
forming stable dispersions of a variety of therapeutics and drug delivery systems in 
pMDIs, and consequently, formulations that give rise to aerosols that are inductive to 
enhanced deep lung deposition.[13, 15, 19, 20]  One of the strategies consists in 
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forming polymeric nanoparticles of this excipient – co-oligomer of oligo(lactic acid) 
(OLA) grafted onto chitosan (CS; OLA-g-CS), which can act as a steric barrier to the 
flocculation of micron-sized colloidal drug particles (crystals or amorphous) due to its 
high stability in the propellant,[13] due to the presence of the ester groups in the co-
oligomer, that interact well with the propellant.[15, 17]  Another pMDI platform that 
may find application in the delivery of therapeutics to and through the lung, is the 
formation of core-shell micron particles containing polymeric nanoparticles (NPs; the 
drug carriers) in the interior (core) of the micron-particles, which are ‘coated’ with the 
co-oligomeric shell.  We have shown that the shell is capable of enhancing the 
aerosol characteristics of such formulations, so as to achieve high fine particle 
fractions (deep lung deposition) of the NPs.  This is an important platform, as 
polymeric NPs have great versatility, and may be used for the controlled and targeted 
delivery to the lung tissue.  These can be designed to have enhanced extra-cellular 
transport and improved cellular uptake,[19, 20] thus opening up new opportunities for 
the delivery of a range of therapeutics to and through the lungs.[1, 21, 22] 
Is this work we have evaluated the in vivo residence time and inflammatory 
response of this OLA-g-CS co-oligomer upon lung delivery, in conditions 
representative of the study where NP of this co-oligomer were capable of stabilize 
drug dispersions in HFAs.[15]  We also studied the in vivo interaction of the OLA-g-
CS co-oligomer in the presence of poly(lactic glycolic) (PLGA) NPs, in a composition 
similar to that used in the formation of the core-shell particle formulations in 
pMDIs.[19]  We determined the impact of this versatile excipient on the inflammatory 
status of the lungs by evaluating the changes in inflammatory cell population by 
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bronchoalveolar lavage (BAL) and collagenase tissue dispersion of the tissue upon 
transnasal administration.  Experiments were conducted to assess the impact of the 
OLA-g-CS accumulation in the lungs upon repeated administration, and the lung’s 
ability to deal with an allergen induced immune response was also studied.  The 
inflammatory response of co-oligomer administered with the PLGA NPs nanoparticles 
was also assessed. 
 
5.2. Materials 
Chitosan (CS, medium molecular weight) was obtained from Aldrich 
Chemicals.  Toluene, hydrochloric acid, hydrogen peroxide and sodium hydroxide 
were sourced from Fisher.  Deionized water (NANOpure DIamond UV ultrapure water 
system, Barnstead International, DI water) was used in all experiments.  D,L-lactide, 
poly(vinyl alcohol) (PVA, 87-90 KDa, cold water soluble), fluorescein isothiocyanate 
(FITC), fluoresceinamine (FA), dicyclohexylcarbodiimide (DCC), N-
hydroxysuccinimide (NHS), and stannous octoate were purchased from Sigma.  
Ester and carboxylate terminated poly(lactic-co-glycolic) acid (PLGA, 50:50, 31.3-45 
KDa) was purchased from Birmingham Polymers.  Anhydrous dimethylformamide 
(DMF) was procured from Acros Organics.  All other chemicals were purchased from 
Fisher and used as received, unless otherwise specified. 
 Pathogen free female Balb/c mice, 8-10 weeks old, weighing between 17 and 
23 g (Hilltop farms, Scottsdale, PA) were housed in polycarbonate cages upon 
arrival, and kept under high efficiency particulate filtered air (HEPA).   The mice 
were quarantined for a week prior to experiment.  They received food and water ad 
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libitum.  The protocols used in this study were approved by Wayne State University’s 
Institutional Animal Care and Use Committee (IACUC), consistent with guidelines 
prescribed by the US government.  Sodium pentobarbital was obtained from Meds for 
Vets and was diluted to 50 mg·Kg-1 in PBS.  Protein microassay was purchased from 
BioRad Labs.  Isoflurane was purchased from VetOne Pharmaceuticals.  
Collagenase (100 IU·ml-1) was obtained from Worthington Biochemical.  Fetal Bovine 
Serum (FBS) was procured from Gibco.  Tissue strainer was purchased from BD 
Falcon.  Cytospin slides and cytology funnels were purchased from Fisher Scientific.  
Ethylenediaminetetraacetic acid (EDTA), RPMI medium (without phenol red), isotonic 
saline, DNase (50 U·ml-1), Ovalbumin (OVA, grade V), and phosphate buffered saline 
(PBS) (1X, pH 7.4) were procured from Sigma.  Zap-O-Globin Lytic reagent was 
purchased from Beckman Coulter.  Wright’s Giemsa stain (Diff Quik) was obtained 
from Fisher chemicals. 
 
5.3. Methods. 
5.3.1  Synthesis and characterization of OLA-g-CS cooligomer.   
OLA-g-CS was prepared and characterized as detailed in our previous 
work.[13, 15]  Commercial CS was depolymerized using hydrogen peroxide.  The 
resulting degraded CS was characterized using size exclusion chromatography 
(SEC) using a Shimadzu LC-10ADVP liquid chromatograph equipped with a seven 
angle static light scattering detector (BIMWA) and a differential refractometer 
(Brookhaven Instruments).  The CS was degraded down to 1350 Da as determined 
by SEC, which corresponds to ca. 8 repeat units of CS.   Oligo-lactic acid (OLA) was 
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grafted onto the degraded CS backbone by ring opening polymerization.  A known 
amount of CS NPs was charged into a round bottom flask containing D, L Lactide 
and stannous octoate in toluene.  The mixture was stirred at 373K in an atmosphere 
of nitrogen for 24h.  The water soluble product was washed multiple times with 
acetone, dried and characterized by 1H-NMR and FTIR.  For 1H-NMR (Varian 
Mercury 400) ca.10 mg of OLA-g-CS was dissolved in 0.8 mL DMSO-d6 for analysis.  
For FT-IR, 5 mg of OLA-g-CS was ground with potassium bromide, pressed into a 
pellet and subjected to FT-IR spectroscopy (Bruker Tensor 27).   The molar grafting 
ratio of CS to OLA was determined from 1H-NMR to be 2.4, resulting in a highly water 
soluble co-oligomer of 1730 Da, as estimated from 1H-NMR.  From the FT-IR 
spectra, the presence of a sharp peak at 1750 cm-1 can be attributed to the carbonyl 
bond arising from the LA graft.[15]  The length of LA units tethered onto CS chain 
was estimated to be ca.3.   The molar ratio of CS to LA in the co-oligomer was 
determined from 1H-NMR to be 2.4.  
 
5.3.2  Synthesis of FITC-labeled OLA-g-CS and FA-labeled PLGA.   
           FITC labeled Polylactic acid -Chitosan (PLA-g-CS) oligomer was synthesized 
according to an earlier method described in the literature.[22]   Briefly, known 
amounts of OLA-g-CS (4 mg•ml-1) and FITC (1.5 mg•ml-1) were dissolved in 
deionized water and anhydrous methanol respectively. Both solutions were added 
into a round bottom flask containing 10 ml of anhydrous methanol. The contents were 
stirred in dark at ambient temperature for 5 hours after which, they were precipitated 
in excess of acetone. The precipitate was centrifuged and washed further with 
200 
 
 
 
copious amounts of acetone to remove unreacted FITC. After each wash a sample of 
the supernatant was analyzed spectrophotometrically for the presence of FITC. The 
washing was continued until no FITC was detected in the supernatant. The FITC 
labeled OLA-g-CS was solubilized in DI water and lyophilized in order to obtain the 
final product.   The resulting product was characterized by 1H-NMR (Varian 400) and 
UV-spectroscopy (Cary50) to obtain the final product.   
           FA conjugated PLGA NPs were prepared according to procedure detailed in 
the literature with minor modifications.[23]  The fluorophore was conjugated to PLGA 
through a simple coupling reaction wherein the carboxylic acid end of the polymer is 
coupled to the primary amine group of FA via an amide linkage.    Briefly, 500 mg of 
PLGA was dissolved along with equimolar amounts of DCC (1 mmol) and NHS (1 
mmol) in anhydrous DMF.  The contents were stirred under room temperature for 4h 
in order to activate the carboxylic end groups located on PLGA.  To the activated 
polymer solution, 25mg (0.07 mmol) of fluoresceinamine solubilized in 2 ml DMF was 
added and the reaction was continued overnight.  The insoluble dicyclohexylurea 
(DCU) formed as a byproduct of the reaction was removed by filtration. The polymer 
was isolated by precipitating the filtrate into cold anhydrous diethyl ether followed by 
purifying the contents in methylene chloride and precipitating the resulting solution 
back into anhydrous diethyl ether.  The precipitate was then subjected to repeated 
washings in 5 mM HCl to remove any remnants of unconjugated fluoresceinamine 
and was lyophilized and stored at -20°C until further use. The polymer was 
characterized using 1H-NMR (Varian 400 MHz) in d-DMSO in order to confirm the 
chemical structure.  
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5.3.3 Preparation and characterization of FA-PLGA nanoparticles. 
FA-PLGA NPs were prepared by emulsification solvent evaporation as 
described earlier.[24]  Briefly, 100mg of FA-PLGA was dissolved in 3 ml of a mixture 
containing 4 parts dichloromethane (DCM) and 1 part acetone.  The organic mixture 
containing PLGA was emulsified over an ince bath with 5 ml of 2% PVA using a 
sonicating probe (OMNIruptor 250) set a 50W power for 3 minutes.  The resulting 
primary emulsion was immediately added to a solution containing 150ml of 0.5% PVA 
maintained under stirring.  The diluted emulsion was stirred overnight to evaporate 
the organic solvent.  The NPs were collected by centrifugation (Thermo Fisher) at 
12000 RPM, and washed thrice with DI water to remove the residual PVA.  The NPs 
thus obtained were snap frozen in liquid N2 and lyophilized to obtain the final product.  
The particles were then physically characterized for size and shape using scanning 
electron microscopy (SEM, Hitachi S2400) and dynamic light scattering (DLS, 90Plus 
Brookhaven Instruments). 
 
5.3.4 Administration of OLA-g-CS and OLA-g-CS laden PLGA NPs to mice.    
  Transnasal administration was employed to deliver the OLA-g-CS co-oligomer, 
and the combination of co-oligomer and PLGA NPs to mice.  OLA-g-CS solutions 
were freshly prepared on the day of the experiment by dissolving a known amount of 
the co-oligomer in sterile isotonic saline and filtered using a 0.22µM syringe filter 
(VWR).[25-27].  The mice were weighed and anesthetized under isoflurane in an 
oxygen atmosphere for 30s, with the help of an integrated multi-patient anesthesia 
center (IMPAC, Pfizer).  Mice were held under vertical position, and 15µL of OLA-g-
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CS or co-oligomer and PLGA NPs was administered transnasally, followed by 15µL 
of isotonic saline as chaser.  The material thus administered is rapidly taken into the 
lungs, and mice recovered within a couple of minutes.  Mice were allowed to recover 
after instillation, before returning them back to their cages. 
  Acute dose experiments were conducted with three co-oligomer dosages: 10, 
100 and 500µg per 15µl of saline, and a control - 15µl of saline only.  For each 
condition, a cohort of six mice was used.  The estimated dose of material reaching 
the lungs using this delivery strategy was evaluated with the help of a tracer.  
Transnasal administration of Evans’ Blue dye (0.5% w/v in isotonic saline) and 
chaser followed by immediate excision of the lungs and quantification of the amount 
recovered, showed that that 39±4% of the dye reached the peripheral parenchymal 
regions of the lungs.  This result compares well with the previous literature, thus 
confirming the reproducibility of the approach.[25] 
  For repeated administration experiments, mice were initially placed in nose-
only exposure chambers and allowed to inhale sterile, aerosolized saline for 60 
minutes.  Prior to aerosol exposure, on day 1, mice were instilled with saline solutions 
of OLA-g-CS via transnasal administration of 10 or 100µg per 15µl solution, followed 
by chaser.  The inhalation of saline aerosols is not expected to adversely affect the 
inflammatory state of the lung and was done here, in order to compare the results 
obtained in this study to that of data obtained from the allergen induced response 
experiment (where mice are exposed to aerosols containing an allergen, as 
discussed below).  The aerosols were generated by a collision nebulizer (CH 
Systems, New York) that supplies a relatively mono-dispersed aerosol with a mean 
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aerodynamic diameter of 0.25 µm.  On day 2, mice were exposed to saline aerosols 
for an hour, followed by administration of the co-oligomer (3h after saline exposure).  
This aerosol exposure was repeated four more times, resulting in a total of 5 
consecutive days of aerosol exposures and six consecutive excipient administrations. 
24h after the last exposure to saline (day 7), the animals were subjected to 
brochoalveolar lavage (BAL), and collagenase digestion of the lung tissue to assess 
the inflammatory cell population.  These steps are detailed in sections that follow.  
Mice exposed to saline aerosols and administered with only 15µl saline and the 
chaser, also for a total of six times,  were used as controls   
  For studying the allergen induced immune response, animals were 
sensitized with intraperitoneal (IP) injection of with 0.2 ml of sterile isotonic saline 
containing 10 µg ovalbumin (OVA) and 2 mg of aluminum hydroxide.[28]  
Sensitization procedure was undertaken on day 1 and day 14, and daily aerosolized 
OVA (1% ovalbumin in sterile saline) exposures were conducted 21 days after the 
first sensitization.  The procedure for aerosol exposure was similar to that described 
above.  Cohorts of OVA-sensitized mice were treated (transnasal administration) with 
saline carrier containing 0 (just saline), 10, or 100µg OLA-g-CS per 15µl, 24h prior to 
first OVA exposure.  On day 2, cohorts were exposed to OVA aerosols for 60 
minutes, followed by the second administration of OLA-g-CS.  This procedure was 
repeated, as mentioned before, 4 more times for 4 consecutive days amounting to a 
total of 5 OVA exposures and 6 transnasal administrations of OLA-g-CS at stipulated 
dosages..  Generation of OVA aerosols was done using a nebulizer as described 
before and the airflow was adjusted to ensure a constant concentration of 25 mg 
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OVA·m-3 is supplied to the animals as described in previous studies.[25, 28]  The 
animals were then subjected to BAL, and collagenase digestion of the lungs to 
estimate the inflammatory cell populations 24h after the final OVA exposure. 
Administration of Combination of OLA-g-CS and PLGA NPs.  Known 
concentrations of the NPs (10 and 30µg per 15 µl) were dispersed in a saline solution 
of OLA-g-CS using gentle sonication for 30s.  The resulting solution was 
administered to mice transnasally, as explained earlier.  The animals were then 
subjected to BAL, to estimate the inflammatory cell population, 24h after dosing.  
Mice were also administered with two different dosages of bare PLGA NPs – no co-
oligomer (10 and 30µg NP per 15µl isotonic saline solution) in order to assess the 
impact of NPs on the inflammatory state of the lung.  A total of 4 mice were used for 
each condition. 
 
5.3.5  Estimation of inflammatory cell infiltration into lungs.   
           The infiltration of inflammatory cells in mice receiving the OLA-g-CS and NPs 
was estimated using BAL and collagenase tissue dispersion of perfused lung as 
described earlier.[26, 29]  For BAL, the treated animals were sacrificed with a lethal 
injection of sodium pentobarbital, their chest opened, and the mice were 
exsanguinated by incising the heart to release the blood pressure from the lung.  The 
lungs were perfused with warm isotonic saline via the pulmonary artery, lavaged with 
1ml warm (37 °C) PBS (pH 7.4), which was collected in centrifuge tubes and stored 
at -80ºC for protein analysis.  This was followed by serial lavages with PBS-EDTA (3 
mM EDTA, 1 mL) of the lung 5 times to ensure maximum recovery of inflammatory 
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cells.  The recovered BAL fluid (BALF) was centrifuged at 300×g (Sorvall) at 4 °C, for 
12min to obtain the inflammatory cell population as a pellet.  The washed cells were 
resuspended in a 0.3 ml of PBS-EDTA, diluted in Isotone® II Diluent (Beckman 
Coulter), treated with two drops of Zap-O-Globin Lytic reagent (to mask the red blood 
cell population) and counted using a Coulter Counter (Coulter Electronics, Hialeah, 
FL) calibrated against a haemocytometer to obtain the total cell count.  The cells 
were then cytospun and stained with Wright’s Giemsa Stain to estimate the individual 
inflammatory cell populations viz. macrophages (MAC), lymphocytes (LYM), 
neutrophils (PMN), and eosinophils (EOS).  A total of at least a 100 cells was 
counted per slide. 
  Tissue dispersion studies to estimate the total cell count was performed 
according to procedure detailed in the literature.[28]  Lungs subjected to BAL, were 
excised from mice, washed in saline and sliced into tiny pieces.  They were subjected 
to collagenase digestion for 90min in a shaker maintained at 37°C.  The digestive 
agent was freshly prepared on the day of the experiment and it comprised of a 60ml 
RPMI solution supplemented with DNase and 100 Units per ml collagenase and 5% 
FBS.  The digested tissue components were filtered using a cell strainer (BD Falcon) 
to separate the undigested components, and the filtrate was centrifuged at 1250 
RPM for 12min to recover the cell pellet.  The supernatant obtained was discarded, 
and the recovered cells were resuspended in RPMI medium supplemented with FBS.  
They were subjected to another round of centrifugation at same conditions (described 
above) after which they were washed and redispersed in PBS-EDTA.  Total cell 
count in the dispersion was estimated using Coulter counter as described earlier.  
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Finally, the dispersed cell pellet was cytospun and the slides were stained as detailed 
before using Wright’s Giemsa stain.  In addition to the Wright Stain, cells were also 
subject to a nonspecific esterase stain for the identification of monocytes and 
MAC.[26] 
 
5.3.6 Recovery and estimation of FITC-labeled OLA-g-CS from lungs.  
           Mice were exposed to the FITC-labeled OLA-g-CS using transnasal instillation 
as detailed before.  In this study, a concentration of 500µg per 15 µl of the FITC 
labeled OLA-g-CS was utilized.  This concentration was chosen in order to ensure 
detection of the co-oligomer spectrophotometrically at various time points.  Here, an 
untreated mouse and a mice lung spiked with the FITC-labeled copolymer in saline 
were used as controls.  A single cohort for this experiment comprised of the controls 
(n=3 for each condition) and the mice treated with the labeled co-oligomer (n=4).  
The exposed mice were exsanguinated at different time points in order to track the 
presence of the labeled co-oligomer within the tissue.  Mice were euthanized, their 
lungs were excised, homogenized in saline and extracted with 1.5ml of 3N Sodium 
Hydroxide for 72h.  The extract was then subject to ultracentrifugation (Sorvall) at 
12000×g for 20 min.  The supernatant was carefully removed without disturbing the 
tissue layer and was subjected to spectroscopic analysis (DU70, Beckman) at 495 
nm.  The values were corrected for tissue absorbance and compared against a 
previously prepared calibration curve of OLA-g-CS labeled FITC to estimate the 
concentration of the excipient in the lung at different times.  The results were plotted 
as percent retained in the lung as a function of time.  The data obtained at time t=0 
207 
 
 
 
was deemed as 100%, and the values obtained at later times were normalized with 
respect to this value.  In order to unambiguously ensure that the approach utilized in 
detecting the co-oligomer was accurate, mice lungs were excised, spiked with a 
known amount of FITC labeled OLA-g-CS (500µg  per 15µl), and extracted as 
described above.  The absorbance values obtained from this study were tissue 
corrected and compared against the calibration curve.  This approach yielded a 
recovery of 88±4% (n=3) of the spiked co-oligomer. 
A similar methodology was employed to study the clearance of FA-PLGA NPs 
from the airspace.  In this case, 10µg per 15µl of NPs dispersed in a saline solution 
of OLA-g-CS (100µg) was administered to the mice via transnasal administration.  
The extraction procedure was performed in a 2 ml solution of 0.5% sodium sulfate in 
acetone for 72h in darkness. 
 
5.3.7  Serum protein determination.   
           Determination of serum protein in BALF was accomplished using a Bio-Rad 
Micro Assay procedure (Bio-Rad labs).  Frozen BALF was thawed and diluted in the 
ratio 1:100 with DI water.  The diluted samples were then treated with 250µl of 
filtered BioRad protein assay, mixed thoroughly and analyzed using a UV-
spectrophotometer (DU-70, Beckman Instruments) at 595 nm .  The absorbance of 
each sample was compared against a previously prepared calibration curve of to 
determine the protein content in the BALF. 
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5.3.8  Statistical analysis.  
 Data from these studies were analyzed for statistical significance using one-
way analysis of variance (ANOVA).  Comparisons of means were conducted using 
Dunnett’s or Student-Newman-Keul’s multiple range tests.  Data with p<0.05 was 
deemed significant. 
 
5.4. Results and Discussion. 
5.4.1 Retention of FITC-labeled OLA-g-CS in the lungs after transnasal 
administration. 
  Conjugation of FITC to the water soluble OLA-g-CS co-oligomer with a 2.4 
CS:LA molar ratio) was accomplished by linking the isothiocyanate group of FITC to 
the amine groups on the CS backbone through the thiourea bond.[23]  The presence 
of FITC on the backbone was ascertained based on the aromatic proton (4H) peak 
between 6.42 and 6.7 ppm observed in the 1H-NMR spectra.  UV spectroscopy of the 
co-oligomer revealed a distinct peak at 495 nm, which can be attributed to the UV 
absorbance of FITC. 
  The lung retention of FITC-labeled OLA-g-CS after transnasal administration 
was assessed by quantifying the amount of co-oligomer in the lung homogenates as 
a function of time after instillation.  The retention results are shown in Figure 5.1.  
Unexposed lung homogenates were used as baseline - to remove contributions from 
auto-fluorescence of the tissue. 
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The results are shown relative to the amount delivered at zero time, which was 
determined to be 42.2% of the total dosage, a number consistent with that 
determined for Evan’s blue in this study, and also consistent with results obtained for 
dendrimer-FITC conjugates delivered using the same methodology,[25] indicating the 
reliability of the approach chosen for this study. 
 From the results, as much as 42% of the OLA-g-CS co-oligomer that reaches 
the lungs is cleared by 24h, and only 22% is left by 48h.  Assuming a linear trend in 
Figure 1, the results suggest a half-life for the co-oligomer in the lungs of 31.6h, and 
total clearance after 62h.  A study conducted with generation 4 (G4) poly(amido 
amine) dendrimers with 18 times the MW of the co-oligomer investigated in this study 
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Figure 5.1.  Retention of FITC-tagged OLA-g-CS in the lungs as a 
function of time after transnasal administration.  OLA-g-CS was 
administered at 500 µg in 15 µl of saline.  Unexposed lung 
homogenates were used as baseline.  Results represent mean ± s.d, 
with n=4 mice per time point. 
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revealed that the clearance of those compounds from the peripheral regions of the 
lung to be as high as 14 days.  In contrast, bare FITC, with MW of 390Da, is 
eliminated from the lungs within a few hours, with as little as 12% of the compound 
recovered from the peripheral part of the lung by 2h.[25] 
 Previous studies have shown that CS alone may reside in the airspace for 
extended time periods of time, in some cases for several days, owing to its 
mucoadhesiveness,[30, 31] which can be traced back to its cationic nature that help 
interact with hydrophilic biomacromolecules present in the lung tissue.[32]  However, 
most of the experiments conducted in vivo on rodent models employed CS with MW 
greater than 30 KDa,[31, 33] whose aqueous solubility is very low in aqueous 
environments (at physiological pH).  The relatively rapid clearance of the CS-g-LA co-
oligomer from the airspace can be, therefore, attributed to a combination of low molar 
mass and enhanced aqueous solubility. 
 A size dependent clearance of intratracheally instilled hydrophilic molecules 
such as proteins has been reported in the literature, with larger protein molecules 
being cleared at a slower rates (days) compared to their smaller MW counterparts 
(peptides), which are cleared from the lung within a matter of hours.[3, 34, 35]  For 
instance, albumin, a 66 KDa protein, is cleared from the lungs of various animal 
models at a rate of ca.1-2% per hour.[34]  Along similar lines, rapid disappearance of 
hydrophilic molecules of ca.1000 Da has also been well documented in literature.[36]  
For instance, FITC-labeled calcein, a hydrophilic molecule with a MW of 623 Da, 
when administered intratracheally, cleared from the airspace of rat lungs within 3 
hours.[35]  Interestingly, OLA-g-CS, based on size alone, would be expected to be 
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cleared out from the very rapidly.  However, we expect the co-oligomer to interact 
with compounds in the lung tissue to a larger extent than biomacromolecules 
(proteins and peptides), and thus possess longer residence times in the lungs.[3]  
Additionally, since not all the administered OLA-g-CS reaches the lung upon 
transnasal administration, there is a possibility that the co-oligomer trapped in the 
nasal cavity and the upper airways could translocate to the airspace during the 
course of the study, thereby contributing towards the detection of the excipient during 
the latter part of the study. 
 
5.4.2 Estimation of Inflammatory Status of the Lungs upon Transnasal 
Administration of the OLA-g-CS Co-oligomer. 
Single Acute Dose.  The inflammatory status of the lungs was evaluated after 
single and repeated dose administration of OLA-g-CS using BAL and collagenase 
tissue dispersion analysis.  The dosages of OLA-g-CS administered were 10µg 
(0.5mg/Kg body weight), 100µg (5.0mg/Kg body weight) and 500µg (25mg/Kg body 
weight) - the dosages were estimated based on average weight of the animals at 
ca.20g.  BAL was used to investigate the cell population present in the airways and 
the lower respiratory tracts.  This was done by sampling both the cellular and 
acellular components recovered from the bronchi and alveolar regions of the 
lungs.[37]  Analysis of BALF was done for total and differential cell counts.  
Additionally, specific cell types (MAC, PMN, EOS, and LYM) that populate the 
airspace were identified by appropriate staining procedures, and counting of the cells 
was achieved using an optical microscope.[26]  A summary of the percentage of cell 
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population recovered from BALF after transnasal administration is shown in Figure 
5.2. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
The total cell count recovered from mice exposed to OLA-g-CS and control 
using BAL averaged 2.8±0.7×105 per lung, which are values similar to what has been 
reported in the literature upon administered of various excipients to the lungs of 
mice.[25, 29, 38]  As much as 95% of the cells recovered were MAC, at 0.5 and 
5.0mg per Kg dosages.  These figures are within the stipulations prescribed by the 
Figure 5.2. Percentage of individual cell population recovered from 
bronchoalveolar lavage fluid (BALF) of healthy mice 24h after transnasal 
administration of single acute doses of OLA-g-CS at different 
concentrations.  Animals treated with sterile isotonic saline were used as 
control.  Data shown as average ± s.d (n=6), for each condition.  MAC = 
macrophages; LYM = lymphocytes; PMN= neutrophils; EOS = eosinophils.   
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American Thoracic Society (ATS), which suggests that a lavage of a typical healthy 
lung is expected to comprise primarily of alveolar macrophages (95-99%).[39, 40] 
 A dose dependent increase in the PMN content was observed, as mice were 
exposed to 10, 100 and 500 µg of the co-oligomer.  The cohort exposed to 500 µg of 
OLA-g-CS showed a neutrophil count of 0.42±0.17×105 cells, which corresponded to 
ca. 11.5±4.9% of the total cells recovered.  This represents a percentage that is 
higher than what is recommended for a typical healthy lung.  Interestingly, the data 
was not significant with respect to control, as mice exposed to saline had ca.7±3.2% 
of cells recovered as PMN.  While this dosage elicited a slight increase in the PMN 
content, it was within the statistical purview when compared to control, and all other 
cell types were well within the recommendations of the ATS. 
 Mice exposed to a single dose of 10 and 100µg of the co-oligomer did not 
exert any noticeable increase in granulocyte counts, suggesting that the co-oligomer 
was benign within those dosages.  Interestingly, BALF recovered from mice exposed 
to isotonic saline also contained neutrophils, however they were around the 
stipulated 3% recommendation.[37]  These results indicate that the excipient, upon a 
single acute dose administration, induces no noticeable inflammatory response 
above and beyond that of the carrier up to a dosage of 100µg per 15µl carrier, or 
5mg/Kg body weight of mice. To put these results in perspective we can 
extrapolate the dosages administered to mice in this study to that of a typical MDI 
formulation administered to humans.  The concentration of OLA-g-CS required to 
stabilize aerosols of drug particles in typical concentrations found in commercial 
pMDI formulations is 2 mg OLA-g-CS per mL of the propellant.  Upon actuation, 
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through a 50 µl metering valve, about 100 µg of the OLA-g-CS will be released out 
through the aerosol plume.  Based on the assumption that the aerosol plume is orally 
inhaled by a healthy human of 75 Kg, the single puff dose delivered to the lungs 
would be 1.3µg per Kg body weight.  Along similar lines, a 500µg dose of the 
excipient delivered to 20g mice (taking into account 40% dose delivery to the lung) 
would correspond to 30 mg/kg human, which corresponds to 3000 doses 
(administered simultaneously) to a healthy individual, thus further indicating the fact 
that the co-oligomer is highly benign at doses expected in typical formulations. 
  Repeated Administration.  In order to understand the effect of excipient 
accumulation in the lung on the infiltration of inflammatory cell population, repeated 
administration of OLA-g-CS to mice was undertaken.  A total of 6 administrations for 
each condition (saline, 10 and 100µg) were conducted, after which mice were 
sacrificed and subjected to lavage.  Percentages of cells recovered from this study 
are shown in Figure 5.3(a).  The 500µg dose was not implemented here owing to the 
fact that it represents an exceedingly high concentration when compared to typical 
formulations as detailed above, and it was shown to cause an inflammatory response 
at a single dose.   
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The data from Figure 5.3(a) suggests an increase in inflammatory cell 
infiltration into the lung milieu with an increase in OLA-g-CS concentration.  Total 
cells recovered from mice in this study were slightly higher than the single dose 
studies, with average cell counts estimated to be ca.4.0±0.2×105 cells, with 
macrophages contributing to the majority of the cell count (>92%) for both saline and 
10 µg OLA-g-CS.  However, a reduction in the percentage of macrophages to 
Figure 5.3. Percentage cell population of the total recovered from 
bronchoalveolar lavage fluid (BALF) of mice initially exposed to (a) saline 
aerosols, and (b) ovalbumin (OVA) aerosols, and subsequent intranasal 
administrations of six repeated doses of OLA-g-CS in sterile isotonic saline.  
Dosages administered of OLA-g-CS were 10µg and 100µg.  Animals treated 
with sterile isotonic saline were used as controls.  Data shown as average ± 
s.d (n=6), for each condition.  MAC = macrophages; LYM = lymphocytes; 
PMN = neutrophils; EOS = eosinophils.  * denotes statistically significant 
data compared to control (p<0.05). 
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ca.76% was observed for the cohort administered repeatedly with 100µg per µL.  At 
this dosage dosage, a significant increase in the presence of inflammatory cell 
population was detected with counts of both PMN and EOS being statistically 
significant (p<0.05) over and above the effect of the carrier, amounting to 14% and 
9% of the total cell population.  The enhanced recovery of the granulocytes at 
dosages beyond 10µg of the co-oligomer is indicative of the biological effect caused 
due to the accumulation of the excipient in the peripheral part of the lung at these 
elevated dosages.  Such responses are expected as this represents a total 
accumulation of 1.65 g per Kg body weight. 
It is instructive to compare and contrast the results obtained here with those 
reported in the literature with other polymers that have been tested for drug delivery 
applications to the lungs.  CS in the form of particles has been tested extensively for 
pulmonary toxicity after intratracheal administration in rodents.[41-44]  Inflammatory 
responses to CS have been shown to be size and charge dependency.[44]  Medium 
MW CS microspheres when insufflated to rats at concentrations of 4 and 10mg per 
Kg were shown to induce severe inflammation in the animals as evidenced by protein 
analysis and BAL (high PMN recruitment).[41]  The toxicity in this case, was 
attributed to the MW of CS and the high surface charge of the particles (+45 mV), 
which could lead to their binding with lung tissue enabling them to persist in the 
airspace for an extended times – note such a MW of CS is not soluble in water at 
physiological pH.[41]  A similar observation was reported in another study involving 
high MW CS (100-500 KDa) administered to rats, where acute structural damage and 
high PMN infiltration was reported as evidenced by histopathological evaluation.[33]  
217 
 
 
 
The effect of the cationic character of biocompatible polymers on pulmonary 
inflammation has been documented in an another study, where repeated 
administration of 0.15mg of PLA-polyethylene glycol (PLA-PEG) NPs modified with 
stearylamine (a cationic compound) to mice endotracheally resulted in severe 
pulmonary toxicity, as evidenced by BAL experiments, with high recruitment of 
eosinophils and lymphocytes.[45]  Interestingly, the same study reported that 
unmodified PLA-PEG NPs (no cationic grafts) had no effect on lung status after 5 
days of exposure.  While medium and high MW CS have been shown to induce 
pulmonary inflammation, studies conducted using short chained chitosan oligomer 
(10-18 monomer units) did not induce any noticeable inflammatory response in mice 
upon intratracheal instillation as evidenced by BAL and histology studies.[46]   Those 
studies were conducted at dosages of 0.6µg per µg DNA delivered. 
 
5.4.3   Effect of OLA-g-CS on allergen induced lung inflammation. 
           Sensitization and aerosol challenge of mice with OVA results in airway 
eosinophilia and pulmonary damage analogous to those observed in asthma, 
causing a heavy recruitment of inflammatory cells (EOS in particular) within the 
airspace.[47]  The rationale behind this portion of our study was to determine whether 
the co-oligomer interferes with the ability of the lung to deal with an allergen induced 
immune response in either a positive or negative way.  This information was 
necessary for later studies with the co-oligomer and a therapeutic molecule, where 
such effects should not be confounded.  Figure 5.3(b) is a summary of the percent of 
individual cell populations extracted from the BALF of animals exposed to OVA, and 
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treated repeatedly with the co-oligomers at dosages of 10 and 100µg per 15 µL, as 
detailed in Methods. 
  While the average cell numbers recovered from mice exposed to saline 
aerosols was quantified to be 3.0±0.2×105 (mean ± s.d) for all conditions tested, the 
total cell recovery from OVA exposed mice increased to 11±2.5×105.  Cell recovery 
for the studies with OVA+10µg co-oligomer was 9±0.9×105, and that for OVA+100µg 
co-oligomer 12.1±2×105.  In addition to a change in cell recovery, significant changes 
in the individual inflammatory cell count were also observed upon OVA 
administration, as expected.  While the cell counts of MAC increased, their presence 
in the total cells recovered diminished to as low as ca.34% ( under all conditions 
tested) for cohorts exposed to OVA, representing a dramatic reduction when 
compared to mice exposed to saline only.  This also greatly contrasts with a much 
higher MAC recovery observed after repeated administration of the the co-oligomer 
alone, where the lowest MAC recovery in that case (for 100µg OLA-g-CS) was still at 
76%.   These results are similar to what has been previously reported in the literature 
for OVA exposed mice.[26, 28] 
  The average percent of EOS in the BALF of OVA-exposed mice was 52±7%, 
which is also in agreement to literature values.[28]  It was observed, however, that 
the EOS count does not change significantly among the cohorts treated with OVA 
alone and those with OVA along with various doses of OLA-g-CS, indicating that the 
administration of the co-oligomer did not interfere with the EOS infiltration into 
airspace arising from OVA exposures, which is a very important observation, as it 
may suggest that this excipient could be potentially used to deliver asthma related 
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therapeutics.  Mice exposed to OVA and treated with CS nanoparticles for 24 days, 
were also shown to have an increase in EOS count as evidenced by BAL 
analysis.[42]  In this study, the MAC count upon OVA exposure remained fairly 
similar in all the conditions tested.  Interestingly, while the BAL data indicated that 
infiltration of EOS into the airspace was not affected for all excipient dosages 
investigated, a statistically significant reduction in the PMN was observed for cohorts 
treated with OLA-g-CS when compared to that of those treated with saline only after 
OVA exposure.  The reduction in these numbers indicates that the excipient could be 
suppressing MAC associated recruitment of PMN, but not EOS.  However, 
categorical establishment of this hypothesis would require further, more elaborate 
studies.  Another interesting observation from this study is the reduction in the LYM 
numbers for cohorts administered with 10µg OLA-g-CS when compared to contents 
recovered from control mice.  However, this observation was not extended to the 
cohorts receiving 100µg OLA-g-CS; the percentage of LYM recovered in that case 
was similar to what was observed for control mice.  
  In addition to BAL, inflammatory cell populations isolated from collagenase 
tissue dispersions of mice lungs exposed to OVA (allergen induced / inflamed lungs) 
and administered with repeated doses of OLA-g-CS were counted and compared to 
those from animals exposed to saline aerosols and the co-oligomers.  These results 
are complementary to the BALF studies, and provide a more detailed picture of the 
inflammatory status of the lungs, and any changes in inflammatory status upon 
further exposure to the co-oligomer (beyond that induced by OVA) .[26, 28, 48]  This 
approach is important as it helps us correlate the time course of inflammatory events 
220 
 
 
 
with airway reactivity, and other relevant provocative occurrences in the lung.[28, 48]  
For instance, studying inflammatory cells recovered from BALF combned with cell 
contents from marginated tissue and interstitial compartments can provide a platform 
for the correlation with airway responses to methacholine challenge.  This data could 
provide us with a better perspective on the inflammatory status of the lung.[26, 28, 
48] 
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Figure 5.4.  Percent increase in cell population recovered from collagenase 
tissue dispersion of lungs administered with repeated doses of OLA-g-CS at 
10 and 100µg following exposures to OVA aerosol.  Data was obtained by 
comparing the individual cell counts to those of cohorts exposed to saline 
aerosol followed by repeated dosing of OLA-g-CS.  Data shown as average 
± s.d (n=6), for each condition.  NSE +ve = non-specific esterase positive; 
LYM = lymphocytes; PMN = neutrophils; EOS = eosinophils. 
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  Consistent with previous trends, cell populations isolated from tissue 
dispersion after mice exposed to OVA aerosols were significantly higher compared to 
those isolated from mice exposed to saline aerosols.[25, 26, 28]  Among the 
individual cell populations, the greatest increase was in the EOS count, which 
amounted to a 90% increase when compared to that of mice exposed to saline 
aerosols only.  This dramatic increase in the eosinophils from OVA-exposed mice 
agrees well with previous report in the literature.[28, 48]  The impact of OVA 
exposure can also be attributed to the increase in NSE +ve cells whose increase was 
60% greater than that of NSE +ve cells recovered from saline exposed aerosols.  It is 
also worth noting that, for the mice exposed to OVA, the extent of increase in cell 
counts, particularly for EOS and LYM, were similar for all conditions tested viz., 
saline, 10 and 100µg per µL, reaffirming the fact that the presence of co-oligomer in 
the lungs does not seem to interfere with the allergen induced response. 
  Overall, from our set of experiments comprisied of BALF and tissue dispersion 
analyses we conclude that the inflammatory potential of OLA-g-CS on mice lung is 
dose dependent, with dosages as high as 100µg (5mg per Kg body weight) being 
tolerable to mice upon single acute exposure.  Repeated exposures of OLA-g-CS 
resulted in increasing lung inflammation for mice administered (after 6 exposures) 
over with 100µg OLA-g-CS, while10 µg (0.5mg per Kg body weight) was found not to 
cause any inflammatory response above and beyond that of the saline control.  It can 
be also concluded that, within the dosage ranges studied, the excipient did not 
interfere with the allergen-induced immune responses in OVA exposed mice. 
 
222 
 
 
 
5.4.4  Integrity of Pulmonary Epithelium. 
           The membrane integrity of the pulmonary epithelium is the most important 
barrier to the systemic circulation.  It controls and regulates the transport of different 
species across the air-blood barrier, and thus the permeability of the epithelium.[49]  
Infections in the lower respiratory tract can lead to an influx of protein rich fluids into 
the airspace due to increased epithelial cell permeability.[50]  This influx of proteins 
can also be accompanied by an enhanced recruitment of PMN into the airspace.[51]  
This protein increase was quantitatively assessed from the BALF using a protein 
assay procedure as detailed in the methods section. The results are summarized in 
Figure 5.5. 
  In Figure 5.5(a) we report the total protein content of the BALF after single 
acute intranasal exposure of the co-oligomer.  The results indicate no significant 
exudation of serum protein into the airspaces compared to saline controls after a 
single acute exposure of the co-oligomer.  In Figure 5.5(b) we report the protein 
concentration following repeated doses of the co-oligomer.  We can observe that 
while mice exposed to repeated doses of OLA-g-CS at 10µg did not develop any 
significant damage to the epithelium when compared to saline control cohorts 
repeatedly exposed to 100 µg of OLA-g-CS had an increase in flux of protein into the 
airspaces.  These results corroborate our earlier observations that show that mice 
repeatedly exposed to 100µg of OLA-g-CS, developed an increased recruitment of 
PMN - Figure 5.5(a).  These results, in conjunction with BAL and tissue dispersion 
analyses further confirm the dose dependent inflammatory effect exerted by OLA-g-
CS in the airspace. 
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  While, mice exposed to repeated doses of OLA-g-CS at 10 µg concentrations 
did not develop any significant damage to the epithelium compared to saline controls, 
cohorts repeatedly exposed to 100 µg of OLA-g-CS had an extensive in flux of 
protein into the airspace as shown in the plot.  Furthermore, BAL studies conducted 
on mice exposed to 100 µg of OLA-g-CS resulted in an increased recruitment of 
neutrophils to lungs as evidenced by cell recovery plots shown in Figure 5.4 
corroborating earlier observation.[48]  These results, in conjunction with BAL and 
tissue dispersion analyses, further confirm the dose dependent inflammatory effect 
exerted by OLA-g-CS in the airspace.   
Figure 5.5.  Total protein content recovered from BALF of mice 
exposed to a (a) single acute dose of OLA-g-CS; (b) repeated 
administration of OLA-g-CS.  Protein content is plotted as a function 
of OLA-g-CS concentration.  Data shown as mean ± s.d n=6, for each 
condition. * denotes statistical significance (p<0.05) 
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5.4.5 Retention of PLGA NPs in the lungs after transnasal administration with 
the co-oligomer. 
 Retention of the FA-labeled PLGA NPs in the lungs as a function of time after 
transnasal administration is shown in Figure 5.6.  Conjugation of FA to the carboxyl 
end of PLGA was determined by the presence of the aromatic proton peak between 
6.5 and 7 ppm in the 1H-NMR spectrum.[24]  NPs with the FA-PLGA were formed by 
emulsification solvent evaporation, and had an average diameter of 260nm, and a 
polydispersity of 0.2, as determined by DLS (90Plus, Brookhaven Instruments).  The 
ζ potential of the NPs was determined to be -12.3±1.2 mV.  The particles were 
smooth spheres as evidenced by the SEM micrograph shown as inset in Figure 6.  
The sizes from were also estimated from SEM suing ImageJ (v1.4, NIH), and the 
values were in good agreement with the DLS (240nm). 
 The NPs were administered at a concentration of 10µg in 15 µl of saline, with 
100µg of the OLA-g-CS co-oligomer.  This concentration was selected as it 
represents the mass ratio of the NP formulation in the propellant-based inhalers that 
we have recently reported,[19] where we have shown that the formulation possesses 
aerosol characteristics conducive to deep lung deposition of the NPs. 
 It can be observed that a large percentage (ca. 60%) of the NPs was flushed 
out from the airspace within the first two hours.  This was followed by a period where 
the removal of NPs from the lung was relatively slow, with only about 5% of the NPs 
eliminated within the next 10 hours.  By 24h, almost 90% of administered NPs were 
eliminated from the airspace, and by 48h, as little as 5% of the administered NPs 
remained in the lung.   To put these results in perspective, a comparison of  
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elimination rates of various polymeric NPs from the lungs was made.  The rapid 
elimination of PLGA NPs upon pulmonary administration has been also reported in 
earlier studies by others.[31, 52]  The majority of the PLGA NPs administered 
intratracheally to guinea pigs was shown to be eliminated within the first hour of 
administration.  In the latter study, over 75% of the administered dose was cleared 
from the lungs by 2h and corroborate the observations made in our study.[31]  
However, in the same study, authors reported that CS coated PLGA NPs persisted 
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Figure 5.6. Retention of FA-labeled PLGA NPs in the lungs as a 
function of time after transnasal administration.  NPs administered at 
100µg in 15 µl of saline, with 100µg of the OLA-g-CS co-oligomer.  
Unexposed lung homogenates were used as baseline.  Results 
represent average ± s.d, with n=4 mice per time point.  Inset: electron 
micrograph of the FA-PLGA NPs prepared with the emulsion solvent 
evaporation technique.  Bar denotes 1 µm. 
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longer within the lung owing to the mucoadhesive nature of CS coating the NPs.  It is 
worth mentioning that the profile observed in our study (and those in the literature as 
well), may potentially include NPs that are initially trapped in the upper region of the 
airways and the nasal cavity following administration, and that may later descend to 
the airspace. 
 The residence time of NPs in the airways has also been shown to be a strong 
function of the particle chemistry.  In general, polystyrene (PS) NPs have been 
shown to persist in the airspace for extended durations, owing to their non-
biodegradable, and hydrophobic nature.[53]  PS NPs (100 nm in size) pharyngeally 
aspirated to rats, were reported to linger in the lungs for extended periods of time, 
having half-lives as high as 44 days.[54]  In another independent study, PS NPs of 
size 220 nm modified with polyacrylate were administered intratracheally to rats.  
Elimination of these NPs from the lungs was found to be very sluggish, with <0.02% 
of NPs observed in lymph nodes 1h after administration.[55] 
 
5.4.6. Inflammatory response of the lungs upon transnasal administration of 
PLGA NPs combined with the OLA-g-CS co-oligomer. 
We have demonstrated that we can successfully encapsulate PLGA NP within 
a shell of OLA-g-CS, and shown that such structures can be stably dispersed in 
pMDIs and produce aerosols that enhance the deposition of NPs in the deep 
lungs.[19]  In vitro toxicity studies indicated that these core-shell structures were non-
toxic to pulmonary epithelial cell lines (A549 and Calu-3) within the concentration 
ranges tested.  Here, we extend the study to evaluate the inflammatory status of the 
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lungs upon in vivo administration of PLGA NP mixed with the OLA-g-CS co-oligomer 
that form the shell discussed in the study above. 
PLGA NPs formed as described above were gently dispersed in a 100 µg 
OLA-g-CS solution at concentrations of 10µg and 30 per 15µl, and administered 
transnasally to mice.  The dosages were chosen in order to mimic the typical 
composition of a core-shell formulation administered using a pMDI.  As a 
comparison, bare NP (without OLA-g-CS in sterile saline) dispersions of the same 
dosages were prepared and their response in mice were evaluated as well.  The data 
reported here are the analysis inflammatory response from mice subjected to BALF 
24h after instillation of the core-shell formulation – PLGA NP and co-oligomer.  
Individual cell counts recovered from mice are given in Table 5.1, and the results are 
recast in Figure 7 as percentages to better highlight the composition of each cell type 
after administration of individual formulations. 
Total cell population recovered from mice instilled with various formulations 
varied greatly with respect to the formulation.  While mice instilled with OLA-g-CS 
had an average recovery of ca.4×105 cells from BALF (n=4), cells isolated from mice 
treated with NPs only and those instilled with the NPs and the co-oligomer averaged 
ca.2.5×105 cells, with mice administered with 30µg NPs having the fewest cells 
recovered.  Data obtained here are similar to an earlier study by others, where lavage 
of mice administered with PLGA NPs at concentrations of 1 and 2.5µg per µl carrier 
resulted in cell recoveries of ca.2.5×105 cells per cohort.[38]  Except for the 
formulation comprising of 30µg PLGA NPs in combination with OLA-g-CS, MAC 
count recovered from all other systems exceeded 90%.  For the formulation 
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comprising of 10µg NP in combination with the co-oligomer, no appreciable 
inflammatory response was detected.  This is important as this concentration range is 
the typical composition of the core-shell particles describe earlier; the loading 
deduced from our previous studies confirm 10% loading of NPs within the OLA-g-CS 
shell.[19] 
 
 
 
 
 
 
 
 
 
 
 
Data represents mean±s.d. (n=4) 
Cells were recovered from treated mice by bronchoalveolar lavage.  Data shown here 
represents average cell population recovered from lungs of 4 animals per condition. 
* represents statistically significant data compared to control (saline) 
 
Interestingly, the results obtained for the bare NPs and the NPs along with the co-
oligomer compare well with other biodegradable polymeric NPs that have been 
 
Table 5.1.   Individual count of inflammatory cells population recovered 
from the bronchoalveolar lavage of mice after intranasal administration of 
nanoparticles and/or the OLA-g-CS co-oligomer.  Results represent 
mean ± s.d, with n=4 for each condition. 
 
Dosage           
(µg·15 µl
-1
) 
Macrophages 
(×10
3
) 
Lymphocytes 
(×10
3
) 
Neutrophils 
(×10
3
) 
Eosinophils  
(×10
3
) 
0 (Saline) 279.6±49.6 30.2±16.4 6.1±2.4 0 
100 OLA-g-CS 410.7±54.1 31.6±12.5 27.5±11 0.6±0.02 
10 PLGA NPs 341.4±80.5 34.1±1.4 14.9±1.3 0 
30 PLGA NPs 181.1±17 25.1±1.13 15±3.3 0.7±0.1 
100 OLA-g-CS +   
10 PLGA NPs 
251.3±78.9 21±10.2 16.8±4.6 1.23±0.12 
100 OLA-g-CS +   
30 PLGA NPs 
243.2±52.4 0 132.7±58* 14.1±4.7* 
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tested for potential inflammation in lungs.  For instance, PLGA NPs (ca.100 nm) and 
another variant of PLGA, DEAPA-PVAL-g-PLGA NPs (ca. 200 nm) administered to 
mice at a concentration of 1µg and 2.5µg per µl carrier did not induce any 
pronounced adverse effect in the lungs 24h after intratracheal instillation.[38]  Within 
the same observation times as this study, in another study, polystyrene NPs of 
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Figure 5.7.   Percentage of individual cell population recovered from 
bronchoalveolar lavage fluid (BALF) of healthy mice treated with single 
acute doses of the NP and co-oligomer.  OLA-g-CS concentration was 
maintained at 100 µg of per 15 µl, while the NP concentration was set to 
either 10 or 30 µg per 15 µl of carrier.  Data shown as mean ± s.d (n=4), 
for each condition.  MAC = macrophages; LYM = lymphocytes; PMN = 
neutrophils; EOS = eosinophils.  *-  indicates statistically significant data 
when compared to carrier. 
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220nm in size had a substantial toxic effect on the lungs, with PMN recruitment as 
high as 80%.  In another study, anionic PLA-PEG NPs administered to Balb/c mice at 
dosages of 0.15mg per 25µl carrier via endotracheal instillation, did not induce any 
appreciable inflammation compared to their cationic counterparts.[45]  Along similar 
lines, repeated administration of solid lipid NPs (100 nm, -15 mV) for 16 days did not 
induce any notable inflammation as evidenced by absence of PMN and lack of 
increase in protein content in the BALF.[29] 
 The formulation of 30µg PLGA NPs in the presence of 100µg OLA-g-CS 
caused a reduced percentage of MAC (68%), and infiltration of inflammatory cell 
populations evidenced by increased PMN content to as high as 29%.  The 
percentage of EOS recovered from mice receiving this formulation was as high as 
3%.  However, NPs administered at the same dosages in the absence of OLA-g-CS, 
did not induce an inflammatory response, and their cell counts were similar to saline 
control.  It is interesting to observe that only at the highest dose of NPs in 
combination with the excipient was a statistically significant spurt in the PMN and 
EOS (p<0.05) is observed.  One potential explanation to this effect may be a lower 
physical stability of the NPs in a physiological environment when at higher 
concentrations, when aggregates would behave differently compared to 
free/unaggregated NPs.  It is worth mentioning, however, that DLS results show that 
aggregation does not happen in vitro (buffer with NPs). 
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5.5. Conclusions. 
In this work we evaluated the lung inflammatory potential of a versatile, water-
soluble, biodegradable co-oligomeric excipient for pMDIs, namely OLA-g-CS through 
an extensive set of in vivo experiments encompassing BAL, collagenase tissue 
dispersion analysis and serum protein evaluation.  Retention studies of the co-
oligomer revealed that ca. 80% of the OLA-g-CS co-oligomer was removed from the 
lungs within 48h.  Results from the inflammatory response suggest a dose dependent 
increase in the response upon intranasal administration of a single acute dose of 
OLA-g-CS, with the co-oligomer eliciting an inflammatory response only at very high 
dosages - greater than 5 mg/Kg body weight.  However, repeated administration of 
OLA-g-CS to mice resulted in adverse infiltration of granulocytes into the lung milieu 
at lower dosages (>0.5 mg/Kg body weight) possibly due to the enhanced 
accumulation of the excipient in the peripheral part of the lung.  This concentration is 
still exceedingly high compared to typical dosages from pMDI formulations – this 
would be equivalent of 1400 puffs per day, for a total of 6400 puffs within 6 days.   
BAL and collagenase tissue dispersion analysis conducted on mice exposed to OVA 
demonstrated that the co-oligomer does not interfere with the ability of the lung to 
deal with an allergen as showcased by the increase in eosinophil content in the lungs 
of mice upon exposure to OVA.  PLGA NPs administered along with the OLA-g-CS 
co-oligomer at concentrations similar to that utilized in the preparation of core-shell 
formulations for pMDIs did not elicit a significant immune response as indicated by 
BAL results.  It is also observed that the NPs are rapidly flushed from the airways - > 
90% within the first 24h.  These results taken together suggest that the co-oligomeric 
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excipient has great potential to be employed safely not only in the treatment of acute 
conditions of the lungs, but also for patients with chronic lung diseases, and for the 
controlled and targeted delivery to and through the lungs, potentially with the help of 
biodegradable polymeric NPs formulations. 
 
Note – This work was done with the assistance of Dr. David J P Bassett, Professor of 
Occupational and Environmental Health and Mr. Xiufeng Gao.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
233 
 
 
 
5.6 References. 
[1] M.M. Bailey, C.J. Berkland, Nanoparticle formulations in pulmonary drug delivery, 
Med Res Rev, 29 (2009) 196-212. 
[2] W. Berger, Aerosol devices and asthma therapy, Curr Drug Deliv, 6 (2009) 38-49. 
[3] J.S. Patton, P.R. Byron, Inhaling medicines: delivering drugs to the body through 
lungs, Nat Rev Drug Discov, 6 (2007) 67-74. 
[4] G. Pilcer, K. Amighi, Formulation strategy and use of excipients in pulmonary drug 
delivery, Int J Pharm, 392 (2010) 1-19. 
[5] P. Rogueda, Novel hydrofluoroalkane suspension formulations for respiratory drug 
delivery, Expert Opinion in Drug Delivery, 2 (2005) 625-638. 
[6] N. Islam, E. Gladki, Dry powder inhalers (DPIs)--a review of device reliability and 
innovation, Int J Pharm, 360 (2008) 1-11. 
[7] R.U. Agu, In vitro and in vivo testing methods for respiratory drug delivery, Expert 
Opin Drug Deliv, 8 (2011) 57-69. 
[8] B. Laube, The Expanding Role of Aerosols in Systemic Drug Delivery, Gene 
Therapy, and Vaccination, Respir Care, 50 (2005) 1161-1176. 
[9] H. Chrystyn, D. Price, Not all asthma inhalers are the same: factors to consider 
when prescribing an inhaler, Prim Care Respir J, 18 (2009) 243-249. 
[10] D.S. Conti, J. Grashik, L. Yang, L. Wu, S.R.P. da Rocha, Solvation in 
hydrofluoroalkanes: how can ethanol help?, J Pharm Pharmacol, (2012). 
[11] H.D.C. Smyth, Propellant-driven metered-dose inhalers for pulmonary drug 
delivery, Expert Opinion in Drug Delivery, 2 (2005) 53-74. 
234 
 
 
 
[12] J. Bell, S. Newman, The rejuvenated pressurized metered dose inhaler, Expert 
Opin Drug Deliv, 4 (2007) 215-234. 
[13] L. Wu, S.R.P. da Rocha, Nanoparticle-Stabilized Colloids in Compressible 
Hydrofluoroalkanes, Langmuir, 27 (2011) 10501–10506. 
[14] D. Lechuga-Ballesteros, B. Noga, R. Vehring, R.H. Cummings, S.K. Dwivedi, 
Novel cosuspension metered-dose inhalers for the combination therapy of chronic 
obstructive pulmonary disease and asthma, Future Med Chem, 3 (2011) 1703-1718. 
[15] L. Wu, B. Bharatwaj, J. Panyam, S.R.P. da Rocha, Core–shell Particles for the 
Dispersion of Small Polar Drugs and Biomolecules in Hydrofluoroalkane Propellants, 
Pharm Res, 25 (2008) 289-301. 
[16] L.A. Dellamary, T.E. Tarara, D.J. Smith, C.H. Woelk, A. Adractas, M.L. Costello, 
H. Gill, J.G. Weers, Hollow porous particles in metered dose inhalers, Pharm Res, 17 
(2000) 168-174. 
[17] R.P.S. Peguin, L. Wu, S.R.P. da Rocha, The ester group: How 
Hydrofluoroalkane-philic is it?, Langmuir, 23 (2007) 8291-8294. 
[18] L. Wu, S.R.P. da Rocha, Applications of Atomic Force Microscope in the 
Development of Propellant-based Inhalation Formulations, KONA  Powder and 
Particle Journal, 26 (2008) 106-128. 
[19] B. Bharatwaj, L. Wu, J.A. Whittum-Hudson, S.R. da Rocha, The potential for the 
noninvasive delivery of polymeric nanocarriers using propellant-based inhalers in the 
treatment of Chlamydial respiratory infections, Biomaterials, 31 (2010) 7376-7385. 
235 
 
 
 
[20] D.S. Conti, B. Bharatwaj, D. Brewer, S.R. da Rocha, Propellant-based inhalers 
for the non-invasive delivery of genes via oral inhalation, J Control Release, 157 
(2012) 406-417. 
[21] S. Azarmi, W.H. Roa, R. Lobenberg, Targeted delivery of nanoparticles for the 
treatment of lung diseases, Adv Drug Deliv Rev, 60 (2008) 863-875. 
[22] M. Smola, T. Vandamme, A. Sokolowski, Nanocarriers as pulmonary drug 
delivery systems to treat and to diagnose respiratory and non respiratory diseases, 
Int J Nanomedicine, 3 (2008) 1-19. 
[23] M. Huang, E. Khor, L.Y. Lim, Uptake and cytotoxicity of chitosan molecules and 
nanoparticles: effects of molecular weight and degree of deacetylation, Pharm Res, 
21 (2004) 344-353. 
[24] P. Xu, E. Gullotti, L. Tong, C.B. Highley, D.R. Errabelli, T. Hasan, J.X. Cheng, 
D.S. Kohane, Y. Yeo, Intracellular drug delivery by poly(lactic-co-glycolic acid) 
nanoparticles, revisited, Mol Pharm, 6 (2009) 190-201. 
[25] R. Inapagolla, B.R. Guru, Y.E. Kurtoglu, X. Gao, M. Lieh-Lai, D.J. Bassett, R.M. 
Kannan, In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for 
the treatment of lung inflammation, Int J Pharm, 399 (2010) 140-147. 
[26] M.P. DeLorme, H. Yang, C. Elbon-Copp, X. Gao, H. Barraclough-Mitchell, D.J.P. 
Bassett, Hyperresponsive airways correlate with lung tissue inflammatory cell 
changes in ozone-exposed rats, J. Toxicol. Environ. Health. A, 65 (2002) 1453-1470. 
[27] A.H. Schultheis, D.J. Bassett, A.D. Fryer, Ozone-induced airway 
hyperresponsiveness and loss of neuronal M2 muscarinic receptor function, Journal 
of Applied Physiology, 76 (1994) 1088-1097. 
236 
 
 
 
[28] D. Bassett, F. Hirata, X. Gao, R. Kannan, J. Kerr, N. Doyon-Reale, S. Wilson, M. 
Lieh-Lai, Reversal of methylprednisolone effects in allergen-exposed female BALB/c 
mice, J Toxicol Environ Health A, 73 (2010) 711-724. 
[29] M. Nassimi, C. Schleh, H.D. Lauenstein, R. Hussein, H.G. Hoymann, W. Koch, 
G. Pohlmann, N. Krug, K. Sewald, S. Rittinghausen, A. Braun, C. Muller-Goymann, A 
toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug 
delivery system for the lung, Eur J Pharm Biopharm, 75 (2010) 107-116. 
[30] J.C. Sung, B.L. Pulliam, D.A. Edwards, Nanoparticles for drug delivery to the 
lungs, Trends Biotechnol, 25 (2007) 563-570. 
[31] H. Yamamoto, Y. Kuno, S. Sugimoto, H. Takeuchi, Y. Kawashima, Surface-
modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin 
by mucoadhesion and opening of the intercellular tight junctions, J Control Release, 
102 (2005) 373-381. 
[32] M. Amidi, E. Mastrobattista, W. Jiskoot, W.E. Hennink, Chitosan-based delivery 
systems for protein therapeutics and antigens, Adv Drug Deliv Rev, 62 (2010) 59-82. 
[33] B.I. Florea, M. Thanou, H.E. Junginger, G. Borchard, Enhancement of bronchial 
octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in 
vivo correlation, J Control Release, 110 (2006) 353-361. 
[34] K.J. Kim, A.B. Malik, Protein transport across the lung epithelial barrier, Am J 
Physiol Lung Cell Mol Physiol, 284 (2003) L247-259. 
[35] C. Lombry, C. Bosquillon, V. Preat, R. Vanbever, Confocal imaging of rat lungs 
following intratracheal delivery of dry powders or solutions of fluorescent probes, J 
Control Release, 83 (2002) 331-341. 
237 
 
 
 
[36] M. Sakagami, In vivo, in vitro and ex vivo models to assess pulmonary 
absorption and disposition of inhaled therapeutics for systemic delivery, Adv Drug 
Deliv Rev, 58 (2006) 1030-1060. 
[37] R.A. Goldstein, P.K. Rohatgi, E.H. Bergofsky, E.R. Block, R.P. Daniele, D.R. 
Dantzker, G.S. Davis, G.W. Hunninghake, T.E. King, Jr., W.J. Metzger, et al., Clinical 
role of bronchoalveolar lavage in adults with pulmonary disease, Am Rev Respir Dis, 
142 (1990) 481-486. 
[38] L.A. Dailey, N. Jekel, L. Fink, T. Gessler, T. Schmehl, M. Wittmar, T. Kissel, W. 
Seeger, Investigation of the proinflammatory potential of biodegradable nanoparticle 
drug delivery systems in the lung, Toxicol Appl Pharmacol, 215 (2006) 100-108. 
[39] H. Klech, W. Pohl, Technical recommendations and guidelines for 
bronchoalveolar lavage (BAL): report of the European Society of Pneumology Task 
Group on BAL., Eur Resp. J, 2 (1989) 561-585. 
[40] O. Kowal-Bielecka, K. Kowal, K.B. Highland, R.M. Silver, Bronchoalveolar 
Lavage Fluid in Scleroderma Interstitial Lung Disease: Technical Aspects and Clinical 
Correlations: Review of the Literature, Semin Arthritis Rheum, (2009). 
[41] Y.C. Huang, A. Vieira, K.L. Huang, M.K. Yeh, C.H. Chiang, Pulmonary 
inflammation caused by chitosan microparticles, J Biomed Mater Res A, 75 (2005) 
283-287. 
[42] M. Kumar, X. Kong, A.K. Behera, G.R. Hellermann, R.F. Lockey, S.S. 
Mohapatra, Chitosan IFN-gamma-pDNA Nanoparticle (CIN) Therapy for Allergic 
Asthma, Genet Vaccines Ther, 1 (2003) 3. 
238 
 
 
 
[43] A. Grenha, S. Al-Qadi, B. Seijo, C. Remunan-Lopez, The potential of chitosan for 
pulmonary drug delivery, J Drug Deliv Sci Tec, 20 (2010) 33-43. 
[44] B. Sarmento, J. das Neves, A.S. Halim, L.C. Keong, I. Zainol, A.H.A. Rashid, 
Biocompatibility and Biodegradation of Chitosan and Derivatives, in: B. Sarmento, J. 
das Neves (Eds.) Chitosan-Based Systems for Biopharmaceuticals: Delivery, 
Targeting and Polymer Therapeutics, John Wiley & Sons, Chichester, UK, 2012. 
[45] O. Harush-Frenkel, M. Bivas-Benita, T. Nassar, C. Springer, Y. Sherman, A. 
Avital, Y. Altschuler, J. Borlak, S. Benita, A safety and tolerability study of differently-
charged nanoparticles for local pulmonary drug delivery, Toxicol Appl Pharmacol, 
246 (2010) 83-90. 
[46] M. Koping-Hoggard, K.M. Varum, M. Issa, S. Danielsen, B.E. Christensen, B.T. 
Stokke, P. Artursson, Improved chitosan-mediated gene delivery based on easily 
dissociated chitosan polyplexes of highly defined chitosan oligomers, Gene Ther, 11 
(2004) 1441-1452. 
[47] G.R. Zosky, A.N. Larcombe, O.J. White, J.T. Burchell, T.Z. Janosi, Z. Hantos, 
P.G. Holt, P.D. Sly, D.J. Turner, Ovalbumin-sensitized mice are good models for 
airway hyperresponsiveness but not acute physiological responses to allergen 
inhalation, Clin Exp Allergy, 38 (2008) 829-838. 
[48] M.A. Birrell, C.H. Battram, P. Woodman, K. McCluskie, M.G. Belvisi, Dissociation 
by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine 
airways, Respir Res, 4 (2003) 3. 
239 
 
 
 
[49] R. Lucas, A.D. Verin, S.M. Black, J.D. Catravas, Regulators of endothelial and 
epithelial barrier integrity and function in acute lung injury, Biochem Pharmacol, 77 
(2009) 1763-1772. 
[50] J.P. Mizgerd, Acute lower respiratory tract infection, N Engl J Med, 358 (2008) 
716-727. 
[51] S.P. Kantrow, Z. Shen, T. Jagneaux, P. Zhang, S. Nelson, Neutrophil-mediated 
lung permeability and host defense proteins, Am J Physiol Lung Cell Mol Physiol, 297 
(2009) L738-745. 
[52] F. Alexis, E. Pridgen, L.K. Molnar, O.C. Farokhzad, Factors affecting the 
clearance and biodistribution of polymeric nanoparticles, Mol Pharm, 5 (2008) 505-
515. 
[53] J. Todoroff, R. Vanbever, Fate of nanomedicines in lungs, Curr Opin Coll Int Sci, 
16 (2011) 246-254. 
[54] K. Sarlo, K.L. Blackburn, E.D. Clark, J. Grothaus, J. Chaney, S. Neu, J. Flood, D. 
Abbott, C. Bohne, K. Casey, C. Fryer, M. Kuhn, Tissue distribution of 20 nm, 100 nm 
and 1000 nm fluorescent polystyrene latex nanospheres following acute systemic or 
acute and repeat airway exposure in the rat, Toxicology, 263 (2009) 117-126. 
[55] H.S. Choi, Y. Ashitate, J.H. Lee, S.H. Kim, A. Matsui, N. Insin, M.G. Bawendi, M. 
Semmler-Behnke, J.V. Frangioni, A. Tsuda, Rapid translocation of nanoparticles from 
the lung airspaces to the body, Nat Biotechnol, 28 (2010) 1300-1303. 
 
 
 
240 
 
 
 
CHAPTER 6 
Conclusions and Future Directions 
 
Although universally recognized as one of the fastest modes for non-invasively 
administering therapeutics to the bloodstream, the lungs have been highly 
underutilized in the targeting systemic ailments.  More surprising is the fact that no 
commercial formulation is used for the treatment or to support the treatment of 
serious pulmonary disorders such as cancer and tuberculosis.  Lack of delivery 
vehicles to overcome cellular barriers and effective therapeutic modulation to ensure 
efficient delivery of the drug to either the regional milieu or the bloodstream are some 
of the impediments that need to be addressed in order to develop new opportunities 
in the oral inhalation (OI) market.  Another important issue to be addressed is the 
poor (at best) understanding of the interaction of biomaterials that can serve as 
deliver vehicles and the lung tissue.  More research in this area will be necessary to 
improve on the design of safe chemistries that have the appropriate functionality to 
achieve the tasks expected from the drug delivery carriers. 
Polymeric nanocarriers (PNCs) are excellent delivery vehicles as they have 
several advantageous traits that can be harnessed to address some of these issues.  
The synergy of PNCs with compact OI devices such as pressurized metered-dose 
inhalers (pMDIs) is expected to greatly expand the spectrum of diseases that can be 
targeted utilizing such inexpensive devices.  However, the size range of PNCs falls 
well outside the stipulated aerosol size range required for effectively targeting the 
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alveolar region of the lungs, which is in the micron range.  Within this context, we 
have put forth in this work, approaches to formulate PNCs in pMDIs, the least 
expensive portable inhalers in the market, and efficiently deliver them to deep lungs.  
Furthermore, the interaction of PNC candidates with in vitro and in vivo models of 
pulmonary epithelium was evaluated, in an effort to understand their ability to 
modulate transport and uptake into and across well characterized monolayers, and to 
gain a better understanding of the toxic profile of those biomaterials. 
 
Some of the main conclusions drawn from this work are: 
(i)  We were the first group to develop a propellant-based inhaler formulation for the 
delivery of PNCs to the lungs.  Poly(lactic-glycolic acid) PLGA NPs were successfully 
encapsulated as core-shell structures within a HFA-philic, biodegradable co-
oligomeric shell.  The structures formed were characterized to have an aerosol size 
range between 1 and 5 µm, effective for deep lung deposition and the NP loading 
within the shell was determined to be ca.10%.  Dispersion formulations thus formed 
were stable in HFA over extended time periods and exhibited respirable fractions as 
high as 60%, as evidenced by cascade impaction studies. 
 While NPs were successfully encapsulated within the co-oligomeric shell, the 
loading obtained through this strategy was relatively poor, especially in settings 
where the quantity of payload required is high.  Therefore, suggested future work in 
this area would be to devise strategies to enhance and optimize the loading of NPs 
within the shell, which in turn could improve the payload of the therapeutic to be 
administered via this approach.  Furthermore, another relevant study for the future 
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would be preparation of these structures through spray drying (in an effort to improve 
loading of the encapsulants) and formulating them as powders in DPIs, another class 
of compact OI devices that are highly used commercially – in spite of being more 
expensive, they are somewhat more straight forward in terms of formulations. 
 
(ii)  We have devised several strategies for the modulation of transport of 
therapeutics across the pulmonary epithelium, and to also modulate their cellular 
internalization.  Many of these studies represent innovative concepts and systems in 
the pulmonary drug delivery field.  The interaction of PNCs with in vitro models of 
airway epithelium was investigated in this work. 
 a. Fluorescence microscopy studies involving PLGA NPs loaded with a coumarin-
6 (fluorescent dye) released from the core-shell formulation indicated that the NPs 
were internalized into Calu-3 cells, a model airway epithelium.  In order to guage the 
applicability of the core-shell NP system, we tested its trafficking on cells infected 
with a respiratory pathogen, Chlamydia pneumoniae.  Fluorescence and confocal 
microscopies conducted suggested that the NPs were not only taken up by Calu-3 
cells (as observed before), but were also trafficked into the inclusions housing the 
bacterium.   While these results are promising, the applicability of this approach can 
be greatly expanded and validated if these experiments can be transitioned to 
incorporate therapeutics instead of surrogate moieties.  Preparing and characterizing 
PLGA NPs loaded with antibiotics, optimizing their size and loading and studying 
their internalization and their efficacy in eradicating the infection after administering 
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them as core-shell formulation could be a potential study that can be undertaken in 
the future.  In vivo studies would also be of great relevance. 
 b. The internalization and transport of DNCs and DNCs loaded into NPs were 
also investigated in this study.  DNC loaded NPs were prepared and characterized by 
emulsification solvent evaporation technique.  The results from this study indicated 
that bare DNCs administered onto the apical side of the insert were able to traverse 
across confluent Calu-3 monolayers, while the DNC from those loaded into NPs did 
not.  Uptake experiments performed on polarized Calu-3 cells using flow cytometry 
and cell lysis revealed that the kinetics of uptake for both systems were markedly 
different.  While the uptake of free dendrimers saturated by 5h, DNCs formulated into 
PLGA NPs did not attain levels of saturation within the same time frame and took 
much longer, suggesting that this approach can be used as a potential strategy to 
enhance the rate and total amount of dendrimer uptake, and can thus be utilized to 
modulate not only transport across the monolayer, but also cellular internalization.  
Additionally, we demonstrate that the rate of uptake of DNCs was markedly reduced 
in polarized Calu-3 cells when compared to their non-polarized counterparts, which 
serves to emphasize the need to use polarized models.  This represents the first 
study where the transport of dendrimers was investigated in a polarized in vitro model 
of the lung epithelium, and that such nanoblends has been proposed to modulate 
drug carrier compounds. 
 c. We also evaluated the effect of PEG density on the surface of DNC on the 
uptake and transport into and across confluent Calu-3 monolayers.  DNCs with 
varying PEG densities (5, 13 and 25 PEG per DNC) were synthesized and 
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characterized.  The synthesized conjugates showed no reduction in the viability of 
Calu-3 within the concentration range that would be employed for transport and 
uptake experiments.  Our results indicate that PEGylation greatly enhances the 
transport of DNCs across Calu-3, with a tenfold increase in transport observed for the 
DNC with 25 PEG when compared to DNC with no PEG on the surface.  The 
PEGylation can also be used to modulate cellular internalization.  Within the same 
duration, the uptake of DNCs increases as the degree of PEGylation decreases, as 
evidenced by flow cytometry analysis.  These results indicate that tailoring DNCs with 
appropriate surface density of PEG can greatly assist in the modulation of 
therapeutics across Calu-3.  These represent the first study where the 
functionalization of dendrimers has been studied as an attempt to modulate transport 
across a model pulmonary epithelium.  Preliminary PK evaluation of DNCs delivered 
to Balb/c mice via pharyngeal aspiration revealed that DNCs with greatest PEG 
surface density translocated much faster from the airspace into systemic circulation 
and persisted in the bloodstream for a longer duration compared to DNCs possessing 
5 and 13 PEG.  The bioavailability reported for DNC with 25 PEG was ca.20%.  While 
this data is preliminary, it gives us great insight into the applicability of PEG DNCs 
within the context of being utilized as nanocarriers to modulate therapeutic transport 
across lung epithelia.  Prospective studies of relevance for this part of the study 
include studying the biodistribution of PEG DNC after pharyngeal aspiration to 
understand the trafficking of the conjugate from the lung milieu, and the in vivo 
targeting with relevant therapeutics. 
245 
 
 
 
 In this study, as a model molecule, we employed FITC in order to detail the 
proof of concept study.  Future studies in this area includes conjugating therapeutics 
(to target either local or systemic circulation), and relevant biomolecules to the DNC 
surface and evaluating the transport and uptake of the resultant conjugate across 
and into Calu-3 monolayers.  Another avenue that would benefit from future 
experiments is to enhance and optimize the poor loading of DNCs in the PLGA NPs.  
While all of our studies regarding transport were conducted in Calu-3, a model airway 
epithelial cell line, a lot of our pMDI formulation is delivered to the deep lung, 
populated by the alveolar epithelial cells who cellular properties are different from that 
of Calu-3.  Evaluating the transport and uptake of DNCs, PEGylated DNCs and DNC 
loaded PLGA NPs, can be performed on alveolar epithelial cells by mimicking the 
actual dosage that is effectively delivered to the deep lung.  The effect of dendrimer 
generation and PEG MW on the transport and uptake of PEGylated DNCs across 
Calu-3 can be evaluated. 
 While our results showed that DNCs were able to effectively traffic into Calu-3 
or transport across Calu-3 monolayers, the exact mechanism for either study was 
only hypothesized and not studied in detail.   Hence, future studies in this case 
should narrow down the exact mechanism and transport of the DNCs across Calu-3 
monolayers.  Prospective experiments here include labeling cell organelles with 
specific antibodies, to track the intracellular fate of the DNCs internalized into cells 
(where the DNCs are being trafficked into within the cell cytosol) using confocal 
microscopy.  Furthermore, cellular uptake in the presence of inhibitors of specific 
internalization mechanisms like colchicines, cytochalisins, chlorpromazine, and 
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phorbol-12-myristrate-13-acetate could be conducted in order to deduce the 
mechanism with DNCs are taken up by Calu-3.   
(iii) The interaction of a versatile co-oligomer that can be used to formulate PNCs 
and DNCs in pMDIs, and also as NP to stabilize drug particles 
(crystal/amorphous/hydrophobic/lipophobic) in pMDI formulations and the lung tissue 
was investigated.  Retention studies and the inflammatory potential of the co-
oligomer and the co-oligomer with PLGA PNPs system that mimics the core-shell 
formulation described in this dissertation were investigated in vivo.  Our  results 
indicate that the compound exerted little or no toxicity for dosages up to 5 mg/Kg 
(100 µg·15 µl-1) bodyweight upon a single acute dose, and up to 0.5 mg/Kg (10 µg·15 
µl-1) bodyweight upon repeated administration of the co-oligomer as evidenced by 
analyzing the inflammatory cell populations isolated from BAL and tissue dispersion 
studies.  Furthermore, the combination of OLA-g-CS and PLGA NPs (to mimic the 
NP laden core-shell formulation) did not induce any pronounced inflammation within 
the dosages that would mimic the actual core-shell formulation.  The excipient had a 
half-life of 31h in the airspace, while ca. 90% of PLGA NPs administered as core-
shell formulation were flushed out from the airways within 24h. 
It must be mentioned that, for this study, OLA-g-CS was delivered intranasally 
to anaesthetized mice and hence we expect only about 40% of the formulation 
administered to reach the lung lobes.  Although this is acceptable, a better approach 
would be to study the inflammatory response after administering the dose utilizing 
another technique that can better control the total deposition – such as instillation or 
pharyngeal aspiration – techniques that would ensure maximal deposition of the 
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formulation in the deep lung.  A potential future study could be to administer the 
formulation through an alternative strategy as mentioned above and then evaluate 
the inflammatory response in the lung using BAL and tissue dispersion analysis.  
Future work here could include the histological evaluation of mice lung administered 
with OLA-g-CS, and to encapsulate a therapeutic molecule into the proposed PNPs.  
Additionally, biodistribution studies can be conducted to determine the fate of the 
PLGA NPs administered as core-shell particles to the lungs, and to evaluate the PK 
of therapeutics relevant to both local and systemic delivery. 
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APPENDIX A 
CHARACTERIZATION OF G3-NH2-nPEG1000 
A1. Characterization of carboxy-methyl poly ethylene glycol (cmPEG). 
cmPEG (MW 1000 Da)was synthesized according to method detailed in the 
literature and the procedure has been explained in the manuscript.  The compound 
sourced was purified and characterized using 1H-NMR, MALDI-TOF and FT-IR 
spectroscopies.  The results of the characterization is given in Figure a1.  The 
formation of cmPEG can be corroborated by the absence of peak at 4.6 ppm 
attributed to the –OH peak of mPEG.  The unique stretching band at 1735 cm-1 
(distinct to carbonyl moiety of cmPEG) in the FT-IR peak (Figure a1(b)) also confirms 
the conversion.  MALDI-TOF analysis, shows an increase in MW of the mPEG from 
1035 Da to 1201 Da with a distinct change the MW distribution also attributed to the 
formation of cmPEG (Figure a1(c) ). 
 
A2. Characterization of PEGylated G3-NH2 
cmPEG was tethered to the G3-NH2 surface using a widely accepted EDC-
NHS chemistry.  The characterization of the final product was done using 1H-NMR 
and MALDI-TOF.  The conjugation of FITC to G3-NH2 was accomplished through the 
formation of the thiourea bond.[3]  Reaction between cmPEG, FITC and G3-NH2 was 
done as a one pot reaction.  Figures a2 to a5 are the MALDI and NMR spectras of 
the prepared G3-NH2-nPEG 1000 conjugates starting with 0 (a2), 5(a3), 13(a4) and 
25(a5) PEGs on G3-NH2 surface.   
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All NMR spectras are shown In Figures a2(a) – 0 PEG, a3(a) – 5 PEG, a4(a) – 
13 PEG and a5 (a) – 25 PEG.  The presence of multiplets between 6 and 7 ppm can 
be attributed to the presence of aromatic protons of FITC.  Singlet at 2.2 ppm is due 
to the presence of methylene protons of G3-NH2 and they were set as an internal 
standard at 120 in order to estimate the extent of PEG conjugation.  Broad peaks 
arising between 3.2 and 3.6 ppm can be traced to the CH2CH2O repeat unit of 
PEG.[5]  The singlet at 3.23, due to the presence of –CH3 group of PEG was used to 
determine the number of tethered PEG molecules on the G3-NH2 backbone.   
The increase in MW of the prepared G3-NH2-nPEG 1000 compounds was 
documented using MALDI TOF and the resulting spectras are given in the figures 
a2(b) – 0 PEG, a3(b) – 5 PEG, a4(b) – 13 PEG and a5 (b) – 25 PEG.  A gradual rise 
in MW with increase in PEG density is evident along with the change in the MW 
distribution when compared to bare G3-NH2 (Figure a2(b) –Inset).  The combination 
of NMR, MALDI and DLS results (discussed in the manuscript) confirm the presence 
of PEG on the dendrimer surface.   
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Figure a1.  (a) MALDI-TOF spectra of cmPEG obtained using DHB as a 
matrix.  (inset) MALDI-TOF spectra of mPEG.  (b) FT-IR spectra of mPEG 
and cmPEG obtained using a KBr crystal.  The distinct stretching at 1735 
cm-1 is assigned to the C=O bond formed in the cmPEG.  (c) 1H-NMR 
spectra of cmPEG - CdCl3 as the solvent.  The absence of an -OH peak at 
ca. 4.6 ppm indicates the conversion of mPEG to cmPEG. 
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Figure a2. (a) 1H-NMR spectra of G3-NH2-0PEG1000 (b) M ALDI-
TOF spectra of G3-NH2-0PEG1000 determined using DHB as a 
matrix.  The average number of FITC molecules conjugated here 
were 2. ((inset) MALDI-TOF spectra of pure G3-PAMAM dendrimer. 
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Figure a3. (a) 1H-NMR spectra of G3-NH2-5PEG1000 (b) MALDI-
TOF spectra of G3-NH2-5PEG1000 determined using DHB as a 
matrix.  The average number of FITC molecules conjugated here 
were 1.5.  
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 Figure a4. (a) 
1H-NMR spectra of G3-NH2-13PEG1000 (b) MALDI-
TOF spectra of G3-NH2-13PEG1000 determined using DHB as a 
matrix.  The average number of FITC molecules conjugated here 
were 1.7.  
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Figure a5. (a) 1H-NMR spectra of G3-NH2-13PEG1000 (b) 
MALDI-TOF spectra of G3-NH2-25PEG1000 determined using 
DHB as a matrix.  The average number of FITC molecules 
conjugated here were 2.  
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The lungs are considered as one of the fastest portals of entry to the 
bloodstream and oral inhalation (OI) has long been accepted as the preferred mode 
of administration of therapeutics to the respiratory tract.  However, despite its 
advantages, the lungs have been largely underutilized to target ailments not only of 
systemic relevance but also several other grave conditions including lung cancer and 
tuberculosis.  Polymeric nanocarriers (PNCs) have several advantages over other 
drug delivery vehicles including sustained release of moieties, ease of cellular 
internalization and improved targeting, and hence hold the promise to greatly 
augment the potential of OI therapies.  The surface chemistry, architecture, and size 
of PNCs may be potentially altered in order to modulate their interaction with the 
extra and intracellular barriers present in the lung epithelia, and thus their transport, 
overcoming challenges observed when delivering free drug molecules. They can be 
utilized to enhance the residence time of drugs required to exert prolonged 
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therapeutic effect in the airspace (regional therapy), and conversely speed up the 
transport of drug molecules that would traverse sluggishly to the bloodstream 
(systemic therapy).  In this work, we report the preparation, characterization of a 
series of PNCs ranging from polymeric nanoparticles (PNPs) to surface modified 
dendrimer nanocarriers (DNCs) and we studied their interaction with in vitro and in 
vivo models of the lung epithelium.  We observed that transport and cellular uptake 
can be efficiently modulated as the surface characteristics of the PNCs is varied, 
suggesting that OI strategies incorporating such nanoscopic entities may potentially 
be employed for targeting regional diseases and also the systemic circulation.  
Finally, we also discuss the formulation, dispersion stability and aerosol 
characteristics of the aforementioned PNCs in portable, inexpensive pressurized 
metered dose inhalers (pMDIs). 
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